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ABSTRACT

ROLE OF MEIBUM AND TEAR PHOSPHOLIPIDS IN
THE EVAPORATIVE WATER LOSS ASSOCIATED
WITH DRY EYE
Samiyyah M. Sledge
August 20, 2021

It is generally believed that the tear film lipid surface film inhibits the rate of
evaporation (Revap) of the underlying tear aqueous. It is also generally believed that
changes in the composition of the tear film lipid layer is responsible for an increase in
Revap in patients with dry eye. Both of these ideas have never been proven. The purpose
of the current studies was to test these ideas. Revap was measured in vitro
gravimetrically. Lipid spreading was measured using Raman spectroscopy and
microscopy. The influence of the following surface films on the Revap of the sub phase
of physiologically buffered saline (PBS) was measured: 1-hydroxyl hydrocarbons,
meibum from normal donors and donors with dry eye with and without added
phospholipids and phospholipids. The Revap for longer chain 1-hydroxyl hydrocarbons
was significantly higher compared with shorter chain 1-hydroxyl hydrocarbons.
However, the differences were minor, < 1%. The Revap of tears and PBS were not
vi

different. None of the combinations of lipids mentioned above altered Revap more than
1%. A 50% reduction in Revap would be expected if lipid films inhibited Revap.
Although surface lipids did not attenuate Revap, phospholipids appeared to facilitate the
spreading of meibum. All of the lipid systems studied completely covered the aqueous
surface. Meibum from patients with dry eye on the surface aggregated into clusters, but
when the same meibum samples were applied to a layer of phospholipids, clustering
decreased (66 ± 16 %) significantly.
In conclusion, it is unlikely that 1-hydroxyl hydrocarbons can be used to inhibit the
Revap of reservoirs. Our data do not support the idea that meibum with or without
phospholipids inhibit the Revap of the tears. Perhaps stiff ordered lipids cause the surface
lipids to aggregate into ‘islands’ that inhibit the spreading of the tear film which may
contribute to tear film instability associated with dry eye symptoms.

vii

TABLE OF CONTENTS

DEDICATION ................................................................................................................... iii
ACKNOWLEDGEMENTS ............................................................................................... iv
ABSTRACT ....................................................................................................................... vi
LIST OF TABLES ........................................................................................................... xvi
LIST OF FIGURES ....................................................................................................... xviii
1.

INTRODUCTION ....................................................................................................... 1
1.1. DRY EYE DISEASE ............................................................................................................ 1
1.1.1. DEFINITION ................................................................................................................. 2
1.1.2. TYPES ........................................................................................................................... 3
Aqueous Production Deficient DED ................................................................................ 4
Evaporative DED ............................................................................................................. 4
Meibomian Gland Dysfunction (MGD) ........................................................................... 5
1.1.3. CLINICAL SIGNS AND SYMPTOMS ........................................................................ 7
1.1.4. PREVALENCE OF DED .............................................................................................. 8
1.2. ETIOLOGY OF DED ........................................................................................................... 9
1.2.1. ENVIRONMENTAL ..................................................................................................... 9
1.2.2. DRUG AND MEDICATION MEDIATED ................................................................ 10
1.2.3. PHYSIOLOGICAL AND GENETIC CAUSES OF DED .......................................... 10
Age ................................................................................................................................. 10
viii

Sex Hormones ................................................................................................................ 13
Gender ........................................................................................................................... 14
1.2.4. SECONDARY TO OTHER DISEASES ..................................................................... 15
Sjögren’s Syndrome ....................................................................................................... 15
Graft-versus-Host Disease ............................................................................................. 16
1.3. TEAR FORMATION AND FUNCTION........................................................................... 18
1.3.1. LACRIMAL GLAND .................................................................................................. 18
Tears .............................................................................................................................. 19
1.3.2. MEIBOMIAN GLANDS AND THE MEIBUM ......................................................... 21
Meibomian Gland .......................................................................................................... 21
Meibum .......................................................................................................................... 24
1.4. OCULAR SURFACE ANATOMY .................................................................................... 28
1.4.1. THE CORNEA, SCLERA, AND CONJUNCTIVA.................................................... 28
1.4.2. TEAR FILM LAYER .................................................................................................. 29
Mucin Layer ................................................................................................................... 29
Aqueous Layer ............................................................................................................... 31
Tear Film Lipid Layer.................................................................................................... 31
1.5. TEAR FILM FUNCTION .................................................................................................. 31
Tear Film Stability ......................................................................................................... 33
1.6. MEDICAL MANAGEMENT OF DED ............................................................................. 36
1.6.1. INCREASING TEAR VOLUME ................................................................................ 37
Artificial Tears ............................................................................................................... 37
Punctal Occlusion .......................................................................................................... 39
Surgical Occlusion ......................................................................................................... 39

ix

1.6.2. TOPICAL ANTI-INFLAMMATORY THERAPY TO DECREASE OCULAR
OSMOLARITY ..................................................................................................................... 40
Inflammation .................................................................................................................. 40
Corticosteroids............................................................................................................... 41
Cyclosporine .................................................................................................................. 42
Omega 3 Fatty Acids ...................................................................................................... 43
Vitamin A ....................................................................................................................... 46
1.6.3. AUGMENTING LIPID CONTENT ............................................................................ 47
Temperature Treatment ................................................................................................. 47
iLux® ............................................................................................................................. 49
1.7. CURRENT CHALLENGES RELATED TO TREATING DED ....................................... 51
Problems with Evaluations ............................................................................................ 52
Problems with Therapy .................................................................................................. 53
Appropriate Models ....................................................................................................... 56

2. HYPOTHESIS AND SPECIFIC AIMS ....................................................................... 60
2.1. GENERAL BACKGROUND AND RATIONALE ........................................................... 60
2.1.1. SOURCES OF TEAR FILM LIPIDS .......................................................................... 61
2.1.2. LIPID PROPERTIES AND STRUCTURES RELATED TO A SOUND BARRIER
TO EVAPORATION. ............................................................................................................ 62
2.1.3. SURFACE FILMS ....................................................................................................... 67
2.2. HYPOTHESIS .................................................................................................................... 68
Specific Aims ..................................................................................................................... 68
2.2.1. SPECIFIC AIM 1 ......................................................................................................... 68
2.2.2. SPECIFIC AIM 2 ......................................................................................................... 69
2.2.2.1. SPECIFIC AIM 2.A .............................................................................................. 69
x

2.2.2.2. SPECIFIC AIM 2.B .............................................................................................. 70
2.2.3. SPECIFIC AIM 3 ......................................................................................................... 70
3.1. MATERIALS ...................................................................................................................... 72
3.1.1 MATERIALS ................................................................................................................ 72
3.1.2. COLLECTION OF HUMAN TEARS AND MEIBUM .............................................. 72
3.1.2.1 HUMAN TEARS ................................................................................................... 72
3.1.2.2. HUMAN MEIBUM SAMPLES ........................................................................... 75
Clinical Diagnosis of Normal Meibum .......................................................................... 75
Clinical Diagnosis of DED ............................................................................................ 75
How HSCT is Related to this Study ................................................................................ 76
3.2 METHODS .......................................................................................................................... 80
3.2.1 NMR ............................................................................................................................. 80
3.2.1.1. COLLECTION AND PROCESSING OF NMR SPECTRA ................................ 84
3.2.2. MEASUREMENT OF REVAP ................................................................................... 84
3.2.2.1. PHYSIOLOGICAL TEMPERATURE EXPERIMENTS .................................... 86
3.2.2.2. ROOM TEMPERATURE EXPERIMENTS ........................................................ 86
3.2.2.3. ALL SAMPLES .................................................................................................... 87
Measuring the Rate of Evaporation ............................................................................... 87
Statistics ......................................................................................................................... 88
3.2.3 PL CONCENTRATIONS ............................................................................................ 88
3.2.4 LIPID SPREADING ..................................................................................................... 92
3.2.4.1. RAMAN................................................................................................................ 92
3.2.4.2. MICROSCOPY..................................................................................................... 95
3.2.4.3. FIJI ........................................................................................................................ 95

xi

4. SPECIFIC AIM 1. ......................................................................................................... 98
4.1. REARCH DESIGN- SPECIFIC AIM 1.............................................................................. 98
4.1.1. RATIONALE- SPECIFIC AIM 1. ............................................................................... 98
4.1.2. APPROACH- SPECIFIC AIM 1. ................................................................................ 99
Preparation .................................................................................................................... 99
Evaluating Lipid Spreading and Hydrocarbon Chain Conformation Using Raman ... 100
4.2. RESULTS- SPECIFIC AIM 1. ......................................................................................... 100
Revap ........................................................................................................................... 100
Lipid Spreading and Hydrocarbon Chain Conformation ............................................ 104
4.3 DISCUSSION- SPECIFIC AIM 1. .................................................................................... 109

5. SPECIFIC AIM 2. ....................................................................................................... 112
5.1. RESEARCH DESIGN- SPECIFIC AIM 2A. ................................................................... 112
5.1.1. RATIONALE- SPECIFIC AIM 2A. .......................................................................... 112
5.1.2. SPECIFIC AIM 2A. APPROACH............................................................................. 114
Preparation .................................................................................................................. 114
Evaluating Lipid Spreading Using Microscopy and Raman Hydrocarbon Chain
Conformation ............................................................................................................... 115
Statistics ....................................................................................................................... 115
5.2. RESULTS- SPECIFIC AIM 2A. ...................................................................................... 117
Revap ........................................................................................................................... 117
Lipid spreading and Hydrocarbon Chain Conformation............................................. 117
5.3. DISCUSSION- SPECIFIC AIM 2A. ................................................................................ 128

6. SPECIFIC AIM 2/2B. ................................................................................................. 130
6.1. RESEARCH DESIGN- SPECIFIC AIM 2B. ................................................................... 130

xii

6.1.1. RATIONALE ............................................................................................................. 130
6.1.2. APPROACH .............................................................................................................. 130
Preparation .................................................................................................................. 131
Evaluating Lipid Spreading ......................................................................................... 132
Statistics ....................................................................................................................... 133
6.2. RESULTS- AIM 2B. ........................................................................................................ 133
Revap ........................................................................................................................... 133
Lipid spreading ............................................................................................................ 140
6.3. DISCUSSION- AIM 2B. .................................................................................................. 144

7. SPECIFIC AIM 3 ........................................................................................................ 147
7.1. RESEARCH DESIGN- AIM 3. ........................................................................................ 147
7.1.1. RATIONALE ............................................................................................................. 147
7.1.2. APPROACH .............................................................................................................. 147
Preparation .................................................................................................................. 148
Evaluating Lipid Spreading ......................................................................................... 150
7.2. RESULTS- AIM 3. ........................................................................................................... 150
Revap- PLs ................................................................................................................... 150
Revap- PLs with Meibum ............................................................................................. 156
Lipid spreading and Hydrocarbon Chain Conformation............................................. 161
Cluster quantity and size .............................................................................................. 161
7.3 DISCUSSION- AIM 3. ...................................................................................................... 164

8. DISCUSSION ............................................................................................................. 167
8.1. GENERAL DISCUSSION ............................................................................................... 167
8.1.2. HYDROXYLCARBON CONFORMATION AND THE REVAP ........................... 167
xiii

8.1.3. MEUIBUM SPREADING ON AQUEOUS SURFACE AND THE REVAP ........... 169
8.1.4. PHOSPHOLIPIDS AND THE REVAP .................................................................... 174

9. CONCLUSION ........................................................................................................... 178
9.1. OVERALL SUMMARY .................................................................................................. 178
9. 2. RECOMMENDATIONS FOR FUTURE STUDIES ...................................................... 178

REFERENCES ............................................................................................................... 180
APPENDIX ..................................................................................................................... 197
COPY RIGHT CLEARANCE ........................................................................................ 197
LIST OF ABBREVIATIONS ......................................................................................... 198
CURRICULUM VITAE ................................................................................................. 200

xiv

LIST OF TABLES

Table 1.2(1). Systemic and Ocular Medications and Herbal Supplements that Cause or
Exacerbate Dry Eye Disease. ............................................................................................ 11
Table 3.1(1). Synthetic Lipid and Chain Length. ............................................................. 73
Table 3.1(1). Meibum Demographics. .............................................................................. 78
Table 5.1(1). Meibum Demographics. ............................................................................ 116
Table 5.2(2). Sample Parameters for Meibum. ............................................................... 122
Table 5.2(3).332 Raman Band Assignment. ..................................................................... 124
Table 5.2(4). Pooled Meibum and Reflex Tear Sample Demographics. ........................ 127

xv

LIST OF FIGURES

Figure 1.3(1). Lacrimal Gland. ......................................................................................... 20
Figure 1.3(2). Meibomian Glands. .................................................................................... 23
Figure 1.3(3). Meibum and the Meibomian Gland. .......................................................... 26
Figure 1.3(4). Meibum Components. ................................................................................ 27
Figure 1.4(1). Human Tear Film. ...................................................................................... 30
Figure 1.5(1). Tear Film Lipid Layer................................................................................ 34
Figure 1.5(2). Tear Film Stability. .................................................................................... 35
Figure 1.6(1). iLux® MGD Treatment System. ............................................................... 51
Figure 2.1(1). Meibum Lipid Arrangement on the Ocular Surface. ................................. 63
Figure 2.1(2). A Multilamellar Sandwich Model. ............................................................ 64
Figure 2.1(3). Monolayer Scaffolding Model. .................................................................. 66
Figure 3.1(1). Materials. ................................................................................................... 74
Figure 3.1(2). Image of a Patient Undergoing a Slit-Lamp Biomicroscopic Exam. ........ 77
Figure 3.1(3). Meibum stiffness as it Relates to Age and Disease ................................... 79
Figure 3.2(1). A Typical Nuclear Magnetic Resonance (NMR) Spectrum for Human
Meibum. ............................................................................................................................ 81
Figure 3.2(2). The Standard Curve for Wax. .................................................................... 82
Figure 3.2(3). The Standard Curve for Cholesterol. ......................................................... 83
xvi

Figure 3.2(4). Eye Tear Film Lipid Layer Model. ............................................................ 85
Figure 3.2(5). Heat Source. ............................................................................................... 89
Figure 3.2(6). Mettler-Toledo AT261 Analytical Balance (Columbus, OH). .................. 90
Figure 3.2(7). Average Phospholipid Concentration in Tears. ......................................... 91
Figure 3.2(8). Raman Spectrometer. ................................................................................. 93
Figure 3.2(9). Raman Laser. ............................................................................................. 94
Figure 4.2(1). Average Revap of Synthetic Lipids. ........................................................ 102
Figure 4.2(2). Calculated Lipid Layer Thickness. .......................................................... 103
Figure 4.2(3). Lipid Alcohol Films. ................................................................................ 105
Figure 4.2(4). Raman Spectra. ........................................................................................ 107
Figure 5.2(1). Average Rate of Evaporation of Human Reflex Tears and Physiologically
Buffered Saline with and without Human Meibum. ....................................................... 118
Figure 5.2(2). Microscopic Images of Human Reflex Tears and Physiologically Buffer
Saline Exposed to Human Meibum from Healthy Donors. ............................................ 119
Figure 5.2(3). Raman Spectra. ........................................................................................ 121
Figure 5.2(4). Raman Spectra. ........................................................................................ 123
Figure 6.2(1). Average Evaporation Rates of Physiologically Buffered Saline Exposed to
Normal, Dry Eye Disease, and Hematopoietic Stem Cell Transplant Human Meibum
After a 10-Minute Equilibration. .................................................................................... 135
Figure 6.2(2). Average Rate of Evaporation of Physiologically Buffered Saline Exposed
to Normal, Dry Eye Disease, and Hematopoietic Stem Cell Transplant Human Meibum
After a 3-Hour Equilibration. .......................................................................................... 136

xvii

Figure 6.2(3). Average Evaporation Rates of Physiologically Buffered Saline Exposed to
Normal and Hematopoietic Stem Cell Transplant Human Meibum at 22°C and 35°C
After a 10-Minute Equilibration. .................................................................................... 138
Figure 6.2(4). Average Evaporation Rates of Physiologically Buffered Saline Exposed to
Normal and Hematopoietic Stem Cell Transplant Human Meibum at 22°C and 35°C
After a 24-Hour Equilibration. ........................................................................................ 139
Figure 6.2(5). Hematopoietic Stem Cell Transplant Donor Meibum. ............................ 142
Figure 6.2(6). Dry Eye Disease Donor Meibum. ............................................................ 143
Figure 7.2(1). The Average Rate of Evaporation of Physiologically Buffered Saline
Layered with Different Types of Phospholipids After a 10-Minute Equilibration, at 35°C.
......................................................................................................................................... 152
Figure 7.2(2). The Average Rate of Evaporation of Physiologically Buffered Saline
Layered with Different Types of Phospholipids After a 3-Hour Equilibration, at 35°C. 153
Figure 7.2(3). Rate of Evaporation of Physiologically Buffered Saline Alone and
Physiologically Buffered Saline Layered with Combined Phospholipids After a 10Minute Equilibration, at 35°C. ........................................................................................ 154
Figure 7.2(4). Rate of Evaporation of Physiologically Buffered Saline Alone and
Physiologically Buffered Saline Layered with Combined Phospholipids After a 3-Hour
Equilibration, at 35°C. .................................................................................................... 155
Figure 7.2(5). Rate of Evapoartion of Combined Phospholipids Layered with Normal and
Hematopoietic Stem Cell Transplant Meibum, After a 10-Minute Equilibration, at 35°C.
......................................................................................................................................... 157
Figure 7.2(6). Rate of Evaporation of Combined Phospholipids Layered with Normal and
Hematopoietic Stem Cell Transplant Meibum, After a 3-Hour Equilibration, at 35°C. 158
xviii

Figure 7.2(7). Rate of Evaporation of Physiologically Buffered Saline Layered with Dry
Eye Disease Meibum or Dry Eye Disease Meibum and Combined Phospholipids After a
10-Minute Equilibration, at 35°C. .................................................................................. 159
Figure 7.2(8). Rate of Evaporation of Physiologically Buffered Saline Layered with Dry
Eye Disease Meibum or Dry Eye Disease Meibum and Combined Phospholipids After a
3-Hour Equilibration, at 35°C. ........................................................................................ 160
Figure 7.2(9). Micrographs of Human Meibum from Donors Clinically Diagnosed with
Dry Eye Disease Before and After Phospholipid Application........................................ 163

xix

1. INTRODUCTION

1.1. DRY EYE DISEASE
Dry eye disease (DED) is a disease in which the quality and quantity of tears are
reduced, compromising the eye's surface. DED affects 5 to 50 % of people worldwide,
especially Asians.1 Symptom of DED includes itching, foreign body sensation, dryness,
burning, and swelling. Signs of DED include conjunctival redness, lid margin debris and
redness, and a turbid meibum secretion. The disease can profoundly affect daily
activities, causing a reduction in quality of life and visual impairment because ocular
irritation may limit basic visual tasks such as driving, reading, and computer use.
DED is often caused or exacerbated by many overlapping conditions, such as
autoimmune disorders, surgeries, and medication use. Environmental triggers may
include but are not limited to low humidity and prolonged use of electronics. While
diagnosing and treating DED, physicians must consider symptoms and environmental
triggers while ruling out such conditions as allergies. DED is also associated with mental
disorders, including anxiety and depression,2-4 Risk factors and pathophysiological
features must be assessed to classify and treat DED properly.
Over-the-counter drugs and other pharmacologic therapeutics, non-pharmacologic
therapeutics, and office and hospital visits are estimated to cost patients 3.8 billion dollars
annually.5 Indirect costs, including low quality of work and loss of work hours,6 are
1

estimated to cost Americans alone 55 billion dollars annually.5 Stress at work and lost
wages can reduce quality leisure time and social interactions.6 The discomfort caused by
DED can be debilitating, as more extreme cases may cause a fluctuation in vision.5 This
limits the ability to drive and interferes with reading and computer use. Some
environments exacerbate the condition to the point that working is intolerable altogether.5
This can have a profound economic impact on the patient, including adequate health
insurance, to treat the condition.

1.1.1. DEFINITION
DED was first defined in 19957 as qualitative and quantitative abnormalities in tears,
resulting in damage to the ocular surface’s epithelia.7 That same year, a definition was
published by the National Eye Institute that included changes to the tear film (TF), such
as evaporation, which resulted in abnormalities to the ocular surface, leading to
discomfort.7-8 In 2007, the definition was expanded to include the dysfunction of one or
more parts of an integrated unit, including tear-producing glands (lacrimal gland), the
cornea, and Meibomian glands, eyelids, and sensory and motor neurons. All or some of
these units may be compromised, leading to increased osmolarity, inflammation, and,
eventually, visual disturbances.9-15 There is debate about whether these components have
casual or causative effects.8 Recently, DED was defined DED as a multifactorial
disorder of the TF and ocular surface.16 The definition includes a loss of homeostasis in
the tear film layer (TFL), resulting in symptoms in which instability, hyperosmolarity,
inflammation, and neurosensory abnormalities contribute to the disease's etiology.16 This
definition considers the symptoms of DED and does not address the signs of DED.8 The

2

Japan DED and Asian DED Societies brought awareness to DED signs, such as an
unstable TF evident by a decreased tear break-up time (TBUT).8, 17
Thus, committees composed of clinicians and researchers focus on the pathogenesis
symptoms,8, 17 while committees made up of only clinicians focus on the signs of the
developing disorder.18-19 So DED is defined as:
“Multifactorial disease characterized by the unstable tear film, causing a variety of
symptoms and/or visual impairment, potentially accompanied by ocular surface
damage.”17; or
“A multifactorial disease of the ocular surface characterized by a loss of homeostasis of
the tear film, and accompanied by ocular symptoms, in which tear film instability and
hyperosmolarity, ocular surface inflammation and damage, and neurosensory
abnormalities play etiological roles.”16

1.1.2. TYPES
One of the first comprehensive definitions of DED divided DED into two categories
based on the notion that both tear deficiency and excessive evaporation cause changes in
the TF.7 It was suggested that these TF changes were direct causes of DED.8 DED can be
classified as Aqueous Production-Deficient DED (ADDE) or Evaporative DED
(EDED).20 The latter is associated with Meibomian Gland Dysfunction (MGD), and the
former is caused by insufficient aqueous tears production.2,3 Both development
mechanisms of DED share the common feature of the TF's instability with rapid TBUT,
suggesting there may be shared structural abnormalities of the TF responsible for the
instability. Many cases involve both forms and characteristics common to both often
elude proper diagnosis.21
3

Aqueous Production Deficient DED
Approximately 10%22 of patients diagnosed with DED suffer from ADDE.23 This
DED form is characterized by decreased production and secretion5 of tears lending to low
volume on the ocular surface. The disease is primarily caused by lacrimal gland
dysfunction. Hyposecretion of tears is seen, which causes increased osmolarity of tears
and inflammation.24 In cases less often seen, the dysfunction is in the conjunctiva, where
water secretion is reduced.24
Aqueous production deficient DED is commonly caused by Sjögren's Syndrome,
sarcoidosis, chronic graft-versus-host disease, acquired immunodeficiency syndrome due
to infection by human immunodeficiency virus, thyroid disease, and diabetes mellitus;
An inflammatory disease that may exist as a primary disease or autoimmune. Although
the lacrimal gland is not the primary target of these diseases, inflammation of the lacrimal
gland is often seen. Lacrimal gland inflammation reduces the number of tears released
and therefore reduced aqueous in the TF; This often occurs with aging.

Evaporative DED
There was a long-standing belief that DED was caused by tear deficiency, and
therefore, artificial tears were used to attenuate DED in all cases.25-29 However, more than
80% of all DED incidences are categorized as EDED, as this DED type induces a high
rate of evaporation of tears.23 We believe that DED does not involve increased rates of
evaporation (see Section 7). The issue is not with tear production but rather the inability
to retain enough tears to keep the surface of the eye lubricated and well hydrated.

4

Meibomian Gland Dysfunction (MGD)
MGD is an umbrella term encompassing diseases of the Meibomian gland.30 MGD
involves the blockage of the Meibomian glands causing subsequent morphological
changes in the glands.31 A combination of MGD and ADDE primarily causes evaporative
DED type.23 It is reported the most common cause of EDED32 (the second primary
classification of DED), with clear pathology related to both structural and functional
changes. The disease may be the single leading cause of DED (all types considered)
worldwide.31 MGD is defined as:
“A chronic diffuse abnormality of the Meibomian glands, commonly characterized by
terminal duct obstruction and/or qualitative or quantitative changes in glandular
secretions. It results in alteration of the tear film, symptoms of eye irritation, clinically
apparent inflammation, and ocular surface disease.”31
The prevalence of MGD varies significantly across the globe, but Asian populations tend
to have significantly higher incidences than Caucasian populations,33-38, and prevalence
increases with age.
The causes and etiology for MGD are unknown31 and differ from DED.32 However,
MGD is a cause of DED's most common form, and MGD and DED have many clinical
features in common.32 Ocular surface irritation, visual fluctuation, and TF instability seen
in dry are also seen with MGD.32 It is crucial to evaluate morphological features of the
eyelids, lipid expressibility and quality, and gland dropout to distinguish MGD from
other subtypes of DED.
In the early stages of MGD, patients may be symptomatic and present with posterior
blepharitis or asymptomatic.31 However, as the MGD progresses, symptoms become

5

apparent, and patients may present with red and inflamed lid margins.31 Changes in the
quality and expressibility of the meibum will become apparent.31
A classification scheme for MGD considers anatomical and pathophysiological
changes with a depressed delivery rate of meibum and the severity of the disease.31 Under
the low-delivery state classifications, MGD can be classified as hyposecretory, which
describes the low delivery of meibum due to the gland's abnormalities. For the lowdelivery state hyposecretory classification, MGD may be sub-classified as cicatricialobstructive, where the glands are obstructed, and the orifices are dragged posteriorly into
the mucosa. In the non-cicatricial subtype, the glands remain in their natural position. For
the high-delivery, hypersecretory classification, large volumes of lipids are expressed
onto the tarsus with applied lid pressure31 and are accompanied by regular tear Revap.39
In assessing and diagnosing MGD, two approaches should be used.32 Primary
objective assessments evaluate aspects of the glands and gland secretions.32 The lipid and
protein components of the gland’s secretory product are a focus. Secondary objective
assessments evaluate the physiological consequences of changes or damage to the
glands.32 Decreased output of gland secretions compromises the integrity of the tear film
lipid layer (TFLL). Therefore, the consequences of those changes, such as evaporation
and osmolarity, are measured.
Subjective clinical approaches to diagnosing MGD use biomicroscopy to evaluate the
eyelids for telangiectasia, margin injection, and keratinization. The quality of meibum,
the ability to express meibum, and gland orifice plugging are also evaluated.
Meibography reveals signs of Meibomian gland atrophy,
The signs and symptoms of MGD are often the same or are very similar to the signs
and symptoms we have described for DED. Treatment for MGD focuses on treating the
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symptoms rather than eliminating the condition, as the symptoms are the most significant
concern for patients and clinicians alike.31

1.1.3. CLINICAL SIGNS AND SYMPTOMS
The eye's surface, along with the Meibomian gland, lacrimal gland, and innervation,
form one complete functioning unit.23 Any change in the homeostasis of a single
component may result in DED. DED is frequently characterized by subjective symptoms
that cause discomfort and ocular surface irritation such as photophobia (light intolerance),
burning, stinging, pruritus (feelings of itching or scratching), and foreign body
sensations, which likely result from dysfunctional nerves in the cornea.40 It is often
described as annoying and causes stress and limit activity.24 In more severe cases, these
components cause pain, which can also be evoked by wind and temperature extremes.
Utility assessments suggest that patients equate the severity of their symptoms with
severe angina or hospital dialysis symptoms.5, 41-42
Signs of DED include redness and folding of the conjunctiva with superficial punctate
keratosis.23 Reduction in the tear meniscus is often seen in patients.23 Signs of MGD are
evident when glands are obstructed with abnormal secretions that sometimes must be
forced with applied pressure.39 The hue and the appearance of meibum from donors with
MGD are different from meibum from donors without DED. It is more opaque and
grainy, whereas the meibum from normal donors is clear.39 The eyelid margins and
telangiectasia are thickened.23 When associated with MGD, inflammation is seen across
eyelid margins and glands.23
DED can range from mild, where symptoms are episodic and occur with
environmental stress, to more severe forms that are chronic and sometimes disabling.24
7

When DED symptoms occur more frequently, more objective clinical findings such as
inflammation and mucous clumping may be observed.24 In the most severe cases, the
eyelids adhere to the ocular surface, and eyelashes are introverted.24 Conjunctival
scarring, ulcerations, and corneal perforation can occur.23 The most severe clinical
manifestations result in diminished or total loss of visual acuity.23 These too objective
clinical findings are rare but are seen with autoimmune and other inflammatory disorders.
Chronic ocular surface inflammation is a sign that accompanies DED, often caused by
immune-mediated conditions, infection, disease and often triggered and exacerbated by
one’s environment.43-44 Although clinical signs and symptoms are more easily described,
the findings are not always correlated.45-46 In some cases, patients diagnosed with severe
DED experience milder symptoms, while patients with no significant signs complain of
more discomfort.45-46

1.1.4. PREVALENCE OF DED
DED affects more than a tenth of the population worldwide.47 It is one of the most
prevalent ophthalmic disorders to date.47-48 However, under-recognized and undertreated.5 Considered a significant and critical public health issue,49 affecting hundreds of
millions of people globally,20 approximately 16.4 million adult Americans alone are
estimated to have DED.50 DED is a complex functional disorder of the ocular surface that
involves many pathways that lead to an array of clinical findings and symptoms.20 The
prevalence of the disease increases markedly with age, gender, and chronic illness.23
Adults between the ages of 18-45 have an estimated occurrence rate of 2.7%.51 This
number differs for persons over 40, as prevalence rates range from 5% to 50%51 with
increasing age and gender. With an estimated average prevalence rate of 14.4%52i, the
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occurrences of DED double for both men over age 8053 and women above age 7554 in the
US and is twice as prevalent for women at any age.54-55ii
With time and aging populations, the prevalence of DED will continue to increase.
More importantly, this will have a snowball effect on the prevalence of an
underdiagnosed and undertreated population. Diagnosis is often hindered by an
inconsistent correlation between signs and symptoms, inconsistent results from clinical
testing, variations in the disease process, and an individual’s tolerance of symptoms.56
Delays in proper diagnosis hamper adequate treatment and create appreciable
socioeconomic costs. It is vital to use an approach that considers various presentations to
diagnose and treat DED. To do this, a classification based on pathophysiological features
and risk factors5 is necessary.

1.2. ETIOLOGY OF DED
The cause of DED is not entirely known. The occurrence of DED may be persistent or
intermittent. Several factors that increase one’s susceptibility to the development of DED
have been observed.57 The etiologies of DED may be classified into several broad
categories, including environmental.58

1.2.1. ENVIRONMENTAL
Some of the factors contributing to DED development include environmental factors
such as low humidity, environmental pollution, extended visual tasks, and prolonged use
of electronic devices.24, 47, 58-62 These environmental causes are exclusive of the various
ophthalmic pathologies contributing to DED. “These causes may directly result in the
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development or aggravation”58 of the disease,24 or instead, trigger or exacerbate the
disease that may already exist because of other biological factors.

1.2.2. DRUG AND MEDICATION MEDIATED
Ophthalmic and systemic medications may contribute to the development of DED.
These medications may aggravate the condition of the disease already present.24, 47, 62-63 A
broad range of systemic medications used to treat other conditions has been known to
induce or exacerbate DED. The occurrence of medication-induced DED is higher in older
adults and women. Multiple-use of systemic and ocular medication, which often occur in
older men and women, can trigger DED.63 A list of such medications and use may be
viewed in Table 1.2(1).

1.2.3. PHYSIOLOGICAL AND GENETIC CAUSES OF DED
Age
The prevalence of DED increases with age.24 Just as we see with many other tissues in
the body, changes occur in various parts of the integrated unit with the eye. We see
decreased stability of the TF. These changes are due in part to decreases in tear volume
and increases in osmolarity.24
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Systemic and Ocular Medications 5, 64-65
Methotrexate, cyclophosphamide

Treatment
Rheumatoid arthritis, systemic lupus
erythematosus
Diuretic
Beta-blocker
Antihypertensive agent
Antihistamine

Furosemide
Propranolol
Candesartan
Cetirizine, Desloratadine, Fexofenadine, Loratadine,
Diphenhydramine, Brompheniramine maleate
Pseudoephedrine, Phenylephrine
Trihexyphenidyl, Pramipexole
Amitriptyline, Fluoxetine, Sertraline, Bupropion,
Duloxetine
Lorazepam
Valproic Acid
Thioridazine, Clozapine
Ranitidine, Famotidine, Cyclobenzaprine,
Methocarbamol

Decongestant
Parkinson’s Disease
Depression
Anxiolytic Agent
Anticonvulsant Agent
Antipsychotic agent
Antispasmodic Agent; Gastric Protection Agent
Oral Contraceptives; Other (Implanted or
Injected)
Cystic Acne
Pain
Menopausal Hormone Therapy
*Ocular Products for Specific Ocular Disorders
Inflammation

Isotretinoin
Morphine
Benzalkonium Chloride, Latanoprost, Verteporfin
Ibuprofen, Ketoprofen, Acetylsalicylic Acid,
Diclofenac, *Bromfenac sodium
Acyclovir, Idoxuridine
Metoprolol, Atenolol, Lisinopril
Iodine
Herbal Supplement5, 64
Echinacea
Niacin
Kava
Alkaloids

Antiviral
Hypertension
Thyroid
Treatment
Common Cold
Anorexia, Depression, Diabetes, and Migraines
Insomnia, Anxiety, and Menopause
Anticholinergic

Table 1.2(1). Systemic and Ocular Medications and Herbal Supplements that Cause or Exacerbate Dry Eye
Disease. 5, 64-65 The table above lists some medications that contribute to dry eye disease. Most of the
medications are systemic; however, some are administered by another route. Also, the use of such
medications is indicated. A portion of this list includes medication used for other ocular disorders. Treating
disorders such as glaucoma and age-related macular degeneration can exacerbate dry eye disease. It is also
worth noting that inflammation is a common feature of evaporative dry eye disease and that systemic
medications used to treat inflammation, namely non-steroidal anti-inflammatory drug (NSAIDs), may
exacerbate the condition. Many of the NSAIDs are also in the ophthalmic formulation. *The ophthalmic
medications are indicated by this symbol.
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The use of herbal supplements may also cause or exacerbate dry eye disease. It is important to note that
although this list contains many medications and supplements, it is not exhaustive. There are many more
contributing factors. The list contains the generic names of the medications only. All items in the list were
collected from several authors.
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Sex Hormones
DED is more prevalent in women suggesting that sex hormones contribute to
developing the disease by altering the homeostasis of the ocular surface structures
responsible for average TF production.66 Although the mechanism is difficult to
elucidate, sex hormone receptor mRNA and proteins in the ocular structures suggest the
surface is susceptible to hormones' actions.66 Sex hormone receptors are expressed in
various components of the eye, and therefore, sex hormones can affect the eye's surface
by way of an inflammatory response. Sex hormones profoundly affect the immune
system, and DED is recognized as an inflammatory disease.66 The hormone receptors
expressed include androgen, estrogen, and progesterone, with androgens having the most
robust effect.67
A decrease in androgens, hormones associated with growth and reproduction in both
genders, may contribute to DED development.24, 56 Androgen receptor protein is
expressed in almost every structure throughout the ocular surface.68-69 The proteins have
a consequential effect on lipid secretion- with low androgen, quality or quantity may
become compromised. Age, congenital androgen deficiency syndrome, and anti-androgen
therapy are contributors to androgen deficiencies. In women, it is suggested that
exaggeration of low serum levels can contribute to other physiological processes and
pathological conditions that cause endocrine imbalances that antagonize the effects of
androgen.
Estrogen is one of the most ubiquitous hormones found in the female human body.70 It
is a primary hormone important for the growth, development, and maintenance of the
female reproductive system. The hormone accounts for 6% of the most widely used and
prescribed medications.70 Three endogenous estrogens play pivotal roles in the female
13

life cycle. Other forms are compounded for use as contraceptive or hormone replacement
therapy.
Estradiol is considerably efficacious compared with the other two estrogen hormones.
The hormone fluctuates from 40 pg/mL in circulation to double that amount during
menstrual cycles and drops to less than half that amount in women after menopause.70
The remaining two hormones are metabolites of estrogen.
Postmenopausal women and women with premature onset of menopause have higher
incidences of DED than premenopausal women. The occurrence may be due to estrogen
replacement therapy used to replace endogenous estrogen to normalize levels. A large
study involving 25,665 postmenopausal women showed that for every 3-year increase in
the duration of use, hormone replacement therapy increased the risk for development of
DED by 15%.71

Gender
Both biological and sociocultural factors may explain why DED incidence is higher in
women compared with men.5 Women are more likely to report health-related problems
and seek medical intervention.72 Factors that contribute to dry such as contact lens
wear,73 elective refractive surgeries74 and high medication use is seen more in women
than in men.5 A study conducted on a large female twin cohort showed that in
monozygotic and dizygotic twins, genetic factors contribute moderately to the diagnosis,
symptoms, and signs of DED.75 The heritability rate for symptoms of DED was 29%, and
this number increased to 41% with clinical diagnosis.75
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The ocular surface is sensitive to circulating sex hormone level changes66, and this
sensitivity can be altered during menstrual cycles, pregnancy, menopause, contraceptive
use, and hormone replacement therapy.76

1.2.4. SECONDARY TO OTHER DISEASES
As previously mentioned, autoimmune diseases and chronic illnesses are risk factors
for the development of DED. The lacrimal adnexa are not the primary target of the
disease. However, inflammation affecting TF function is often seen. Surgeries intended to
improve the quality of life often have unintended consequences. These conditions are
often debilitating.

Sjögren’s Syndrome
Sjögren’s syndrome is a chronic systemic77 disease of the immune system commonly
characterized by sicca symptoms, including xerostomia (20%) and keratoconjunctivitis
(5%-35%).78-79 Exocrine involvement inducing loss of salivary function and other
extraglandular manifestations,80 is associated with ADDE.77 In primary Sjögren’s
syndrome, one of two major classifications of the disease, progressive reduction of tears
are caused by autoimmune-mediated exocrinopathy.5, 81 Patients are diagnosed and
classified according to criteria proposed by the European Study Group on the
Classification of Sjögren’s syndrome based on a census report.82 Patients must present
with four of six of the criteria to be diagnosed with the disease. Two of the criteria were
based on symptoms reported by the patient. The questions accessed positive responses for
ocular symptoms such as foreign body sensation, ocular irritation lasting longer than
three months, and use of tear substitutes exceeding three times daily and oral symptoms
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including recurrent or persistent swollen parotid glands, dry mouth exceeding three
months, and use of fluids to aid in swallowing food.82 Other criteria accessed objective
clinical findings for evidence of ocular involvement and salivary involvement,
histopathology, and presence of serum autoantibodies.82 Revised rules designated scores
> 3 and included exclusion criteria.
Sjögren’s syndrome mechanism is not fully understood, but T-cell infiltration of the
lacrimal glands is suspected. The disease may also cause changes in the Meibomian
glands, as more profound destruction of glands in the upper tarsus is found when
compared with controls.83 Secondary Sjögren’s Syndrome presents secondary to other
autoimmune diseases such as lupus erythematosus (15-36%) and rheumatoid arthritis (2032%).78 Patients often complain of foreign body sensation, burning, soreness,78 and some
present with corneal ulcers.77 The overall prevalence rate for the disease, including both
forms, is 0.4% worldwide78 and increases with age.77 The occurrences for women are
more frequent at 0.11% compared with men at 0.05%.78 Women account for 90% of
Sjögren’s Syndrome patients that develop DED. Artificial tears, containing cyclosporine
A, are used to treat DED symptoms.78

Graft-versus-Host Disease
Allogenic hematopoietic stem cell transplantation (HSCT), a procedure performed
more than 25,000 times annually,84 involves infusion of stem cells into compromised
immune systems or defective bone marrow (including certain forms of cancer) to
reestablish hematological function. The stem cells are collected from the bone marrow,
peripheral blood, or umbilical cord from the patient or a donor. Unrelated84 donor
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transplanted tissue and peripheral blood products remain a significant risk factor for
graft-versus-host disease development.
Graft-versus-host disease (GVHD), a life-threatening complication,85 is a major84 and
common complication of allogeneic hematopoietic stem cell transplantations (HSCT).
GVHD affects 30-70%86 of patients undergoing allogeneic HSCT and has many clinical
presentations that involve different organs, with the first of many hallmark signs
beginning with the cutaneous membrane.87 These signs often mimic other inflammatory
skin diseases and, therefore, heavily depend on dermatologists for diagnosis and
treatment at the onset. The disease presentation involves the attack of recipient tissue
perceived as foreign by donor immune-competent T-cells.85 The aftermath is often
debilitating and carries a 15% mortality rate. In some rare cases, GVHD will develop
following autologous HSCT, blood transfusions, and organ transplants.87 Although the
disease can be fatal, some presentations are mild and are considered positive indicators of
the treatment's efficacy, which causes HSCT.87 No evidence of disease (or complete
remission) or reduced hematopoietic malignancy relapse (or partial remission) are often
the targeted prognosis.87
GVHD is classified under two major categories depending upon time and onset:88
Acute GVHD targets the skin, gastrointestinal tract, and liver.85 Chronic GVHD is often
associated with DED with mixed MGD or mixed with ADDE.
Chronic GVHD is the primary cause of death following HSCT unrelated to relapse.89
The chronic phase of the disease, which occurs 100 days after HSCT,90 often follows
acute GVHD presentation, whether progressive or quiescent.84 Protocols to treat acute
GVHD are beneficial because they can prevent the onset of the chronic phase, the disease
progression, which is challenging to treat.84 Despite enhancements in immunotherapies
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and human leukocyte antigen typing, a favorable prognosis is challenging90 because the
disease progression limits the use of these therapies.91
Patients with GVHD suffer a significant reduction in quality of life92-93 due to ocular
complications that develop. Incidences of ocular manifestations with GVHD are
severe,92-93 ranging from 60-90%, and may appear in advance of other systemic
symptoms.94-96 Disease presentation may begin with milder symptoms such as foreign
body sensation, blurred vision, erythema, and photophobia that advanced to chronic
inflammation, resulting in total Meibomian gland loss, lacrimal gland scarring, and
corneal erosion.24, 92-93 Individuals suffer from pain92-93 and, in some cases, total loss of
vision. Studies using mice have suggested that GVHD negatively affects ocular surface
glycocalyx. Ocular surface glycocalyx decreases in area and depth after transplantation,
suggesting there may be a reduction in mucins' glycosylation. The role of this structure in
the secretion and maintenance of a healthy TF is significantly diminished with GVHD.97

1.3. TEAR FORMATION AND FUNCTION
1.3.1. LACRIMAL GLAND
Lacrimal glands are bi-lobular, almond-shaped exocrine glands located on the orbits'
lateral side under the brow region [Figure 1.3(1)]. The glands' primary function is to
produce and secrete the aqueous component of the tear film layer by way of the lacrimal
ducts. Lacrimal glands produce a rich milieu of substances dissolved in water. This fluid
is commonly known as tears. Neural feedback loops drive basal tear production by the
lacrimal gland.5
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Tears
Tears are produced to nourish, lubricate, and protect the eye. Tears are enriched with
enzymes and electrolytes such as dissolved inorganic salts and glucose. Tears contain
antibodies, vitamins, microbial proteins, enzymes, glycoproteins, urea, biopolymers, and
other substances to nourish the conjunctival epithelial and goblet cell lining beneath.5
Lacrimal glands, corneal epithelial cells, and conjunctiva blood vessels contribute to
water, electrolytes, and protein to TF aqueous.21, 98
Upon nervous stimulation, the lacrimal glands secrete tears. The fluid flows from the
temporal edge of the eyelash and pools at the naso-corner of the eye. The tears then drain
into the lacrimal sac and nasolacrimal duct via the canaliculus ducts in the nasal corner of
the eye.
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Figure 1.3(1). Lacrimal Gland.99 The image above was adapted from Wrede et al. Lacrimal glands are bilobular, tear/pear/almond-shaped exocrine glands located on the lateral side of the eyes inferior to the brow
region, as seen here in the figure. The primary function of the lacrimal gland is to produce and secrete tears
to nourish and protect the ocular surface. When the lacrimal gland secretes tears, the rich aqueous solution
flows across the globe's anterior surface from the eyelash's temporal edge, depositing the tear film's middle
layer (aqueous phase). Tear drainage is achieved through the lacrimal sac and nasolacrimal duct, via the
lacrimal punctum and canal, on the eye's opposing side toward the midline of the face. The valve of Hasner
prevents the flow of air from the nose into the tear duct. Tears leave the nose, enter into the nasopharynx,
and are eventually swallowed. Tear secretion is controlled through nerve stimulation.
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1.3.2. MEIBOMIAN GLANDS AND THE MEIBUM
Meibomian Gland
Glands of the ocular adnexa produce and excrete the different constituents of the
precorneal TFL.100 One of these glands is the tubule-acinar Meibomian gland.
Meibomian
glands are large modified holocrine sebaceous glands located in the superior and inferior
palpebrae (the upper and lower eyelids) tarsal plates [Figure 1.3(2)]. The glands,
embedded in the tarsus vertically, run parallel to the eyelid margin and differ in number
between the upper and lower lids.5, 39, 101 The superior tarsal plate contains between 30-40
glands, while the inferior tarsal plate has fewer glands, about 20-30.39, 101 The Meibomian
glands contain grapelike clusters of acini connected by multiple lobules that drain into a
common duct.39 The orifice of the duct, lined with modified and keratinized
epithelium,102 opens into the lid margin100 posteriorly,31 instead of connecting with hair
follicles.31
Standard lid margins width varies from 1.5 mm in children to 2.0 mm in adults as the
lids thicken over the first 20 years of life. Lid margins are mucocutaneous structures that
follow the contours of the globe, merging with the oil-wet vascular cutaneous and lashes
anteriorly and with the tear wet avascular conjunctiva posteriorly. The two zones are
separated by the mucocutaneous junction, which runs smoothly parallel to the posterior
lid margin in youth and more irregular in the elderly. The upper lid margin faces
downward and forwards to the lower lid margin; margins are tilted upward and forward
in the lower lid.
The standard Meibomian gland orifices present in a parallel, irregular arrangement
along standard eyelid margins in youth. The orifices contain opaque and darker
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translucent cuffs arranged in concentric zones around a central punctum. The superficial
cuff most likely represents the Riolan’s muscle, the muscle responsible for expelling the
Meibomian gland secretion onto the lid margin, moving inward,
With aging, these anatomical features are less pronounced. The opacity of the mucosa
becomes obscured by increasing vascularization of the conjunctiva. The orifices also
become distorted over time as thinning, narrowing, and plugging of the orifices increase
in frequency over time from glandular loss associated with hyper-keratinization of the
ducts and atrophy of acini. These changes result in telangiectasia, blepharitis,
lipogranulomatosis inflammation, and possibly chalazia over time. These conditions
become apparent after age 50.
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Figure 1.3(2). Meibomian Glands.103 Meibomian glands, pictured in the image above, are large modified
holocrine sebaceous glands that produce an oily secretion called meibum. The glands are located in the
superior and inferior palpebrae (the upper and lower eyelids) and are embedded in the tarsal plates. The
glands, embedded in the tarsus vertically, run parallel to the eyelid margin and differ in number between
the upper and lower eyelids. The Meibomian glands above can easily be seen due to obstruction, as seen in
severe Meibomian gland dysfunction.
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Meibum
The primary function of the Meibomian gland is to produce a secretory product called
meibum. The Meibomian gland contains acinar cells that actively produce and secrete
meibum31, mostly made up of lipids that comprise the TF's oily hydrophobic layer. This
oil layer is known as the superficial layer and the TFLL. It is widely believed that the
lipid in these layers functions to prevent tears from spilling out of the eye.5 The lipids
enhance the TFs’ spreading to produce a smooth optical surface at the lipid/air interface
that will allow the lid to glide over during a blink easily.39 The smooth coating enhances
the TF stability. In addition to the functions mentioned earlier, the Meibomian lipids are
thought to help protect and nourish the eye during sleep by sealing lid margins.39
In the Meibomian gland, meibocytes contain acinar cells. In the acinus, the
morphology, ultrastructure, and position of the acinar cells vary according to
differentiation stages.100 Smaller undifferentiated cells are located about the perimeter,
the large mature cells are situated in the center of the acinus, and cells in the intermediate
stages are wedged between undifferentiated and fully differentiated cells. During
differentiation, accelerated lipogenesis, the tropic actions of androgen, stimulate acinar
cells to enlarge as they mature. The cell contours become irregular, the nucleus increase
in size and become spherical, and the cytoplasm interdigitates neighboring acinar cells.
Mitochondria vary in size and shape and are randomly dispersed throughout the
cytoplasm, as are free ribosomes. The rough endoplasmic reticulum is scant and serves a
minor role. Instead, the smooth endoplasmic reticulum and numerous Golgi apparatus
complexes become the more prominent organelles as these organelles inhabit large
amounts of the cytoplasm and populate the remaining space with a multitudinous array of
lipid droplets. As lipid droplets fuse, the immense size of the droplet compresses the
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nucleus. These cells eventually lyse, and their cellular contents are delivered as meibum
to the marginal eyelid reservoir [Figure 1.3(3)].
The immense contribution to the Meibomian gland secretion [Figure 1.3(4)] comes
from non-polar lipids, wax esters (WE) (30-50% of constituents),104-106 cholesterol esters
(CE) (30-45% of constituents),107-109 glycerides (1-9%), and the remainder is non-lipid
components110 such as salt and proteins. The melting range for meibum is 19°C to
32°C.111 The melting range of the lipid mixture is altered by branched and unsaturated
fatty acids and alcohols.112 The meibum constituents may include a tiny amount of polar
lipids that function to stabilize the aqueous lipid interface by binding lipocalins and other
lipophilic proteins found in tears.113
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Figure 1.3(3). Meibum and the Meibomian Gland. The image above is of the ocular adnexa. Starting from
the left and moving right, the Meibomian gland, seen as a yellow structure within the eyelid, is part of the
ocular adnexa. The Meibomian gland contains tubule acinar cells. Acinar cells enlarge as they mature.
When these cells reach full maturity, they can no longer support the large quantity of cellular material.
They lyse; their cellular contents are expressed from the Meibomian gland and delivered as meibum to the
marginal eyelid reservoir. The figure shows the eyelid margin with lipid deposit (middle). The meibum will
eventually get deposited onto the ocular surface and spread by blinking actions, indicated by the figures on
the right. The lid will move in a downward stroke to contact the lower lid. As the eyelid moves upward to
return to its original position, meibum is deposited onto the ocular surface.
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Figure 1.3(4). Meibum Components. The image above shows some of the constituents that make up
meibum. Cholesterol and wax esters account for the large majority, collectively representing 71% of
meibum constituents. Meibum lipids contribute as much as 75% of the lipids found in the tear film lipid
layer. Non-lipid components (20%) and glycerides (9%) account for the remaining meibum constituents.
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1.4. OCULAR SURFACE ANATOMY
The structures that make up the eye's external aspect include the ocular surface and the
ocular adnexa.5 The ocular surface includes the cornea, conjunctiva, and the structure the
nourishes and lubricates the eye, the TF.5 The structures that produce and contribute
constituents of the TF are components of the ocular adnexa. These components include
the lacrimal unit and Meibomian glands.5 The Meibomian glands are found in the eyelids,
which are also components of the ocular adnexa. Other structures are the orbits,
connecting muscles, and connecting nerves.

1.4.1. THE CORNEA, SCLERA, AND CONJUNCTIVA
The cornea is a thin, transparent, avascular dome-shaped structure made up of 5-7
layers114 of squamous epithelial cells some 50 to 100µm thick115 and supported
posteriorly by a basement membrane and Bowman’s layer.116 The cornea's epithelial cells
are directly exposed to the external environment, and therefore, contain tight junction117
or zonulae occludents115, making it highly impermeable to resist changes to the internal
milieu. The cornea is both a structural barrier and a barrier against fluid loss and
functions in the first line of defense against pathogens and other foreign substances. The
epithelial cells also contribute mucin to the glycocalyx, anchor the TF by way of its
microvilli, and contain terminal neurons that control lacrimal gland function.117
The cornea, the eye's anterior surface, provides two-thirds114 of the eye's total
refractive power and is responsible for protecting the eye's surface from ultraviolet light.
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Corneal tissue is connected to the scleral tissue by way of a complex structure known

as the limbus.118 Conjunctival goblet cells contribute mucin that interacts with the corneal
glycocalyx to facilitate the TF's spreading during a blink cycle.114
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1.4.2. TEAR FILM LAYER
The tear film layer (TFL) is divided into three layers: mucin, aqueous, and lipid
[Figure 1.4(1)]. Aqueous fluid produced by the lacrimal gland contributes to the aqueous
phase and contains proteins, some of which exhibit antibacterial properties. Tears flow
from the eyelash's temporal edge to the nasal corner, where they reach lacrimal ducts. On
the surface of the TFL is a 0.1 µm thick TFLL covering the air/tear surface.5,
Mucin Layer
The mucin layer is the deepest or innermost of the three layers of the TF. It is this layer
that is in direct contact with the epithelial surface. It is about 0.8 µm thick and bound to
cells by glycocalyx. The mucin in this TFL is produced by conjunctival and corneal
goblet cells and epithelial cells, respectively. It contributes to the eye's smooth surface by
following the epithelial surface's contours and filling irregularities on the corneal surface.
The mucin layer maintains surface health through immune surveillance and debris
removal- The mucin contains antibiotic properties and produces proteins.
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Figure 1.4(1). Human Tear Film. The image above is a schematic of the tear film layer adapted from
slideshare.net and D. Borchman.119 The Tear Film Layer can be divided into three segments/phases; mucin,
aqueous, and lipid. Mucin: Starting from the bottom of the figure and moving up, the mucin layer is the tear
film's deepest or most interior layer. It is closest to the epithelial surface and measures approximately 0.8
µm. Mucin is bound to cells by glycocalyx and follows the epithelial surface's contours, filling
irregularities of the cornea. Aqueous: The aqueous layer is sometimes referred to as the water layer. It is the
central layer and accounts for the most significant tear film percentage (approximately 90%), measuring 3
µm. The aqueous fluid, known as tears, is produced by the lacrimal gland and contributes to this layer of
proteins, some of which exhibit antibacterial properties. Lipid: The lipid layer is the superficial layer. This
0.1 µm tear film lipid layer covers the surface at the air/tear film interface (the focus of this research) and is
presumed to spread across as a thin film that reduces the evaporation of tears and prevents overflow tears at
the lid margin.
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Aqueous Layer
The aqueous layer, the middle layer of the TF, and sometimes referred to as the water
layer, is in contact with the mucin layer below and the lipid phase above. Aqueous fluid
produced by the lacrimal gland contributes to this phase of the TF. This layer is primarily
secreted water and contains proteins, some of which exhibit antibacterial properties. The
aqueous tear accounts for the largest percentage, approximately 90%, of the TF and
measures about 8 µm in depth. This layer functions to hydrate the eye's surface to prevent
desiccation, as this may result in severe consequences, including infection and blindness.

Tear Film Lipid Layer
The TFLL, on the outermost surface of tears at the air/TF interface, is a 0.1µm thick
layer of oil.120-121 TFL is the focus of this research. The lipid layer is composed of oily
secretions from several sources that include sebaceous and Meibomian glands. The
sebaceous glands contribute sebum;122 however, the primary source of the TFLL lipid,
~65% to ~90%, is produced by the Meibomian glands.109-110, 123-124
It has been suggested that the function of the TFLL is to lower the surface tension and
oppose the outward flow of aqueous tear in an open eye at the lid margin. The TFLL is
essential because it is considered a significant factor in TF stability and tear spreading.
In addition to meibum, other constituents of the TFLL include small amounts of
sebum from sebaceous glands,122 polar lipids, and non-lipid components.110, 125

1.5. TEAR FILM FUNCTION
TFL functions to keep the cornea hydrated and serves as a protective antibacterial
layer. It is also a source of oxygen and lysozymes.114 A full blink consists of the closing
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and reopening of the eye. During a blink, the superior palpebra (commonly known as the
superior or upper eyelid) will move in a downward motion to close. The eyelid lowers to
contact the inferior palpebra (commonly known as the inferior or lower eyelid). The eye
then reopens as the superior palpebra returns to its original position. When the upper
eyelid comes in contact with the lower eyelid during a blink, the TFLL is swept off. As
this occurs, the contraction of the orbicularis oculi and Riolan’s muscles [Figure 1.5(1),
on the left in brown] contract and triggers the release of meibum [Figure 1.5(1), the
yellow secretion] from the Meibomian gland [Figure 1.5(1), pink structure with yellow
inserts]. The secretions are deposited unto the lid margin. The Gland of Zeiss [uniglobular sebaceous gland pictured in [Figure 1.5(1), blue] is located on the eyelid margin
and produces and secretes sebum to services the eyelash. Next to the eyelash base are
modified apocrine sweat glands, known as Gland of Moll [red structure [Figure 1.5(1)].
These glands work with the Gland of Zeiss to contribute sebum. Meibum and sebum mix
to form what will become the TFLL. Other structures also pictured in Figure 1.5(1)
include the mucocutaneous junction- the ocular mucosa area that transitions into the skin;
conjunctival wiper region- superior palpebral marginal conjunctiva in contact with the
ocular surface; and the cornea. When the Meibomian glands are triggered to release
meibum, the lipid is expressed and deposited onto the lid margin. The superior eyelid
movement to its original position during a blink causes a new lipid film to deposit and
spread onto the tear meniscus and cornea. The TF with the new lipid layer must remain
stable for some time to maintain homeostasis; If this does not occur, DED results.
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Tear Film Stability
It is believed that lipids contribute to TF stability. TF stability is directly related to
TBUT. When the eye remains open for more than 5-30 seconds, tears evaporate, and the
cornea's dry areas are observed, and TF breakup ensues, triggering chemical and
temperature sensors on the cornea. We learn to blink before this happens. Blinking
restores the TF and aqueous layer to cover and hydrate the cornea uniformly.
In people with unstable TFs, TBUT is reduced. These individuals must blink more
often to replace the TF because tears break up quickly, the tears are continually
evaporating, and the eye remains dry. The relationship between TF stability and TBUT is
shown in Figure 1.5(2). TF stability is measured by practitioners using TBUT.
Fluorescein is instilled into the patient's TF to observe and measure TBUT. The patient is
then asked not to blink while the TF is observed under cobalt blue illumination.
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Figure 1.5(1). Tear Film Lipid Layer.122 During a blink, the orbicularis and Riolan’s muscles (brown
structures within the eyelid) contract. When this occurs, the muscles press against the gland of Zeiss (blue
structure) and gland of Moll (red structure), which are sebaceous glands, causing these glands to express
sebum (red). Additionally, these muscles' contraction causes Meibomian glands (pink and yellow structure)
to express meibum (yellow). The secretions are deposited onto the eyelid margin reservoir (yellow and
red). Movement of the eyelid upward to its original position deposits and spreads lipids onto the ocular
surface (cornea, represented as the tan structure in the figure). The lipids become the superior layer of the
tear film (yellow with red specs). This figure shows aqueous tears (blue substance layering the cornea), the
conjunctival wiper region and mucocutaneous junction (green), the epidermis (salmon-colored striped
region), and a hair follicle (black).
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Figure 1.5(2). Tear Film Stability.119 Tear film stability, which is directly related to tear breakup time, is
highest in babies. Tear breakup time decreases rapidly with age beginning at age six months and moving
into twenty years of age. Adults, especially older adults, have unstable tear films and significantly
decreased tear breakup times. Tear film instability is exacerbated with the disease. In the graph above,
patients with dry eye disease related to Meibomian gland dysfunction (+MGD) have the most unstable tear
films. Patients diagnosed with dry eye disease unrelated to Meibomian gland dysfunction have significantly
less stable tear films compared with infants and adults (-MGD). The numbers in parenthesis above the bars
in the graph represent the number of patients in each study cohort.
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TF stability decreases rapidly between the ages of 6 months and 20 years of age.111 TF
stability is directly correlated with TBUT. Babies have the most fixed TF126 and higher
TBUT.127 TBUT and tear stability of adults are lower than babies.122, 127 With DED and
other chronic illnesses, TF stability and TBUT are approximately half that of adults with
healthy TFs. TF stability is a little lower for EDED compared with ADDE. People who
suffer from DED are constantly blinking because their TFs are unstable, they have rapid
TBUT, and therefore, their TFs are rapidly turning over.

1.6. MEDICAL MANAGEMENT OF DED
Physicians can prescribe treatment to reduce DED's signs and symptoms, but a cure
does not exist.58 Physicians must eliminate causative factors and use an individualized
approach to treating patients.58 It is crucial to monitor the protocol to assess its efficacy.
Some treatments may contribute to DED rather than attenuate it. The possible effects of
systemic and ocular medication must be considered.5 Modifications should be made to
environmental causative factors such as humidity, cigarette smoking, and electronic
screen time to reduce irritability. Structures that may increase irritability, such as swollen
and inflamed eyelids, should be sought and addressed before applying treatments.
It is also essential to consider both significant DED forms as patients are diagnosed,
treated, and monitored. Consideration of significant forms is important because risk
factors, causes, and treatment may vary with the form and subtypes of DED. Although
DED cannot be cured, three basic therapeutic strategies address the signs and symptoms.5
The aim is to increase tear volume, decrease ocular osmolarity, and augment lipid content
to improve the TF surface by restoring homeostasis. The three therapeutic strategies
should address the various disease components to improve the TFL and be modified and
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adapted to how the disease manifests.5 Alterations in osmolarity instigate inflammation
and disrupt the quality and quantity of tears.128

1.6.1. INCREASING TEAR VOLUME
Artificial Tears
DED results from defects in tear production and hyperosmolarity, causing a
homeostatic imbalance of the ocular TF. The result is often burning and tearing, which
develops into chronic inflammation. The inflammatory process exacerbates the condition
in extreme cases results in irreversible damage and impaired vision. To combat low tear
production effects, practitioners will often prescribe artificial tears (AT)129 as first-line
therapy.26, 45 The Federal Drug Administration regulates. AT include specific demulcents
and emollients to lubricate mucous membranes and soften tissues on the corneal surface.
The demulcents are lubricants that are usually water-soluble polymers.130 They protect
the eye against dryness and irritation.130 Emollients are usually fats or oils that
temporarily relieve dry eye symptoms.130 Demulcents are prescribed for aqueous ADDE.
Emollients are used to treat EDED and MGD. A wide range of preparations can be made
using either component based on the type of disease and severity that range from lowviscous solutions to high-viscous ointments.
The efficacy of AT therapy has been followed by observing lid-parallel conjunctiva
folds (LIPCOF) in a straight gaze using a slit-lamp.23 LIPCOF results from friction
between the lid margin and conjunctiva, and grading has a sensitivity of 84.4% and
specificity of 90%.131
AT often contains preservatives to protect the product from bacterial contamination.
Buffers in AT maintain the TF's physiologic pH.132-133 Benzalkonium chloride is a
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preservative commonly used in eye drops to prevent microbial growth; however, it
aggravates DED.22 The preservative is known to induce toxicity, damage ocular surface
epithelial cells and nerves, and disrupt TF stability. Studies have also shown that high
concentrations and frequent dosing compromise the TF's morphology by impeding lipid
spreading. There are options to using preservatives such as unit dose applicators,
disappearing preservatives, and preservative-free formulations, but this is not without
consequence. Unit dose applicators and preservative-free products can be costly
and difficult to obtain, while disappearing preservatives still can negatively affect the
ocular surface.134
Many over-the-counter AT often does not contain buffers and preservatives.135 The
efficacy of most over-the-counter AT are similar, safe, and valuable.136 Small randomized
studies have shown that overall, the products reduce surface stress, thus improve contrast
sensitivity, optical quality,23, and the quality of life.

Autologous Serums
Autologous serums are made from the patients’ blood. They contain additional
components not found in AT, such as growth factors and anti-inflammatory agents. In
randomized controlled studies, autologous serums are shown to improve DED symptoms
and TF stability.23, 137 Although autologous serums have many biochemical properties
similar to components found in tears, several factors limit their use, such as production
protocols, legal requirements, frequent contamination, infectious disease, storage life, and
overall cost.
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Punctal Occlusion
Punctal occlusions are performed on tear duct orifices to block the punctum,138 the
tear duct's opening. They terminate the pathway for tear clearance and drainage,139
increasing the number of tears in patients with moderate to severe DED. 11 The procedure
can produce temporary occlusion or permanent occlusion by installing plugs, adhesive, or
surgical occlusion by heat and thermal cauterization. Punctal occlusion is beneficial
under various conditions, including ADDE and DED associated with contact lens use,
refractive surgeries, secondary to autoimmune disease, and systemic medication use.27,
140-146

Reduced TF production and rapid TBUT are likely under these conditions.

Occlusion using Devices
Punctal plugs are commonly used for punctum occlusion. Several plug options are
used in the procedure, including absorbable and non-absorbable devices,134 installed
superficially or deeper within structures. Absorbable plugs, usually collagen,134 or
polymer-based,139 and adhesives are temporarily installed to assess the treatment's
efficacy.134 Non-absorbable plugs are devices placed for an indefinite time,139 or used for
permanent occlusion, and come in a wide variety of products and are often siliconebased,134, or labile polymer.139 Silicone plugs are sometimes used to evaluate epiphora
before permanent occlusion.147-148 The varying designs allow for different fitting levels
and can partially or entirely occlude the punctum.134

Surgical Occlusion
Sometimes complications arise with the use of punctal plugs, including but not limited
to extrusion (57.4%),149 canalicular migration, infection,150-151 puncta enlargement, and
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tumors, although rare.152 Under these circumstances, surgical punctum occlusion is an
alternative for permanent occlusion. Several procedures can be employed to obtain
permanent occlusion, including tissue graft,153 extirpations,154 ligations,155 suturing,156
and partial157 laser139, and the gland's thermal cauterization.157-158 With cauterization, few
complications are reported, and comparative studies have demonstrated improvement in
symptoms, TBUT, other diagnostic scores, cornea staining, and TF osmolarity.139
Although punctal occlusion has its success, there are also drawbacks. Studies
demonstrating efficacy with positive results are limited to level 2 studies. Level 1 studies
are few, if they exist at all.134 The rate of recanalization depends on the technique and
inflammatory responses.158 The most successful outcomes are seen when punctal
occlusion is used in conjunction with other DED interventions.134, 159

1.6.2. TOPICAL ANTI-INFLAMMATORY THERAPY TO DECREASE OCULAR
OSMOLARITY
Inflammation
Disruption of the TF resulting from insufficient tear secretion or hyperevaporation of
tears creates stress, thus activating the innate immune system.24 This causes severe
inflammation to the ocular surface. Damage to epithelial cells exposes cornea nerves,
causes neurogenic stress, and exacerbates the innate response.24, 160-161 Inflammation is
also seen within the lacrimal gland.162 In turn, pro-inflammatory events reverberate the
immune response promoting tissue damage.162
Data supporting these events comes from in vitro cell-based models, in vivo animal
models, and clinical studies. Human ocular epithelial cells were exposed to hyperosmotic
induced environments in vitro. The simulations give rise to factors that promote DED and
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set off related inflammatory events that increase human leukocyte antigen (HLA).162
Mice models demonstrate inflammation and tissue damage that resemble humans in
vivo.162 Additionally, key inflammatory effectors such as T-cells under stress-induced
environmental conditions, have shown that experimental models have uncovered key
inflammatory effectors such as T-cells and exposed antigen-presenting cell163
involvement in autoimmune initiation development of DED.139
Thanks to biomarkers and experimental techniques, TF osmolarity can be evaluated
clinically for DED.164 Hyperosmolarity, an indirect sign of inflammation,162 is a critical
factor in inducing surface inflammation and exacerbates the immune response by
diminishing tear production.45, 165 Decreased tear production augments hypoosmolarity.45, 165 Studies have shown matrix metalloproteinase-9,166-167 interferon,163 and
HLA-DR168 are potential biomarkers for DED, as each component has been correlated
with the disease’s inflammatory process and tear hyperosmolarity.162 High throughput
screenings of cytokine output in mice suggest that blocking its production may attenuate
DED's inflammatory response. Lastly, imaging techniques such as in vivo confocal
microscopy (IVCM)169 and anterior segment optical coherence tomography170-171 are
helpful for quantitative, qualitative, or quantitative/qualitative analysis of ocular surface
structures in diagnosing DED. IVCM can diagnose DED-associated inflammation.

Corticosteroids
Although not explicitly,162 corticosteroids are used topically to treat inflammatory
events initiated by DED. Randomized control studies have shown marked improvement
of patients with moderate to severe symptoms,172-173, and a 57% complete regression rate
after two weeks of treatment.23 Studies have shown that treatment involving
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corticosteroids combined with other therapies is more effective than using selected
therapies alone. For example, a study involving 64 subjects found loteprednol to be more
effective than the vehicle after two weeks of treatment in subsets of moderate
inflammation subjects.173 Another study found artificial tears to be more effective when
used in combination with fluorometholone. Punctual plugs, a therapy used to retain
natural tears, alone were almost 60% less effective at reducing ocular irritation and
inflammation than the use of the treatment with methylprednisolone. Improvements are
also seen with methylprednisolone use alone- In murine DED, the anti-inflammatory
medication preserves apical cornea barrier function.174

Cyclosporine
Cyclosporine A is a fungal derivative that possesses immunosuppressive,139 antiinflammatory, and anti-metabolite properties. Treatment with topical cyclosporine A
attenuates inflammation,175-176 improves ocular disturbances,177-179 reduces elevated tear
osmolarity129, and prevents disease progression.180 Cyclosporine A also increases tear
production134 by suppressing the immune system to terminate T-cell activation181 and
possibly releases sympathetic neurotransmitters.182 Significant improvements are also
seen in symptoms, TBUT, and ocular surface staining when cyclosporine is paired with
artificial tears.183-184 Amelioration of DED with cyclosporine A185 treatment supports the
idea that inflammatory processes contribute to chronic DED.186
The FDA approved cyclosporine drops in 2003134 for patients with moderate to severe
DED. Cyclosporine treatment for DED improved tear production with the twice-daily
installation.139 Application exceeding the twice-daily dosage showed significant
improvement in patients with severe DED.187 However, a twice-daily dose is
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recommended,188 with a once-daily maintenance dose after subsided symptoms.139
Maintenance doses suppress inflammation after one year.189
DED's cyclosporine treatment's success rates depend on the signs, symptoms, and
grade scales measured. Cyclosporine A is not effective at treating DED when the disease
results from surgery and contact lens wear or is secondary to other diseases.134 Drug
intolerance evident from burning and stinging183, 185, 190 are the most common, and a
clinician best determines its use.

Omega 3 Fatty Acids
A randomized controlled clinical study involving 26 patients with ocular surface
inflammation showed that omega-3-fatty acid given to patients for 45 days aided in
blocking pro-inflammatory eicosanoid actions to reduce surface staining inflammation in
patients with DED.186 In another study, patients were given both omega-3-fatty acid
supplementation forms (fish oil and krill oil) over 90 days that reduced DED signs and
symptoms and improved TF stability.191
A host of mechanisms involving chemical mediators are responsible for
inflammation.192 Dietary supplementation of omega-3-fatty acid, an essential fatty acid,
maintains homeostasis on the ocular surface.23 Resolvins and protectins are two
mediators synthesized from omega-3-fatty acids with dual anti-inflammatory and proresolution actions and can help control inflammation in diseases192, including DED.
Resolution of inflammation is an active biochemical process,193-194 distinct of the antiinflammatory process,195 involving chemical mediators that help maintain homeostasis193,
195-197

through the restoration of inflamed tissue.192 Resolvin and protectins work in

concert to initiate and shift the onset of response to reduce neutrophils' presence.192 The
43

combined pro-resolution actions stimulate apoptotic neutrophils' removal and reduce
phagocyte presences in lymph nodes and the spleen.192
While results, such as those previously mentioned, show hope for the dietary
supplements and its effect on restoring homeostasis to the TF, other studies are not so
promising. Comparisons from other investigators have shown that the evidence in support
of omega-3 is not substantial.198 A systemic review of clinical trials conducted between
2005-2015 using 2591 subjects in 15 independent randomized controlled trials showed
disparities in results.198 The study aimed to assess the efficacy of omega-3 and omega-6
polyunsaturated fatty acids in DED treatment.198 The rationale of these studies was that
adding omega-3 supplements would create a balance that resulted in anti-inflammatory
status in organisms. In western society, the ratio of omega-3 to omega-6 is commonly
1:16, with omega-6 promoting pro-inflammatory responses.198 Omega-3 consumption
would balance the ratio and decrease the production of pro-inflammatory mediators. In
these trials, varying ratios of omega-3 and omega-6 were used as a stand-alone treatment
for DED.198 Although some favorable results were seen in the subjective Ocular Surface
Disease Index (OSDI) and DED Severity questionnaires and objective measurements of
TBUT and Schirmer’s scores, the evidence was not enough to recommend the
supplements as a stand-alone treatment of DED in practice.198
In evaluating objective improvements in the trials, 6 of 15 studies did not show
improvements with tear breakup times, and 11 of 15 studies did not show improvements
with Schirmer’s scores. As for symptoms, the four studies using the DED Questionnaire
and Scoring System showed improvements, but only 50% of the studies showed
statistically significant improvements in OSDI scores. The remaining studies saw
improvements in symptoms; however, the evaluations employed were not validated. It is
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also notable to point out that preparations of omega-3 and omega-6 combinations varied
among studies. A study that exclusively used omega-6 did not find any significant
differences in results.199 The DED Syndrome Preferred Practice Pattern® panel found
that the efficacy of omega-3-fatty acid use among patients with severe to moderate DED
is challenging to ascertain because standards for formulation vary.47 One study failed to
demonstrate improvements in symptoms following a twelve-month trial of 3000 mg daily
oral doses of the supplement.200 Significant changes were not demonstrated between the
supplement and placebo groups.200
The authors found diversity among age, gender, and dosage parameters between
studies. Although studies have shown that TF stability decreases with age, some studies
were performed in a younger population.198 Although DED is more prevalent in women
and a higher ratio of women is appropriate, some studies included women exclusively,
and other studies included subjects with Sjogren's syndrome.198 The characteristic
differences and asymmetric distribution of women could obscure results and account for
disparities.198 A decline witnessed in parameters involving studies with higher ratios of
omega-6,199, 201-202 should come as no surprise as omega-6 has been associated with
higher incidences of inflammation and DED.22, 203
It is important to note that omega-3 fatty acids may cause gastrointestinal side effects,
further suppress the immune system in patients on immunotherapy, and increase bleeding
risk, especially in conjunction with anticoagulants.22 Other uses204 of essential fatty
acids205-206 include the restoration of thin or irregular lipid layers to relieve symptoms.207208
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Vitamin A
Vitamin A is essential to vision, and it may improve DED symptoms. In the retina, the
vitamin A derivative cis-retinal is needed for rod cell formation and visual
transduction.2,4-7 Vitamin A is a class of fat-soluble retinoids that include retinol, retinal,
and retinyl esters. Humans cannot be synthesized Vitamin A and must obtain it from the
diet in two forms (provitamin A and preformed vitamin A) through fortified cereals,
eggs, dairy, meat (liver),209 fish, and various fruits and vegetables (carotene).210 Vitamin
A has many roles essential to maintaining vision, especially night vision.22 Deficiencies
result in night blindness,210, and eventual retinal cell damage. Vitamin A is responsible
for ocular cell formation and maintenance.
Vitamin A exists in tears released from the lacrimal gland,211 supporting normal
proliferation, differentiation, and the function of corneal epithelial and conjunctival
goblet cells.212-213 Thus, vitamin A plays a role in mucin production and TF function.
Deficient cell density and mucin production are hallmark signs of goblet cell loss.139
Vitamin A deficiency may directly cause or contribute to goblet cell deficiency.139
Findings from studies involving rabbits214 and rats215 show that vitamin A deficiency
prompts goblet cell loss.216-217 Consequently, the mucin deficit reduces tear retention,
which accelerates TF breakup.212, 218-219 Tear break up times less than 10 seconds is an
indicator of DED.220-221 The damage to ocular surface epithelial cells caused by
desiccating stress results in aggravation of DED.212
Retinol palmitate, a derivative of vitamin A222, is recognized223 and is widely used to
treat dye.212 High oral doses of vitamin A restores goblet cell density and heals corneal
injury and damage.224 Retinyl palmitate (0.05% drops; q.4h) significantly improved DED
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over three months compared with preservative-free artificial tears alone.139 Common
adverse events included ocular stinging and burning.139
Retinol palmitate stimulated mucin production in cultured conjunctiva tissue225 and
could heal conjunctival cell damage and recover goblet cells.214, 226 Retinoic acid
ointment heals corneal epithelial injury.227 In a rabbit model in which DED was induced
by removing the lacrimal gland to replicate this study, retinol palmitate improved ocular
surface epithelial cell damage and recovered goblet cells prompting mucin production.212
The study did not ascertain the efficacy and safety for human use.212
Vitamin A also impacts acinar cells of the lacrimal unit220, 224 the amount of mucin in
the TF and the anti-inflammatory properties of carotenoids attenuate cellular damage.

1.6.3. AUGMENTING LIPID CONTENT
Temperature Treatment
Prevailing therapies for the treatment of MGD commonly include the use of heat.
Meibum becomes fluid between 28°C to 32°C. However, meibum from donors with
MGD become fluid above 35° C.228 With higher melting points, meibum is stiff, which
blocks and reduces lipid flow from glands. The lipids must be fluid enough to exit the
gland, deliver to the tear meniscus, and spread across the TF surface. To ameliorate
conditions to improve lipid flow and restore homeostasis, heating apparatus, compresses,
lid warmers, and massage have been used as a treatment in clinical studies.23 Raising
eyelid temperatures above physiologic temperature causes meibum to become more fluid,
unblocking Meibomian glands, allowing more lipid delivery to the ocular surface. Eyelid
warmers are often used as heat treatment to liquefy and release the meibum to the tear
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meniscus.229 Heat treatment provides immediate relief of symptoms and improves signs
of DED such as tear breakup, at safe temperatures.10, 230-234
A randomized study involving 25 patients to investigate the efficacy of an ‘MGDRx
Eyebag’ warming device found that the device improved efficacy scores and ocular
comfort without affecting visual acuity after two weeks of use (P < 0.05).235
During heat treatment, the heat transfer delivers a significant amount of heat to the
cornea, reaching peak temperatures within minutes.236 That is why it is important to note
that too high of a temperature237 could result in temporary or permanent injury to the
outer surface of the eyelid, as well as ocular surface structures.236, 238-239 One study
suggests that optimal temperatures to transition meibum from a less disordered to the
very disordered state to improve flow, is 36°C and 40°C for 66% and 90% disorder with
normal meibum respectively.237 Once optimum temperature range is achieved,
disordering plateaus, as large increases in temperatures above range, only cause minimal
lipid order changes.237 To reach these temperatures to obtain 66% and 90% disorder,
external heat application must range between 41°C to 45°C. However, this differs
significantly with MGD and HSCT. Although with MGD, only an average temperature of
38.5°C needs to be applied to reach the 66% lipid disorder for normal meibum, the heat
applied must be at a minimum of 43.5°C to reach 90% optimal temperatures, external
heat application must exceed this temperature.237 With hematopoietic stem cell HSCT,
for 66% and 90% disordering, optimal temperatures must be 42°C and 52°C,
respectively;237 That increases surface temperatures to 47° and 57°C.237 The study
concludes that with the treatment of severe DED cases, the need for high temperatures
needed to achieve optimal levels of the disorder may limit the success of heat therapy.237
One must bear in mind that with disease transition, temperatures are higher, and to reach
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transition temperatures, surface heat must increase by 5°C240 to warm internal structures
to desired temperatures.

iLux®
This section reviews a randomized, open-labeled, controlled, multicenter clinical trial
that measured the iLux® MGD system's efficacy compared to the LipiFlow® device.204
The iLux® MGD is a handheld DED treatment device that incorporates compressions
and heat to safely, and effectively204 unblock Meibomian glands. The device warms the
eyelid for 90 seconds to melt the meibum lipid; then, it is expressed with gentle
compression. Silicone pads fixed with temperature sensors measure palpebral surfaces'
temperature to maintain an eyelid temperature between 38°C and 42°C, Figure 1.6(1).
Safety mechanisms terminate heat application when surface temperatures exceed 44°C.204
At eight clinical sites, 172 subjects were randomly grouped into cohorts to receive
bilateral treatment using either the iLux® MGD or LipiFlow® systems. Both eyes were
treated on the same day. Masked clinicians measured the signs of DED, including the
MGD score241 and TBUT, and they measured symptoms using the OSDI242 Signs and
symptoms were measured from baseline to 4 weeks. Adverse events were monitored
during and after treatment for up to one hour. Adverse events measured included primary
device-related adverse events and secondary events, including discomfort, pain, baseline
changes in ocular staining, intraocular pressure (OPI), and best spectacle-corrected visual
acuity (BSCVA).
Signs and symptoms of DED improved in both treatment groups. MGS and TBUT
were significantly higher than the established criteria for clinical relevance, with no
significant differences seen between the two treatment groups. OSDI scores were not
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significantly different for the two devices; improvements were similar overall and after
four weeks. Investigators did not report device-related adverse events for either device;
However, there were four procedure-related events involving the iLux® MGD. All events
were resolved in 10 minutes to 2 weeks, with no secondary endpoint changes.
Pain scores were reduced from baseline equally in both groups and did not differ
between devices after four weeks. However, discomfort scores favored the iLux® MGD,
although scores in both groups showed significant improvements with discomfort. Ocular
staining improved relative to baseline at all follow-up visits, but there were no significant
differences between devices. BSCVA improved relative to baseline at four weeks, with
no differences between devices. Significant differences in IOP were not observed.
In conclusion, the two systems were equally safe and effective at improving ocular
surface conditions. The results support the notion that blocked Meibomian glands disrupt
the TF's normal function, and when the Meibomian glands are unblocked, normal
function is restored. Meibomian gland blockage may facilitate inflammation, and the
quality of the tear-film lipid-layer becomes deranged. Unblocking the Meibomian glands
restores the quality of the TF lipid, restoring TF function. Some scientists believe reincorporating lipids into the TF can improve aqueous retention.204 However, recent
studies show that evaporation does not change with tear lipids.243
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Figure 1.6(1). iLux® MGD Treatment System.204 The instrument pictured above is an iLux® MGD system
used to safely deliver compressions and heat to the upper and lower eyelids of patients undergoing
Meibomian gland dysfunction (MGD) treatment.204 The display shows the eyelid temperature, as well as
the melt time in seconds for meibum. Temperature sensors incased in silicon pads help to maintain the
temperature between 38°C and 42°C. The device is equipped with safety mechanism that will terminate
heat application if temperatures exceed 42°C.204

1.7. CURRENT CHALLENGES RELATED TO TREATING DED
Visual impairment is a common feature of DED with a vision that may be dull and
blurry.24, 58, 244 2, 245-246 Visual impairment is quantified by measuring a loss in visual
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acuity related to reductions in the quality and quantity of tears.247 Fluctuations in visual
acuity is physiological and may be exacerbated by environmental triggers. Fluctuating
vision poses a problem with clinicians, as patients experiencing blurry vision due to DED
may have a typical vision at the time of examination. When symptoms are not present at
the time of examination, treating patients is complicated.

Problems with Evaluations
When DED is suspected, diagnostic tests are needed to rule out infections and
allergies which require different medical interventions. The most widely used test for
determining DED is a questionnaire, which documents the timing and duration of
symptoms, the location and environmental conditions at the time of onset, history and
present illnesses, and medication.24,248 The OSDI questionnaire is the most popular. A
limitation of the OSDI test is that it is not used to evaluate holistic effects. Other
questionnaires assess the patient's general health, while some assess the contribution of
other eye diseases. The other questionnaires include more subscales than the OSDI
questionnaire, and only the general health at the time of the evaluation is taken into
account. The other questionnaires are too broad and are not disease-specific. The
collective use of questionnaires is vital as treatments dependent on the results of the
questionnaire.
Other vital diagnostic tests are used, notably, tear breakup time, and ocular staining
with fluorescein, Schirmer’s strip tests, and examination of eyelid margins and gland
orifices, to name a few.24 A stable TF is regarded as a hallmark110 of ocular homeostasis,
and TBUT is commonly used to measure TF stability. The notion here is that with ocular
health, the TF is reinforced with blinking,122 and this structure's integrity remains
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between blinks in healthy individuals.110 With DED, TBUT decreases, increasing tear
surface desiccation. One of the problems here is that TBUT is reported to range from 419 seconds,245, 249-252, suggesting that TBUT has a wide variability.253-254 The
dissimilarities could result from complications in interpreting the results253-254 and
selected values used to improve repeatability.255-256
However, there have been improvements in measuring TBUT. Studies involving
fluorescein suggest a discord between DED, TFLL thickness, and depth;257 however,
TBUT still may be a better indicator of the TF’s ability to resist evaporation.110 TBUT
can offer insight into the TF’s collective ability to resist evaporation, with more
improvements.110

Problems with Therapy
Guidelines for managing DED are based on the severity of symptoms,139 and none of
the treatments cure the disease. Multiple treatment options exist depending on the
subtype and severity of DED. The treatments often overlap, as do symptoms with 3070% of cases involve two DED classifications.134 Most subjects do not fall under one
category134, and signs and symptoms are subjective. Therapeutic strategies that only
address one category do not alleviate some symptoms.134
Artificial teardrops are the most common treatment for DED and while replacing TF
aqueous is ideal, studies have failed to demonstrate the existence of a universal
substitute.258 Artificial tears lack the formulation of natural tears,136 and the
pharmacotherapies are miss many key biological components found in tears.26, 45, 259
Formulation varies in pH, osmolarity, and viscosity, as well. In a review comparing the
efficacy of 43 randomized controlled clinical trials, higher efficacy could not be
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established between formulations nor in favor of placebo products.136 The symptoms of
DED are problematic and may not be caused by tear deficiencies alone. Artificial tear
therapies only partially address replacement therapy, accounting for many variations
between formulations. Artificial tears with preservatives may be used in mild cases of
DED to relieve symptoms. However, long-term use has been proven to be toxic to the
ocular surface, and therefore, is not recommended for treatment in moderate to severe
DED.139 Preservative free medication is an option, but not without economic cost,
availability, and infection risk.134 Artificial tears do not cure DED or emolliate the
underlying conditions that contribute to the disorder's development;58 they only relieve
symptoms. Because of this, frequent instillation of medication and cost can avert
adherence.58
Viscosity enhancing agents as a treatment for DED is regarded as optimal for
improving TF depth, TF thickness, and increasing retention time on the ocular surface in
treating DED.134 The formulations of viscosity enhancing agents vary.134 Less effective
products need to be applied more frequently compared with more useful products.
However, more effective products can leave a residue that interferes with vision and
irritate. Either way, patients can become annoyed and non-compliant with treatment.
Some patients do not feel comfortable instilling medications to the ocular surface,198
while others experience discomfort and serious adverse events.
Although autologous serum may be attractive as a better alternative, one study found
varying results in the benefits of using autologous tears and could not confirm some
possible benefits to be of any use beyond two weeks.134 Laws limit use.134 Prolonged and
unmonitored use of corticosteroids increase the risk of intraocular pressure, cataract
formation,47 and infection.260-261
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Common complications with the use of topical treatments include difficulty
performing visual tasks, loss of visual acuity, eye pain (burning and stinging), discomfort
(foreign body sensation), and eyelash clumping, similar to the symptoms of DED that the
treatment is to ameliorate. The ocular surface disease often recurs after cessation of
treatments.134 Risk of an immune response to foreign antigens is always a cause for
concern.134
Therapies other than artificial tears include the use of omega-3-fatty acids, heat, and
meibum expression therapies. The efficacy of omega-3-fatty acid use among patients
with severe to moderate DED is difficult to ascertain because, like artificial tears,
standards for formulation vary.47 One study has failed to demonstrate improvements in
symptoms following a twelve-month trial.200 With heating devices, prolonged
temperatures, and temperatures greater than 45°C on the surface can cause thermal
damage.134
Removing environmental risk factors for DED can be beneficial, but only if
environmental triggers are known.134 DED can have iatrogenic origins262 and is highly
prevalent in patients using systemic medication. Strategies for reducing the occurrence of
adverse events is not always manageable.134 Reduction in dosage and frequency is a
requisite for reducing or eliminating side effects that instigate DED.134 Other
requirements may include complete dissociation from the drug, such as medication
changes or complete elimination of the drug type.134 These protocols may not be possible
because the benefit is not heavily weighted. Patients may depend on those medications
for survival. In these cases, a vigorous DED treatment protocol is warranted.134
Pharmacists and clinicians can advise patients on non-prescription and prescription
medication use, reducing modifying factors and reducing signs and symptoms to make
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patients comfortable as no real cure exists, and one therapy may not be ideal in most
cases.58 In practice, DED diagnosis in humans is based on overlap263of symptoms, with
differing complex etiologies and poorly understood pathophysiology,139 that vary by
patient264, and poses a significant health problem. Progress toward a cure is hindered, as
an appropriate animal model does not exist.264 The degree of complexity is further
exacerbated by the unparalleled relationship with clinical signs.265

Appropriate Models
The mechanisms behind DED development are poorly understood and cannot be
elucidated because no accurate animal model exists.162, 266 While clinical studies can
assess treatment efficacy in improving symptoms; the mechanism cannot be evaluated in
vivo. Mucin and other animal models are often used;162 however, the ocular adnexa does
not mimic humans.
An example of this comes from looking at the effects of omega-3-fatty acids. The role
of essential fatty acids in treating DED is not fully understood, and treatment protocols
vary.134 Higher omega-3 polyunsaturated fatty acids in the retina and lacrimal system
have been reported to reduce inflammation; however, these reports come from animal
studies.267-268 Hyperosmolarity seen in studies occluding the tear-producing ducts in
rabbit models has been used to explain the correlation between osmolarity and DED
changes,269 but the relevance of rabbits in the study of the human disease remains
unconfirmed. Rabbits do not show clinical signs of epithelial changes seen with DED in
humans.258 Tear osmolarity between the conjunctiva sac and excretory duct differ in
rabbits, and this feature is not duplicated in models or seen in humans.258 Two studies
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involving hypo-osmolar artificial tears did not find the preparations to be beneficial to
improving symptoms in DED.258
Hyperosmolarity initiates inflammatory events and is regarded as the central270
causative mechanism for initiating DED.271 Evaporative loss of TF aqueous due to
meibum deficiency is described as intrinsic. In contrast, evaporation caused by
pathological effects on the ocular surface is described as extrinsic.272 However,
osmolarity studies associated with DED are inconsistent,56, 272-274 and therefore, the
association with DED in humans is not lucid.275 Tear osmolarity is often accepted as 302
mOsm/L,110 but this is misleading, as it does not represent tear osmolarity on all areas of
the ocular surface. The value is a measure of tear osmolarity obtained from the lower
portion of the tear meniscus, and there is no evidence that this value represents the
volume of tears covering the preocular (the exposed area of the ocular surface) surface.110
Variations in tear osmolarity (subject means ranging from 310 to 340 mOsm/kg) have
been observed in asymptomatic healthy adults.258 Additionally, when tears are deposited
to the eye's surface, four compartments are formed, and unlike the lipid layer, the
aqueous components become isolated and do not fuse.110 This could account for the
possibility that osmolarity could differ across the TF. The idea that the TF is thinnest over
some regions compared with others, and that these regions must have properties similar
to water to prevent collapse110, 276 could lend support to variations in osmolarity.
The notion that the TF resists evaporation and that the TFLL is responsible for this
phenomenon is widely accepted.110 However, the TFLL's composition is not wholly
known.26 Examination of Meibomian lipid films suggests that the lipid layer protects the
TF's deeper subphases from collapse as the layers thin.277
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It is questionable that decreased rates of evaporation occur with DED. The review of
Wong et al., claims that enhanced evaporation is a hallmark of DED and an indisputable
fact.278 In this reference, it can be seen that the authors tried to normalize the literature
measurements to the same units and, when possible, to identical experimental conditions,
and indeed they refrained from a conclusion. The reason is that there are significant
discrepancies in the literature, and even publications like the ones of Yamada at al.
reported lower Revap for DED, 8.3 ×10 −7 g/cm2 /s compared with 4.6× 10 −7 g/cm2 /s
for normal eyes.278-279 This is wholly plausible as the “dry” hyperosmolar tears can be
expected to evaporate at a slower rate than the more “diluted” normal tears.
The question of whether the assumption that tears evaporate at a much slower rate
than saline was discussed in detail by Tomlinson et al. .280 There, the assumption came
from studies using rabbit animal model that might not have been relevant to the human
eye, and analysis of tear evaporation rate was made based on the TF thinning rate
measured by interferometry directly at the ocular surface. The review of Tomlinson and
associates used the typical pre-corneal TF thinning rate of 3.75 µm/min, TF thickness of
3 µm, and the average value of 3 cm2 for the total exposed area of the human eye (i.e.,
the cornea, sclera, and caruncle) to convert the TF thinning rate to fluid loss from the eye
and got the value of 1.137 μl/min.280 This is remarkably close to the evaporation rate of
water from an open vessel with an identical area 281 and suggests that the very high TF
thinning rates observed in dry-eye patients may be explained by other mechanisms acting
simultaneously (and prevailing over it) with evaporation. Thus the physics of wetting
films (instability due to Gibbs-Marangoni effect, dewetting) might be more relevant for
explaining TF dynamics than the older assumption for evaporation.
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Studies that utilized intact human tears collected from the eyes of healthy donors
(studies coming from different groups, including- Millar, Herok, Borchman) did not
measure decreased evaporation rate compared to water.282-285 These measurements were
done with intact tears taken from the eye; they are expected to contain all the components
present at the ocular surface. A recent review286 and publication243 suggest that the lipid
layer may not inhibit the rate of evaporation.
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2. HYPOTHESIS AND SPECIFIC AIMS

2.1. GENERAL BACKGROUND AND RATIONALE
The evaporation rate (Revap) of tears has been studied for decades and is relevant to
the etiology of DED. Investigators have speculated that meibum, the primary source of
TFLL,110 inhibits the Revap of tears287 and increases TF stability.243 Recently, the former
idea has been challenged.278 The idea that the TFLL reduces the Revap first came from
studies on rabbits.288-289 The studies focused on removing lipids from rabbits' tears, which
increased the Revap.288-289 It was concluded that the Revap was reduced only after
injecting lipids into the eye's anterior chamber.288-289 The problem with this study was
that meibum was not used; the lipid was injected behind the TF, not on top of it. Later
studies show that Revap does not decrease when using healthy human tears as an aqueous
subphase.282-285 Other studies placed meibum on the buffer's surface, but no reduction in
the Revap was demonstrated.290 A reduction of Revap by surface lipids that were
conventionally seen as significant to TF stability was not seen in vitro.284-285, 291
Evaporation is related to TF breakup, a measure of TF stability; however, evaporation is
static and does offer a complete explanation of TF thinning.278, 292
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2.1.1. SOURCES OF TEAR FILM LIPIDS
Phospholipids (PLs) are a significant polar component of tears, comprising ~10 to
20% of the lipid in tears. The primary source of the TFLL comes from meibum.
However, PLs are not found in meibum. It is speculated that some tear lipids could come
from sebaceous glands122, 293-295 or PLs bound to lacrimal proteins such as lipocalin296-297
and free micelles. PLs from tears may form a monolayer and interphase298-299 between the
TFLL and the aqueous layer.
Our laboratory found that squalene makes up 2 to 6% of the TFLL.294 Because of the
spatial proximity of sebaceous glands, which contain squalene, and the Meibomian
glands, which have much less squalene, it is probable that because there is no physical
boundary between the two glands, meibum and sebum mix and end up in the TFLL
[Section 1.5 Fig. 1.5(1)].15,122, 300-301 Our laboratory proposed that sebum, in addition to
meibum, contribute to the lipid content of the TFLL.122
Another essential class of polar lipids comprising the TFLL is (O-acyl)-omegahydroxyl fatty acid (OAHFAs), accounting for 5% of the TFLL.110 It is speculated that
polar lipids such as OAHFAs are located at the interface between the nonpolar lipid and
the aqueous tear layers.101, 276, 299 The surfactant properties of OAHFAs allow them to
reduce surface tension, promote the segregation of TF molecules, and help with meibum
spreading.302 However, as the TFLL composition of OAHFAs does not change with
DED,302 they are not likely to contribute to the destabilization of tears with DED.
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2.1.2. LIPID PROPERTIES AND STRUCTURES RELATED TO A SOUND BARRIER
TO EVAPORATION.
Lack of a complete TFLL has been proposed as the basis for evaporative DED and TF
instability.241, 303 An effective TFLL should possess the following four characteristics:
high evaporation resistance, good re-spreadability, sufficiently fluid, and gel-like and
incompressible.303 These characteristics are necessary to allow meibum to flow from the
Meibomian glands freely and evenly spread and incorporate into the TF to prevent water
loss due to hyperosmolarity, withstand forces that disrupt the integrity of the film, and
restore the TF to its original state following the blink cycle.303
Lipid layers from the TF, lungs, and skin of humans; the skin secretions on tree frogs;
the cuticles of plants; and lastly, the lipid layer of arthropods from many studies were
compared.304 It is interesting that of the lipid layers studied, only the TFLL and the lipid
layer in human lungs possess the property of re-spreadability.303 In comparing the
primary moieties of these biological lipid layers, polar lipids, such as PLs, were the only
shared component.303
It has been proposed that sound biological barriers to evaporation involve dense, rigid,
two-dimensional arrays of lipids with long and saturated303 hydrocarbon chains [Figure
2.1(1) a-b]. The saturated chains incorporate into the TFLL and are organized so that the
overall TFLL structure is fluid and not disrupted by blinking. The “multilamellar
sandwich model”303 was then proposed as a way of satisfying these requirements. Figure
2.1(2) is a model of the lamellae's possible structure adapted from our lab.305 The model
suggests that polar lipids migrate between the bulk nonpolar lipids and aqueous
interphase. Many of the polar lipids are PLs. One basis of the thesis was to determine if
PLs in the TFLL influence Revap.
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Figure 2.1(1) a-b. Meibum Lipid Arrangement on the Ocular Surface.305-306 The image, adapted from our
lab,305 shows the major lipid components of meibum. The hydrocarbon chains incorporate are organized so
that the overall tear film lipid layer structure is fluid. The cholesterol and wax esters are packed closely
together due to a high percentage of trans rotamers. 111 This conformation changes with higher
temperatures.111
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Figure 2.1(2). A Multilamellar Sandwich Model.119, 305-306 This model is adapted from our lab. The model
illustrates the possible structure for the multilamellar sandwich.305 The cholesterol and wax esters compose
a significant portion of the nonpolar bulk portion of the tear film lipid layer. 106, 124, 307 These lipids are
arranged in an order that maximizes hydrocarbon chain interactions.305 Also seen here (bottom right figure)
are phospholipids that primarily compose the model's polar region. Phospholipids are suspected of
migrating to the aqueous surface and forming a monolayer between tears and the bulk nonpolar lipids. 308
The structure encourages tear film molecules to segregate and acts as a scaffold to facilitate the smooth and
even spreading of meibum at the aqueous/lipid interphase.
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PLs are amphiphilic, possessing both hydrophilic (the heads) and hydrophobic (the
tails) regions. Thus, the hydrophilic head groups face the aqueous phase. The
hydrophobic hydrocarbon chains makeup the hydrophobic bulk lipid composed of wax
ester and cholesteryl esters from meibum [Figure 2.1(1) b] and interact via van der
Waal’s interactions as they do in bilayer membranes.308 The PL monolayer scaffolding is
energetically favored in computer models [Figure 2.1(3)].308 The ordering creates
structural stability, thus reducing the surface tension of the tears.
The structure encourages TF molecules, such as phospholipids, to segregate and act as
a scaffold to facilitate the smooth and even spreading of meibum over the TF during a
blink cycle to prevent rupture of tears and enhance TF stability. The model displays the
characteristic of re-spreadability.295 During a blink cycle, meibum is not thoroughly
swept away and replaced by a new layer. There is a reservoir of meibum on the eyelid
surface and a steady meibum presence on the TF. New meibum is deposited on the TFLL
pushing aside older TF lipids during the palpebra's downstroke to make way for the new
lipid deposits.
One aim of the thesis was to determine if PLs, acting as a scaffold in the TFLL,
influence Revap, an idea that has not been tested.
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Figure 2.1(3). Monolayer Scaffolding Model.308 The image above is a computer-generated model of the
tear film lipid layer. The brown objects in the image represent the bulk nonpolar lipid layer. The objects
pictured in red and green represent the polar lipid layer possibly composed of phospholipids. The polar
heads (red) line up head down to form a monolayer facing aqueous tears. The tails stand up and are in
physical contact with the nonpolar meibum. The phospholipid scaffolding is energetically favored. 308
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2.1.3. SURFACE FILMS
We know about evaporation from lipid film studies focused on the inhibition of the
Revap of large reservoirs', which can lose up to 8 feet of water a year due to
evaporation.309-310 Managing Revap in reservoirs is critical for arid regions, and the idea
that a monolayer of lipid could inhibit Revap came from a classical paper published 90
years ago.311 Twenty-five years later, a study showed that hydrocarbon chain length and
inhibition of Revap were directly correlated.312 Most of the studies related to the role of
lipid films and evaporation before 1986313 and more recently314 have been reviewed.
Revelation of a novel thermogravimetric method allowed for a more careful analysis
of the Revap through films.315 Theoretical studies suggested that the passage of water
molecules through a monolayer occurred through ‘sufficiently large holes which form
spontaneously in the monolayer.’316 Efforts to optimize the conditions for evaporation,
controlled by monolayers,317 involved the study of soluble surfactants,318 mixed
monolayers of octadecanol and cholesterol,319 cetyl alcohol and poly(vinyl stearate)
mixtures,320 and octadecanol and cetyl alcohol.321 It was suggested that cetyl alcohol
dissolved in turpentine could be used to slow the evaporation of water in reservoirs by 0–
65% when the total amount applied forms a layer with an average estimated thickness of
0.14 to 0.6 µm.309, 322
The same approach could be applied to biological membranes. Lipids on biological
surfaces are presumed to cover and reduce evaporation of the aqueous subphase beneath
the lipid layer. Just as addition of lipids may serve to reduce water loss in reservoirs, the
lipids could have the same effect on the ocular surface, notably with DED.

67

2.2. HYPOTHESIS
We hypothesize that the meibum layer alone or with the influence of PLs in the
aqueous portion of the TFL act as a barrier to tear evaporation. In DED, absence or
alterations occurring with meibum or reduced interaction between meibum and PLs in
tear aqueous leads to increased tear evaporation. Tear hyperosmolarity disrupts the
normal function of the TFL resulting in decreased tear breakup time, inflammation, and
other signs and symptoms characteristic to DED. The disease may be exacerbated by
conditions described in Section 1.

Specific Aims
Three specific aims were designed to test the hypothesis:


Investigate the role of lipid films in altering the Revap using synthetic lipids.



Investigate the role of lipid films in altering Revap using human meibum.



Investigate the role of lipid films in altering Revap using synthetic PLs and
meibum.

2.2.1. SPECIFIC AIM 1
To investigate the role of lipid films in altering the Revap. This study will determine if
long-chain alcohols inhibit Revap.

General Rationale:
As outlined above, older studies show that long-chain alcohols, forming a monolayer
with an average thickness of 0.14-0.6 µm, could inhibit Revap. Perhaps methods used to
reduce Revap in reservoirs could be applied to biological surfaces. “Older studies did not
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have the advantage that our lab has of using a more sensitive (to 6 decimal places)
analytical balance.”243

Approach:
This study seeks to repeat earlier studies involving alcohols to inhibit Revap in
reservoirs under carefully controlled laboratory conditions. We propose to test the
efficacy of lipids as a barrier to evaporation.

2.2.2. SPECIFIC AIM 2
2.2.2.1. SPECIFIC AIM 2.A
To investigate the role of meibum in altering the Revap. This study will determine if
meibum influences the Revap.

General Rationale:
It has been speculated that meibum, the primary source of TF lipids, inhibits Revap,
increasing TF stability. However, no one has tested this hypothesis in vitro. Based on
previous studies discussed above, it would be informative to determine how meibum and
the Revap are related using carefully controlled conditions in vitro.

Approach:
We propose to use meibum from healthy donors layered on phosphate buffered saline
(PBS). PBS alone is used as a control to determine if the meibum inhibits or stimulates
the Revap of PBS.
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2.2.2.2. SPECIFIC AIM 2.B
To investigate the role of meibum from donors with DED in altering the Revap. This
study will determine if the Revap is different for meibum from donors with DED
compared with meibum from normal donors.

General Rationale:
It has been speculated that changes in meibum associated with DED influence the
Revap by decreasing TF stability. However, no one has tested this hypothesis in vitro.
Based on the specific aim one and previous studies discussed above, it would be
informative to determine how changes in meibum and the Revap are related using
carefully controlled conditions in vitro.

Approach:
We propose to compare Revap using meibum from healthy donors layered on PBS
with meibum from donors with DED and donors who have dry eye after HSCT. The
study aims to determine if the meibum inhibits or stimulates the Revap of PBS.

2.2.3. SPECIFIC AIM 3
Determine if a reduction of PLs in the TFLL is associated with an increase in the
Revap associated with DED.

General Rationale:
Based on previous studies discussed above, we propose that PLs, not used in other
studies, will help the bulk meibum lipids to spread over the PL scaffolding at the aqueous
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surface and, together with meibum, influence the inhibition of the Revap of tears. This
investigation is relevant because rather than attenuating or preventing DED, therapy
could be designed that restores or alters PL concentrations to treat DED.

Approach:
We will perform evaporation studies using meibum from normal donors, donors with
DED, and donors that had undergone HSCT with and without PLs
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3. GENERAL METHODS AND MATERIALS

3.1. MATERIALS
3.1.1 MATERIALS
Physiological/Phosphate buffered saline (PBS), deuterated chloroform (CDCl3), and
d-hexane were purchased from Sigma Chemical Company (St. Louis, MO). The
following synthetic alcohols and phospholipids were also purchased from Sigma
Chemical Company: 1-undecanol, 1-dodecanol, 1-tridecanol, 1-hexadecanol, 1docosanol, and 1-tetracosanol [Table 3.1(1)]; sphingomyelin, phosphatidylcholine,
phosphatidylethanolamine, and phosphatidylserine. Some of the supplies used in the
studies are pictured in Figure 3.1(1).

3.1.2. COLLECTION OF HUMAN TEARS AND MEIBUM
All procedures were in agreement with the Declaration of Helsinki. Protocols and
procedures for the current retrospective study were approved by the University of
Louisville Institutional Review Board.243

3.1.2.1 HUMAN TEARS
Human tears were collected, as described in an earlier publication.243 Reflex human
tears (TR) were obtained by exposing a 62-year-old Caucasian male, with no signs or
symptoms of DED, to the lachrymatory factor in the vapor of freshly cut onions for about
three-minute intervals.323
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Sample

Number of Carbons

1-Undecanol
1-Dodecanol
1-Tridecanol
1-Hexadecanol
1-Docosanol
1-Tetracosanol

11
12
13
16
22
24

Phase Transition
Temperature (°C)
11
22-26
29-34
49-50
65-72
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Table 3.1(1). Synthetic Lipid and Chain Length.243 The table's left column shows the synthetic lipids used
in the study. Both short and long chain alcohols were used to determine length affects rate of evaporation.
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Figure 3.1(1). Materials. Pictured above are some of the materials used for the study. A) Physiologically
buffered saline was used as an aqueous subphase for many experiments. The rate of evaporation of
physiologically buffered saline was measured in each study. B) Synthetic phospholipids (sphingomyelin,
phosphatidylcholine, phosphatidylethanolamine, and phosphatidylserine) were used in specific aim 3. It
was hypothesized that phospholipids act as a scaffold for meibum spreading in the tear film. C) Meibum
was dissolved in chloroform upon collection. Deuterated chloroform was used as a solvent for Nuclear
Magnatic Resonance studies (NMR). D) Argon was used to help preserve samples. E) Pictured here is a
water sonicator. The sonicator was used to mix meibum and synthetic lipid samples. The time spent in the
sonicator averaged five minutes. The images above are provided by Sledge and the Borchman lab.

TR were collected and pooled for over three weeks. Stimulated tears, such as those
investigated here, have been reported to have a viscosity and shear rate comparable with
those in unstimulated tears.324-325
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3.1.2.2. HUMAN MEIBUM SAMPLES
Human meibum was collected by expressing the meibum from the Meibomian glands
using a cotton application as described in earlier publications.90, 111, 243 The Meibomian
glands were compressed between two cotton tips with attention to avoiding scrapping the
eyelid margin. The expressed meibum was collected from the eye lids using a platinum
spatula and dissolved in 1.5 mL of CDCl3.The amount of meibum collected varied by
patient, clinician, and conditions at the time of collection. The goal was to collect at least
0.5 mg of meibum per individual for spectroscopic studies. The samples were stored
under argon gas at -30°C, and pooled together when necessary for evaporation and
spectroscopic studies. Donors were recruited from the Kentucky Lions Eye Center and
the James Graham Brown Cancer Center in Louisville, Kentucky.

Clinical Diagnosis of Normal Meibum
As described in an earlier publication, subjects were assigned to the normal cohort
based on several criteria.90 The subjects’ Meibomian gland orifices showed no signs of
keratinization or plugging and the meibum was not turbid or thick; no dilated blood
vessels were visible on the eyelid margin; and the donors did not report that they had
DED symptoms.

Clinical Diagnosis of DED
Donors received complete ophthalmic eye exams using slit-lamp biomicroscopy
[Figure 3.1(2)]326, and the diagnosis of DED was determined clinically. Tear breakup
time (TBUT) was measured at the slit-lamp after the installation of one drop of
fluorescein. DED diagnosis was based on fluorescein stain uptake of the cornea and
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conjunctiva, an irregular TF, low tear meniscus, and symptoms. Positive symptoms
included foreign body sensation, excessive tearing, excessive blinking, burning of the
eye, and blurry vision. Schirmer’s tests were performed on patients without anesthesia for
five minutes by placing a standard strip into the lower conjunctiva sac. Meibomian gland
orifices, eyelid changes at the mucocutaneous junction, and meibum expression by gentle
compression were all evaluated for diagnosis of MGD. A third cohort had undergone
HSCT and had clinical MGD.

How HSCT is Related to this Study
HSCT is often associated with DED, as discussed in Section 1.2.4. Meibum order
stiffness is related to age and disease, including DED and HSCT. Figure 3.1(3) is from
data collected and published by our laboratory.126 The Y-axis displays the hydrocarbon
chain order (percentage of trans lipids), which correspond to meibum stiffness.126
Meibum must be fluid enough to spread across the TF surface to be a significant
biological lipid layer barrier to evaporation (See Sections 1.6.3. and 2.1.2.). Meibum
from donors with MGD is more rigid compared with meibum from children or healthy
adult donors [Figure 3.1(3)]. The meibum from donors who have undergone HSCT is
stiffer than the meibum from healthy donors and donors diagnosed with MGD. Table
3.1(1) contains a list of donors used for specific aim 2b. of the study. The table contains
three cohorts including healthy meibum, and two different disease cohorts.
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Figure 3.1(2). Image of a Patient Undergoing a Slit-Lamp Biomicroscopic Exam.326 Slit lamp is an essential
instrument used by an ophthalmologist to determine ocular health. Dry eye disease is diagnosed or
excluded by observation of the cornea and conjunctiva after instillation of fluorescein to the Meibomian
gland orifices and lid margins, in addition to other examinations of the Meibomian glands.
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Sample
Meibum
Meibum
Meibum
Meibum
Meibum
Meibum
Meibum
Meibum
Meibum
Meibum

Disease State
*Normal/P20C
*Normal/P30C
*HSCT/P15D
*HSCT/ P70D
*HSCT/ PMixD
*HSCT/ POtherD
DED
DED
DED
DED

Demographics
BF24
CF27
CM31
CM34

Table 3.1(1). Meibum Demographics. The right column of the table shows the age, race, and gender of
meibum donors. The letters and numbers in the table represent C-Caucasian, B-Black, M-Male, F-male, #Age. *Several of the meibum samples are pulled as indicated by this symbol. Normal status was assigned to
patients with no signs or symptoms of dry eye disease (DED). Patients who have undergone hematopoietic
stem cell transplant (HSCT) often develop Meibomian gland dysfunction-related dry eye disease due to
graft-versus-host disease, a common complication of the procedure. Evaluation of the Meibomian gland
orifices, eyelid changes, and meibum expression was used to diagnose dry eye disease. Fluorescein stain
uptake, Schirmer’s strip test scores, and positive signs and symptoms of foreign body sensation and ocular
disturbance were also used to assign patients to the dry eye disease cohort. Sledge and the Borchman lab
created the table above.
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Figure 3.1(3). Meibum stiffness as it Relates to Age and Disease.119, 237 The graph was adapted from data
collected in a previous study conducted by the Borchman lab. Starting from the far left bar on the graph and
moving to the right, the average for hydrocarbon chain order increases with age- Meibum becomes stiffer
with age. Also seen here, the average hydrocarbon chain order increases with a disease state. Hydrocarbon
chain order in meibum from donors with Meibomian gland dysfunction (MGD) is significantly higher than
normal meibum from adults and children. Meibum from hematopoietic stem cell transplant (HSCT) donors
is stiffer than meibum from Meibomian gland dysfunction donors. The numbers above each bar on the
graph represent the number of subjects in each study cohort.
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3.2 METHODS
3.2.1 NMR
Nuclear magnetic resonance (NMR) spectroscopic studies were used to quantify wax
and cholesteryl esters in our samples. The rationale for using NMR to determine the
meibum composition includes the premise that there are up to 30,000 molecular species
of esters, so determining the molecular weight of meibum needed to calculate the moles
of WE and CE's moles by mass spectrometry is difficult.327 NMR circumvents this
problem because known molecular weight of the esters is not needed for quantification
by NMR. Proton resonances assigned to different constituents in the solution [Figure
3.2(1] shows the resonances unique to the various components of meibum dissolved in
CDCl3. Regardless of the hydrocarbon chain length, saturation, or branching, WE give
resonance at 4.0 ppm, whereas CE, no matter the molecular species, offers a resonance at
4.6 ppm. The intensity ratio of the resonance at 4.0 and 4.6 ppm relative to the intensity
of CDCl3 solvent at 7.25 ppm was used to calculate the molarity.
The moles of ester were extrapolated from the intensity ratios 4.0 ppm / 7.25 ppm and
4.6 ppm / 7.25 ppm of standard CE and WE curves, Figure 3.2(2) and Figure 3.2(3).
Knowing the volume of the solution, the moles CE and WE were calculated. Lastly, we
calculated the amount of meibum needed to deposit a 0.1µm thick film on the aqueous
surface of our model systems. The average lipid layer thickness was estimated using a
density of 0.82 g/cm3, assuming a uniform lipid layer.
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Figure 3.2(1). A Typical Nuclear Magnetic Resonance (NMR) Spectrum for Human Meibum. The image
above shows the peaks for the main constituents in meibum; cholesteryl and wax esters. Cholesteryl ester
has a resonance band of around 4.6 ppm (parts per million). Wax ester’s resonance band is found at 4.0
PPM. Also pictured here in the image is the CH=CH (double bond) stretch for meibum, seen at 5.4 ppm.
Lastly, the solvent at which the meibum is dissolved for performing analysis has a resonance band at 7.25
ppm.
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Figure 3.2(2). The Standard Curve for Wax. The curve is compiled from Nuclear Magnetic Resonance
(NMR) data. Multiple samples of wax ester, at known concentrations, were used to create the curve. The
object here was to use this standard curve to determine the quantity of wax ester in meibum samples to
emulate, as closely as possible, the meibum concentration in ocular surface lipid films. This step was one of
two necessary steps in calculating the amount of meibum needed to deposit a 0.1µm thick film to cover the
aqueous subphase in the ocular surface models.
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Figure 3.2(3). The Standard Curve for Cholesterol. The graph was compiled from Nuclear Magnetic
Resonance (NMR) data. Multiple samples of cholesterol ester, at known concentrations, were graphed to
create the curve. The object here was to use this standard curve to determine the quantity of cholesterol
ester in meibum samples to emulate, as closely as possible, the meibum concentration in ocular surface
lipid films. This step was necessary to calculate the amount of meibum needed to deposit a 0.1µm thick
film to cover the aqueous subphase in the ocular surface models.
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3.2.1.1. COLLECTION AND PROCESSING OF NMR SPECTRA
NMR collection and processing are performed as described in a previous
publication.243 On the day of NMR measurement, the sample was sonicated under an
atmosphere of argon gas in an ultrasonic bath (Branson 1510, Branson Ultrasonics,
Danbury, CT, USA) for 10 min and placed into an NMR tube for spectral measurement.
Meibum-CDCl3 samples were transferred from the micro vial to an NMR tube using a
glass pipet. Spectral data was acquired using a Varian VNMRS 700 MHz NMR
spectrometer (Varian, Lexington, MA, USA) equipped with a 5-mm 1H {13C/15N13C
enhanced pulse-field gradient cold probe (Palo Alto, CA, USA). Spectra were acquired
with a minimum of 250 scans, a 45° pulse width, and a relaxation delay of 1.000 s. All
spectra were obtained at 25 °C. Spectra were processed, and the integration of spectral
bands is performed with GRAMS/386 software (Galactic Industries, Salem, NH, USA).

3.2.2. MEASUREMENT OF REVAP
Revap were measured gravimetrically every 10 minutes for 100 minutes at
physiological or room temperatures. PBS was used as an aqueous subphase to measure
the Revap and to represent lacrimal fluid on the ocular surface.

Preparation
PBS (750 µl) was measured and transferred into a round plastic container measuring
0.8 cm in depth with a 1.5-cm inside diameter [Figure 3.2(4)], using a 100-1000 µm
micropipette.
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Figure 3.2(4). Eye Tear Film Lipid Layer Model. Physiologically Buffered Saline (750µl) was placed in a
round plastic container measuring 0.8 cm in depth with a 1.5-cm inside diameter. The investigators (Sledge
and Borchman) designed the heating apparatus and created it in-house at the University of Louisville.
Sledge and the Borchman lab provide the image above.
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Next, lipids were transferred from the storage vial using a micropipette and layered on
the surface of the PBS. After applying meibum to the model's aqueous surface, meibum
was carefully sonicated for 10 seconds using a microprobe Sonifier® cell disrupter 185
(Branson, Ultrasonics Co., Danbury CT). After a 1-minute delay, the sample was
sonicated again for 15 seconds to ensure the surface's lipid dispersion.
For later experiments, meibum was allowed to equilibrate for 10-minutes to ensure the
lipids' natural spreading on the surface before measuring the Revap. The equilibration
time is necessary because the lipid layer is dynamic and time is necessary to disperse the
lipid.

3.2.2.1. PHYSIOLOGICAL TEMPERATURE EXPERIMENTS
For the measurement of Revap at physiological temperature, Revap was measured at
an average of 35°C, the estimated temperature on the ocular surface. PBS in its respective
containers (the eye models) were then transferred to a heating apparatus designed inhouse at the University of Louisville [Figure 3.2(5)] and heated to an average
temperature of 35°C. The PBS temperature was taken at random intervals to ensure the
desired temperature was reached. After the temperature reached 35°C, a final temperature
reading was taken after one minute to ensure that the desired temperature was reached.
For some experiments, a 10-minute delay followed the application of lipid to allow for
natural equilibration.

3.2.2.2. ROOM TEMPERATURE EXPERIMENTS
Experiments at room temperature were prepared as described in the section above,
with the exception of the heating apparatus. PBS was prepared at room temperature,
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which averaged 22°C. Experiments involving synthetic 1-hyroxyl hydrocarbons were
conducted at room temperature to closely mimic water reservoirs, as the temperature was
determined by the external environment. For some meibum experiments, room
temperature was maintained to determine if temperature effect Revap. The specimens
were not placed on a heating apparatus. However, a 10-minute delay followed the
application of lipid to allow for natural equilibration.

3.2.2.3. ALL SAMPLES
Vials containing donor meibum or synthetic lipids in CDCl3 were sonicated in a bath
sonicator for 5 minutes to ensure the lipids' mixing. Lipids were transferred from the
storage vial using a micropipette and placed on the surface of the PBS. The samples were
then sonicated, as reported above. For some experiments, a 10-minute delay followed to
allow for natural migration and dispersion of lipids. The combinations of models studied
are described in sections 5, 6, 7, and 8 of the thesis.

Measuring the Rate of Evaporation
Revap were measured by weighting each sample every 10 minutes for 100 minutes to
5 decimal places using a Mettler-Toledo AT261 analytical balance (Columbus, OH)
[Figure 3.2(6)]. The balance was calibrated and certified by a Mettler
technician. Revap was calculated from the fitted line slope obtained by least-squares
linear regression analysis of a weight-vs-time curve as reported.243 The Revap for PBS
with no lipid was continuously measured with every sample as a control. In the
Revap calculations, a density of 1 mg/mL was assumed for PBS. After completion of 100
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minutes of measurements, there was an 80-minute delay to allow for more lipid
dispersion. Rates were measured again for another 100 minutes.

Statistics
Data are presented as the mean ± the standard deviation unless indicated.”243 A P < 0.05
was considered statistically significant using the Student’s t-test.

3.2.3 PL CONCENTRATIONS
A literature review was conducted using PubMed to determine the PL composition of
human tear lipids. The PL composition of normal tears (TLn) is shown in Figure 3.2(7).
Our mixture of PLs was: 10% sphingomyelin (SM), 15% phosphatidylethanolamine (PE),
72% phosphatidylcholine (PC) and 3 % phosphatidylserine (PS). These amphiphilic
lipids are expected to form a scaffold on which meibum, during a blink cycle, is spread to
cover and protect the TF.

88

Figure 3.2(5). Heat Source. The investigators (Sledge and Borchman) designed the heating apparatus, and it
was created in-house at the University of Louisville. The water enters into the metal plate from the heat
bath and circles around the samples. The temperature is controlled from the heat bath and measured with a
thermometer.
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Figure 3.2(6). Mettler-Toledo AT261 Analytical Balance (Columbus, OH). Pictured in the image above is a
sample being weighed on a Mettler-Toledo analytical balance. The Mettler-Toledo balance is calibrated
and certified by a Mettler-Toledo Technician. Each sample was removed from the heating apparatus and
placed on the balance to record its weight every 10 minutes for 100 minutes. After the weight was
recorded, the sample was returned to the heating apparatus. The order was never compromised, as each
sample had a designated position on the plate. Notice that the samples are level and positioned close to the
scale. It was important to keep the samples close to minimize sample loss when the samples are transferred
to the scale and returned to the plate. Also, bear in mind that movement during this study is continuous, and
there is less than a 1-minute break between sample weighing. As seen above, ten samples were measured
for every experiment, and the rate of evaporation for physiologically buffered saline was always measured
in each sample group.
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Figure 3.2(7). Average Phospholipid Concentration in Tears. The bars in the graph above represent the
average phospholipid concentrations found in normal tears. These figures were compiled from a literature
review. According to literature, the phospholipids found in tears, and therefore used for the study, are
sphingomyelin (SM), phosphatidylcholine (PC), phosphatidylethanolamine (PE), and phosphatidylserine
(PS). The phospholipids classes determined by the authors are grouped together by phospholipid class. The
different colored bars and the names under the bars represent each study's authors and their estimates of
phospholipids from the studies. The numbers in parenthesis above the bars (and under the phospholipid
abbreviation) are the percent averages for each phospholipid class reported by these authors. The
percentage of phospholipids reported appears to be close in approximation.
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3.2.4 LIPID SPREADING
3.2.4.1. RAMAN
Raman spectra were measured using a laser Raman microscope (Renishaw,
Gloucestershire, UK) [Figure 3.2(8) top and bottom]. The sample was placed on a
temperature-controlled sample stage kept at 33°C for meibum, and 25°C for the hydroxyl
lipids and coherent light from a He-Ne laser with a power of 2 mW and an excitation
wavelength of 632.8 nm was focused on the sample using a 50× objective lens [Figure
3.2(9)]. The measurements were made with the normal mode of the system. To minimize
exposure to the laser and prevent overheating, samples were illuminated ten times for ten
seconds with a total exposure time of one hundred seconds. For every acquisition, 40
spectra were obtained. Each sample was measured for a total of 40 minutes. Raman
scattering from the sample was collected with the same lens and detected by a CCD
camera. A grating of 1/1800 mm/groove for the visible region with confocal mode was
chosen. Raman data analysis was performed with GRAMS/386 software (Galactic
Industries, Salem, NH, USA).
Data are presented as the mean ± the standard deviation unless indicated. A P < 0.05
was considered statistically different when means were tested using the Student’s t-test.
This information was published with specific aims 1 and 2 of this study.243
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Figure 3.2(8). Raman Spectrometer. The Images above (top and bottom) show the front (top) and side
(bottom) views of a Raman Spectrometer. This instrument is located in the Conn Center for Renewable
Energy Research at the University of Louisville. Raman Spectroscopy was used to determine lipid
conformation. The microscope, pictured top, was also used to observe lipid spreading on the surface of
fluids in the ocular surface models. Sledge and the Borchman lab provide the images above.
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Figure 3.2(9). Raman Laser. The red laser of the Raman spectrometer was used for analyses of the human
reflexed tears, human meibum, physiologically buffered saline solution, and the various chains of synthetic
lipids. The laser light, with a wavelength of 632.8nm, was used to focus monochromatic light on the
biological and synthetic samples' surface, measuring an area of about 5μm³. The electrons in the
illuminated area are excited to a virtual state, and the scattered light (figure above) is collected by a
monochromator. The light that returns at a different frequency was also collected. Raman spectroscopy
provides information about the confirmation, structure, and spreading of our samples' lipids. Sledge and the
Borchman lab provide the image above.
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3.2.4.2. MICROSCOPY
Microscopy was used to evaluate the lipid surface for a uniform film over the TF
models' aqueous phase. Images of lipids on the surface was captured using microscopy at
a lipid layer thickness of 0.69 µm. The difference in the clustering of meibum between
healthy and disease states was assessed later assessed using Fiji Image J software.

3.2.4.3. FIJI
Fiji is an open-source image processing package licensed under the General Public
License (GNU). Fiji is maintained by the Eliceiri/Laboratory for Optical and
Computation (LOCI) group at the University of Wisconsin-Madison, in Madison,
Wisconsin, and Jug and Tomancak labs at Max Plank Institute of Molecular and Cell
Biology and Genetics (MPI-CBG) located in Dresden, Germany. It is an extension of
Image J (the core component), and more specifically, a free enhanced version of Image J2
with plugins that enable an uncomplicated scientific image analysis. It is often applied,
yet not exclusively, in biological and medical research328 to quantify cellular material.
Fiji-Image J can also be used to make length, shape, and size (area) determinations.
For the current study, Fiji-Image J was used to quantify and measure the area of lipid
islands observed for the TF models. Here, the idea was to supplement observations made
with microscopy with respect to the spreading of meibum on the aqueous solution's
surface. It is speculated that normal meibum covers the eye's surface and forms a uniform
lipid layer that reduces the aqueous tear exposure and reduces evaporation, as described
in Section 2 of the thesis. Presumably, in patients with DED, a more significant number
of islands form, thus exposing more tear aqueous at the tear/air interface, increasing
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Revap. It is also speculated that PLs at the lipid/aqueous interface influences uniform and
complete meibum spreading by acting as a scaffold.
To measure the cluster area, several steps must be followed. First, the Fiji Image
Processing application must be opened, and the cell counter plugin is selected and set to
8-bit grayscale. To determine the area of the cluster, a known measurement must be
entered into the processor. 10 µm was entered as this was the reference size in
microscopy images. The analyze function reveals the object's length in pixels.
Next, using the analyze feature and set scale function, the known scale values are
entered. Submitting these values sets the measurements at precisely those used for the
study samples. The scale values entered are 40 pixels, which correspond to 10 for the
number of units on the microscopy scale; the unit description entered is microns, and the
aspect ratio is left at 1. The final scale is set at 4 pixels/µm after entering the known
information. Lastly, the scale is set to global. The purpose of setting the scale at global is
to fix the scale for measurements during the session. After obtaining known data, the
information can be input and fixed for each session without repeating the initial
measurement to determine the scale.
The last step involves counting and determining the area of the clusters. The clusters
are first counted and marked with numbers to prevent duplicate counts. To complete the
area measurement and obtain the data, on the control bar, select analyze and then
measurement from the dropdown menu. The area, mean, and max is displayed for each
object measured.
The data was recorded and analyzed using the Student’s t-test. The total number of
clusters and cluster area were compared for each study sample type. Additionally, the
number of clusters and cluster area were compared for each sample group before and
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after application of phospholipids. Student’s t-test values P < 0.05 were considered
significant.
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4. SPECIFIC AIM 1.1

To investigate the role of lipid films in altering Revap. This study will determine if
long-chain alcohols inhibit Revap.

4.1. REARCH DESIGN- SPECIFIC AIM 1.
4.1.1. RATIONALE- SPECIFIC AIM 1.
Large reservoirs can lose up to 8 feet of water a year due to evaporation309-310, thus
managing Revap in reservoirs is critical for arid regions. Inhibition of the Revap of water
through lipid films was studied extensively for years, and the idea that a monolayer of
lipid could inhibit Revap came from a seminal study published 90 years ago.311 Twentyfive years later, a study showed that hydrocarbon chain length and inhibition of
Revap were directly correlated.312 Most of the studies related to the role of lipid films and
evaporation before 1986313 and more recently314 were reviewed. Findings revealed that a
novel thermogravimetric method allowed for a more careful analysis of the evaporation
rate through films.315 These theoretical studies suggested that the passage of water
molecules through a monolayer occurred through ‘sufficiently large holes which form

This chapter is a slightly modified version of the article “Evaporation and hydrocarbon chain
conformation of surface lipid films” published in The Ocular Surface 2016, 14 (4), 447-459, the original
source. © 2016 Elsevier Inc. All rights reserved
1
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spontaneously in the monolayer’316, and efforts to optimize the conditions for evaporation
controlled by monolayers317 involved the study of soluble surfactants,318 mixed
monolayers of octadecanol and cholesterol,319 cetyl alcohol and poly(vinyl stearate)
mixtures,320 and octadecanol and cetyl alcohol.321 It was suggested that when the total
amount of lipids applied forms a layer with an average estimated thickness of 0.14 to 0.6
µm309, 322one could utilize cetyl alcohol dissolved in turpentine to slow the evaporation of
water in reservoirs by 0–65%. Perhaps these same methods could be applied to elucidate
the Revap tear aqueous on the ocular surface, and the addition of lipids, where
evaporation rates are high, could attenuate evaporation and stabilize the TF.

4.1.2. APPROACH- SPECIFIC AIM 1.
Our first objective was to determine the role of lipid films in altering the evaporative
water loss rate. To assess lipid films' contribution to the Revap, we used six 1-hydroxyl
hydrocarbon chain (11-24 carbons) alcohols. Lipid films, namely meibum, on the ocular
surface are expected to decrease TBUT, a process related to evaporation, by 50% in
healthy individuals compared with patients with DED. If we were expecting evaporation
to contribute to DED, we would expect Revap to be reduce by 50%. Similarly, if lipid
films of long chain alcohols effectively inhibit Revap, one would need them to inhibit the
Revap by 50%.

Preparation
Revap were measured gravimetrically, as reported above (Sections 3.2.2.2 and 3.2.2.3)
and in previous experiments at 22°C.243, 329-330 Lipids in Table 3.1(1) were used.
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Evaluating Lipid Spreading and Hydrocarbon Chain Conformation Using Raman
The spreading of lipid on the surface of the eye models was evaluated using
microscopy. The difference in the spreading of meibum on the aqueous surface was
assessed as described in section 3.2.4.1.243 A Raman laser microscope was used to
measure 40 samples.

4.2. RESULTS- SPECIFIC AIM 1.
Revap
Earlier studies involving the inhibition of Revap of water in reservoirs by cetyl and
other alcohols were repeated under controlled laboratory conditions.3 The average
Revap of PBS was linear, r = 0.99 ± 0.01.243 The Revap of models with lipids was also
linear when measured over 100 minutes, with an average correlation coefficient of r =
0.998 ± 0.001, so the Revap using all of the lipids involved were measured over 100
minutes.243 The average Revap of PBS at 22°C was measured with a relative humidity of
55%.243
The estimated film thickness was 0.69 µm, and there were no differences in Revap of
individual shorter chain alcohols between 11–13 carbons or the individual longer chain
alcohols between 16–24 carbons, P > 0.05 for both groups. Differences were not
observed for any individual alcohol, regardless of chain length. Therefore, the results
were averaged together and presented as two groups; The shorter chain alcohols data
were averaged together, and the longer chain alcohols data were averaged together.243
Revap ratio, PBS plus lipid/PBS, of the shorter chain alcohols, was 0.99 ± 0.10, slightly
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but significantly lower than the longer chain alcohols of 1.07 ± 0.15, P = 0.04 [Figure
4.2.(1)].243
Revap of both samples was essentially similar to that of a PBS.243 The thickness of the
lipid film did not influence the Revap ratio (P > 0.05) over a range of 0.69 to > 6.9 µm,
with a respective Revap ratio range of 1.01 ± 0.06 to 0.94 ± 0.24 µm/min [Figure
4.2(2)].243 The estimated thickness range of the samples included in the bar labeled > 6.9
µm was 6.9 to 34 µm, and the bar had the most significant standard deviation since lipid
was applied directly to the PBS, and the amount of the lipid applied varied.243 After
equilibration, the Revap of 1-hexadecanol was the same as that of the PBS, P > 0.05.
Sonication did not change Revap, P > 0.05.243
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Figure 4.2(1). Average Revap of Synthetic Lipids. 243 Two groups of synthetic lipids are shown on the
graph. Carbon lengths 11, 12, 13 are represented in the graph as the short-chain alcohols. Carbon length 16,
22, 24 are the longer chain alcohols. The numbers in parenthesis represent the number of trials for each
group. The figure shows the relative rate of evaporation of physiologically buffered saline exposed to 0.69
µm thick 1-hydroxy n-hydrocarbon films on the surface at 22°C. Significant differences were not observed
between individual alcohols with carbon lengths 11-13 or individual alcohols with carbon lengths 16-24, P
> 0.05, so the shorter chains and longer chains results were average as two groups. The rate of evaporation
ratio for the short-chain alcohols was 0.99 ± 0.10, and the long-chain alcohols were 1.07 ± 0.15. The
difference between the two groups was significant, P < 0.05.
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Figure 4.2(2). Calculated Lipid Layer Thickness. 243 The graph represents the relative rate of evaporation of
physiologically buffered saline exposed to the synthetic lipids listed in table 4.2(1) at 22°C. Each column
shows the average rate of evaporation for different thicknesses of the lipid films. Film thickness did not
influence rate of evaporation, P > 0.05. The rate of evaporation did not change with the layering of
synthetic alcohols. The values in parentheses are indicative of the number of trials.
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Lipid Spreading and Hydrocarbon Chain Conformation
Microscopy
Raman spectroscopy was used to evaluate the behavior of synthetic lipids on the
aqueous surface. The objective was to test if the lipid formed a uniform film over the
aqueous. We chose to consider the spreading characteristics of two synthetic lipids. 1undecanol and 1-tetracosanol were used and represent the extremes of the physical and
structural properties of the lipids we studied. 1-undecanol has 11 carbons and is a liquid
at 25°C (melting point, 11°C), whereas 1-tetracosanol is a longer chain alcohol
containing 24 carbons and is solid at 25°C [melting point, 75°C, Table 3.1(1)]. The
Raman microscope shows that both lipids form irregular crystalline looking patches on
the surface of PBS [Figure 4.2(3) A-D]. There was no instance when aqueous was
exposed.
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Figure 4.2(3)A-D.243 Lipid Alcohol Films. The photo above are images of synthetic lipid alcohol films,
with an estimated thickness of 0.69 µm, layered on the surface of physiologically buffered saline under
white light captured using a Raman microscope. The film is heavily layered, considering the average
standard tear film lipid layer is 0.3 µm. The lipids from left to right and starting at the top in alphabetical
order are 1-tetracosanol, 1-tetracosanol, 1-undecanol, and 1-undecanol. The boxes in the photo are the 5
µm2 fields of view from the Raman laser. The lipids were in motion and moved in and out of the field of
view.
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Raman Analysis
Five bands were resolved in the Raman CH stretching region for liquid 1-undecanol
[Figure 4.2(4) A(a)] and 1-tetracosanol [Figure 4.2(4) A(b)]. The bands were typical for
hydrocarbons, and the assignments for this region were made previously.331 The
CH2 stretching band at 2890 cm−1 is a Fermi resonant band that is sensitive to intra- and
interchain interactions and has been used to measure human meibum's structural order or
fluidity.332 About 50% of the relative intensity of this band is influenced
by trans and gauche rotamer content [Figure 4.2(5)]. Lateral packing interactions
between chains contribute to the other 50% of the intensity. When there are fewer lipidlipid interactions, as when lipids are disordered and fluid, the intensity of the 2890
cm−1 band is less, whereas there is relatively little change in the 2850 cm−1 band.
The peak height ratio I2886/I2850 was used to quantify SLATERAL, an order parameter
designed to provide a quantitative estimate of the degree of lateral interaction.331, 333 The
peak height intensity ratio, I2886/I2850, was 0.76 for 1-undecanol and 1.95 for 1tetracosanol. In other words, 1-undecanol was more fluid with less interaction than 1tetracosanol. 1-SLATERAL calculated from these ratios were 0.04 and 0.83 for 1-undecanol
and 1-tetracosanol, respectively, indicating that 1-undecanol was almost completely
disordered whereas 1-tetracosanol was significantly ordered. When lipid hydrocarbons
are ordered as 1-tetracosanol is, the hydrocarbon chains are strait in an all trans
conformation maximizing van der Waal’s interactions between chains. Bands due to trans
rotamers are well resolved in the Raman spectra of 1-tetracosanol [Figure 4.2(4) B(ii)].
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Figure 4.2(4) A-C.243 Raman Spectra. Image A shows the Raman CH stretching region. Image B represents
the Raman fingerprint region of typical Raman spectra of liquid 1-undecanol and 1-tetracosanol. Image C
shows the Raman spectra of i.1-undecanol and ii.1-tetracosanol layered on the surface of physiologically
buffered saline, iii. human tears, and iv. physiologically buffered saline alone. The density of the synthetic
lipids is 0.69 µm.
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Figure 4.2(5).243 Ordered and Disordered Wax Conformations. The schematic above illustrates ordered and
disordered wax conformations. Lipid order is directly related to viscosity but indirectly related to fluidity.
Gauche rotamers cause kinks in the hydrocarbon chain that hinders tight packing. Increasing lipid order is
owed to less gauche rotamers and a higher quantity of trans rotamers.
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When lipid hydrocarbons are disordered as in liquid 1-undecanol, the hydrocarbon
chains are bent, minimizing van der Waals’ interactions between chains. The bends are
due to gauche rotamers in the hydrocarbon chains. The band due to gauche rotamers is
well resolved in the Raman spectra of 1-undecanol [Figure 4.2(4) B(i)].
The area of the CH stretching bands can be used to estimate the amount of lipid in the
5 µm2 region sampled by the incident laser. Besides the large Raman H-O-H stretching
bands from water near 3,400 cm-1,334 the CH stretching bands predominant the spectra of
1-hydroxylhydrocarbons on the surface of PBS [Figure 4.2(4)C]. The CH stretching band
area was relatively uniform on the surface of the PBS, deviating by only 8 ± 5% of the
average for 1-undecanol and 6 ± 5% of the average for 1-tetracosanol.
The peak height intensity ratio for 1-undecanol and SLATERAL was significantly larger
(P < 0.01) on the PBS surface compared with the liquid, 1.7 ± 0.1 and 0.66 ± 0.02,
respectively. This indicates that the lipid-lipid interactions associated with 1-undecanol
changed from completely disordered when alone to a more ordered state when placed on
the aqueous surface. The peak height intensity ratio for 1-tetracosanol and SLATERAL was
not significantly different (P > 0.05) on the PBS surface compared with the solid, 1.8 ±
0.1 and 0.70 ± 0.03, respectively.

4.3 DISCUSSION- SPECIFIC AIM 1.
Intuitively, one would expect that a hydrophobic uniform layer of lipid on an aqueous
surface would inhibit Revap of water. As stated in the Introduction, studies done over 60
years ago suggest that lipids on the aqueous surface offer resistance to evaporation311312

and perhaps could be used to slow the evaporation of water in reservoirs.322 In the

current study, we repeated earlier studies involving the inhibition of evaporation by 1109

undecanol and other alcohols.309 Raman spectroscopy was used to measure the
conformation of human meibum and synthetic lipids on the surface of tears and PBS in
vitro, and to visualize the film.
In our study, long chain alcohols did attenuate Revap of PBS when excess lipid was
applied, but not at the 50% differences expected with this experiment. This is in
agreement with four trials with control and experimental reservoirs (Capella study) of
equal size and one of three trials using the unequally sized reservoirs at Derenbandi that
showed that cetyl alcohol did not inhibit Revap,309 leading one to wonder if a thin
monolayer on the surface of a reservoir is sufficient to reduce Revap. If careful layering
of lipid on the surface of PBS in the laboratory did not inhibit evaporation, it is unlikely
that simply placing lipid on a pond with the wind, rain, lipid degradation and impurities
will have much of an effect on the Revap.
Chain length had a significant but minimal effect on Revap, but the change was
opposite to a study that calculated the resistance to evaporation increased with
hydrocarbon chain length.312 The attenuation of Revap by lipids was minimal in our
study, and fluid long-chain alcohols such as 1-undecanol and very ordered long chain
alcohols such as 1-tetradecane did not reduce Revap by more than a few percent. We
found that the amount of lipid on the surface (estimated to be 0.7 to over 7 µm thick) did
not affect Revap in agreement with in vivo studies.120, 257, 335-338 Our results indicate that
when a water molecule achieves sufficient energy to escape the surface, it escapes
whether the interface is a layer of lipid or air. The water molecules find their way into the
lipid layer and eventually make their way to escape as a gas into the air. So although the
lipid layer could slow the movement of water through the lipid,312 Revap is unaffected by
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lipid. Unexpectedly, the conformation of fluid 1-undecaol became more ordered when
layered on the surface of PBS.
The next step in our investigation was to relate the structure of synthetic alcohols as it
relates to the structure of meibum. Whether the structures are similar or not, the idea was
to determine if meibum has a preventative effect where meibum is concerned. The
structure of 1-undecanol became more fluid at close to physiologic temperatures of the
eye, which averages 35°C. Meibum should become more fluid, allowing for better
distribution across the aqueous surface if indeed meibum’s role in the TF is to cover the
surface, protect, and impede the Revap. Therefore, one would expect the meibum to have
a better effect than what was observed using synthetic alcohols.
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5. SPECIFIC AIM 2.2

To investigate the role of meibum in altering Revap.

5.1. RESEARCH DESIGN- SPECIFIC AIM 2A.
5.1.1. RATIONALE- SPECIFIC AIM 2A.
The Revap of tears has been studied for decades and is relevant to DED etiology,
including the aqueous production-deficient type and evaporative type associated with
MGD.339 Both DED classifications share the common feature of the TF's instability with
rapid TBUT and higher osmolarity. DED affects more than six million people in the
United States alone,55 and half of all DED cases in the united states have been classified
as purely evaporative or mixed evaporative and MGD.340 Studies have shown that tears
evaporate at the same rate as PBS.329 According to calculations, a wisp of dry air could
evaporate the tears on the eye's surface in 3 s.329
A thin 0.1 µm thick TFLL covers the surface of tears.120-121 It has been suggested that
one of the functions of the TFLL is to inhibit Revap of the 3 µm aqueous layer of tears
below it.287 Investigators have speculated that meibum, the primary source of TFLL,110 is

This chapter is a slightly modified version of the article “Evaporation and hydrocarbon chain
conformation of surface lipid films” published in The Ocular Surface 2016, 14 (4), 447-459, the original
source. © 2016 Elsevier Inc. All rights reserved
2
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responsible for inhibiting the Revap of tears287 and thus, increases TF stability.243 This
former idea has been challenged,278 as support for this idea comes from rabbit studies
done over 50 years ago.288-289 The studies focused on removing lipids from rabbits' tears
and then restoring lipids by injecting lipids into the eye's anterior chamber.288-289 The
studies concluded that adding lipids to lipid-depleted eyes decreased Revap by over
75%.288-289 The problem with this study was that meibum was not used; the lipid was
injected behind the TF, not on top of it. No one has shown a decrease in Revap using
healthy human tears as an aqueous subphase.282-285 Other studies placed meibum on the
PBS's surface, but no reduction in the Revap was demonstrated.290 A reduction of Revap
by surface lipids that were conventionally seen as significant to TF stability was not seen
in vitro.284-285, 291 Evaporation is related to TF breakup, a measure of TF stability;
however, evaporation is static and does offer a complete explanation of TF thinning.278,
292

Furthermore, wax ester films emulating the depth of the TFLL were found to inhibit

evaporation up to 50% when wax esters are within 2% of their melting temperature;341 at this
temperature, fluid and ordered phases co-exist.342 The wax ester, ethyl stearate, had a specific
resistance (to evaporation) between 1-octadecanol and stearic acid.321

In vivo studies show that TBUT decreases and Revap accelerate where the human lipid
layer is absent or divergent, and the TF is unstable.343 However, a durable unscathed
TFLL, regardless of consistency, retards tear evaporation.343 Comparisons of
thermographic images and fluorescein breakup images implicate localized high
evaporation as the cause of the localized breakup but the overall Revap remains the
unaffected.344-346 This suggests that the likely cause of high evaporation is due to the
integrity of the TFLL, and in that specific region, evaporation resistance is low compared
to higher resistance in surrounding regions. In reality, TBUT,343 but not tear
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production,347 inversely corresponded with Revap. Temperature and Revap are also
related.348 Additionally, authors favor the idea that the Revap changes through the lipid
layer, which play a role in TF instability and DED by merit of the TF's dynamics and
function concerning the blink cycles. 349 Three studies have shown that a film of
human,284, 291, 314 and bovine285 meibum does not inhibit Revap of PBS in vitro, justified
by the differences in the rheology of meibum on the surface of artificial tears compared
with PBS.285
Based on the studies above, it would be informative to determine how meibum
composition, structure, and Revap are related using carefully controlled conditions in
vitro.

5.1.2. SPECIFIC AIM 2A. APPROACH
Our second objective was to determine the role of meibum in altering the Revap. In the
current study, to assess the contribution of meibum to the Revap, we used meibum and
TR from healthy donors.
Recall from section 4.1.2. TBUT is decreased by 50% with DED; therefore, lipid films,
namely meibum, on the ocular surface are expected to increase TBUT by 50% compared
with aqueous alone. So we would expect a significant 50% difference in Revap rates
between aqueous subphases layered with and without healthy meibum if indeed meibum
inhibits Revap.

Preparation
Human TR and human meibum from donors without DED was collected as described
in Section 3.1.2.2. The meibum was collected over of range of ages and grouped as
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illustrated in Table 5.1(1) to have a sufficient amount of meibum for experiments. In
addition, Revap was measured gravimetrically as described in section 3.2.2. and
measured at 35°C, as described in section 3.2.2.1.
The following combinations of models were studied in vitro. For experimental
models, meibum from healthy donors was layered on the surface of PBS; and meibum
from healthy donors was layered on the surface of TR. Additionally, the Revap for TR
alone was evaluated. PBS was used as a control in all experiments.

Evaluating Lipid Spreading Using Microscopy and Raman Hydrocarbon Chain
Conformation
The spreading of meibum on the surface of the eye models was evaluated using
microscopy. The difference in the spreading of meibum on the aqueous surface was
assessed." 243 The Raman laser microscope was used to measure 40 Raman acquisitions
as described in Section 3.2.4.1.

Statistics
Data are presented as the mean ± the standard deviation unless otherwise indicated."
243

A P < 0.05 was considered statistically significant using the Student's t-test.
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Sample

Demographics

Pool 1

C61M

Pool 2

C21F, C19F, B39F, C61M

Pool 3

C4M, C4M, C6F

Table 5.1(1). Meibum Demographics.243 The right column of the table shows the age, race, and gender of
the meibum donors. The letters in the table represent the following: C-Caucasian, B-Black, M-Male, and Fmale. The age of donors is represented by the numbers in the chart; #-Age.
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5.2. RESULTS- SPECIFIC AIM 2A.
Revap
The Revap of PBS was linear with an average correlation coefficient r = 0.99 ± 0.01, so
the evaporation rate did not change with time. Revap of PBS and human TR with a film
of human meibum 34.4 µm thick was measured at 35°C. Revap of human TR and PBS
with human meibum was not significantly different, P > 0.05 [Figure 5.2(1)] as was the
Revap of human TR alone compared with PBS alone, P > 0.05 [Figure 5.2(1)]. In
addition, Revap of human TR was not significantly different P > 0.05 [Figure 5.2(1)]
from the PBS at an estimated thickness of 34 µm.

Lipid spreading and Hydrocarbon Chain Conformation
Microscopy
In the Raman spectrometer, the meibum layered on the surface of human TR appeared
in vitro as 2 µm diameter [Figure 5.2(2) A-D] and larger 10 µm diameter [Figure 5.2(2)
E] 'islands' and as no islands at all [Figure 5.2(2) F]. The islands were in motion and
moved in and out of the field of view. Human meibum on the surface of TR appeared
more densely packed with 5 µm2' islands’ occasionally visible [Figure 5.2(2) top].
Sometimes, and at a smaller magnification, large dark 70 µm2 regions were visible,
surrounded by a colorful swirl of surface lipids [Figure 5.2(2) top, E and F], much like
the rainbow swirl of motor oil in a puddle.
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Figure 5.2(1). Average Rate of Evaporation of Human Reflex Tears and Physiologically Buffered Saline
with and without Human Meibum.243 The average rate of evaporation was measured for human reflex tears
(TR) and physiologically buffered saline (PBS) exposed to 34.4 µm thick human meibum films at 35°C.
The meibum was more than ten times the thickness of a biological tear film lipid layer because no
differences were observed with amounts that mimic the true tear film lipid layer. Additionally, Raman
analysis showed that the meibum spread 100% on the tear film lipid layer model. The average rate of
evaporation for the two aqueous subphases without meibum exposure was measured and compared. The
rate of evaporation for human tears and PBS with and without meibum exposure were not significantly
different (P > 0.05). The Bars represent the ± standard error of the mean. The values in parentheses are
indicative of the number of trails for each sample. The numbers above the bars represent the number of
trials for each sample.
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Figure 5.2(2). Microscopic Images of Human Reflex Tears and Physiologically Buffer Saline Exposed to
Human Meibum from Healthy Donors.243 The images above were captured under white light using the lens
and camera from a Raman spectrometer. Images A-E (top) and A-E (bottom) show a 5 µm2 area of the
surface of human tears and physiologically buffered saline exposed to meibum from donors with no sign
and symptoms of dry eye disease, respectively. Note that each image was captured at a different place on
the surface and is the area sampled by the Raman laser to obtain acquisitions for the Raman spectra. The
scale bar pictured at the bottom of the image is 10 µm.
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Qualitative analysis shows that the meibum's surface texture roughness placed on the
PBS [Figure 5.2(2) top] was significantly greater than that of meibum placed on TR
[Figure 5.2(2) bottom]. All of the regions of the surface of TR, even those without
islands, provided a Raman CH stretching region spectrum characteristic of lipid and
water [Figure 5.2(3) A]. From this analysis, it was determined that the lipid film covered
the entire surface. Raman spectra were taken from at least five regions of each of the
samples. The intensity of the CH stretching bands varied by a relative standard deviation
of 21 ± 13%.
Other analyses included measurements below the aqueous surface. Raman spectra
analysis was performed for TR below the surface using tears collected in capillary tubes
[Figure 5.2(3) B]. Spectral analysis shows that no lipid was detected below the surface,
as indicated in these spectra [Figure 5.2(3) B], which were characteristic of PBS. [Figure
5.2(3) C] and water [Figure 5.2(3) D].
[Table 5.2(2)] shows meibum from human donors without DED symptoms collected
over various ages. The CH stretching bands indicative of human meibum were
predominant in the Raman spectra of the human Meibum samples [Figure 5.2(4) A(i)]
and were typical and similar to published Raman spectra data.332 Characteristic band
assignments for this region of the spectra are listed in Table 5.2(3).332 Seven bands were
resolved in the CH2 stretching region.
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Figure 5.2(3). Raman Spectra.243 The image above shows typical Raman spectra for four sample types.
Raman spectrum A is the surface of human reflex tears in vitro. Raman spectrum B was obtained from
human tear in a capillary tube. Raman spectra C is physiologically buffered saline. Raman spectrum D is a
result obtained from water. Notice that the spectra for B-D are identical. No meibum lipid was observed in
spectra B-D.
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Sample

Demographics

Pool 1
Pool 2
Pool 3

C61M
C21F, C19F, B39F, C61M
C4M, C4M, C6F

Phase Transition
Temperature (°C)
29.3 ± 0.4
28.9 ± 0.6
34.8 ± 0.5

Table 5.2(2). Sample Parameters for Meibum.243 The table above illustrates the demographics and phase
transition temperatures for each sample group. The phase transition is the temperature at which lipids
undergo phase changes, going from a more ordered to a less ordered state. At these temperatures the lipids
become more fluid, and thus, should spread better. The middle column of the table displays the
demographics for meibum donors in each experimental group. The letters and numbers in the table
represent the race and age: C-Caucasian, B-Black, M-Male, F-male, #-Age. The right column displays the
phase transition temperature for each sample group. Each sample group were within the temperature range
for phase transition changes as the samples were heated to physiological temperatures for the eye, which
averages 35°C.
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Figure 5.2(4). Raman Spectra.243 The images above are typical Raman spectra of i) human meibum, ii)
human reflex tear surface, and iii) human reflex tears exposed to human meibum. Raman spectrum A
shows the CH stretching region. Spectrum B and C shows the fingerprint region and C-C acoustic mode
region, respectively. The numbers correspond to band assignments listed in the table below [Table 6.2(3)].
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Band Numbers in Figures
1
2

Frequency cm−1
3010
2958

3

2935/2928

4

2894-2884

5
6
7
8
9
10

2870
2846
2725
1740
1650
1516

11
12
13

1439
1300
1260

14

1156

15

1133

16
17

1064

18

720

Assignment
Unsaturated =CH stretch
Chain end CH3 asymmetric
stretch
Out-of-plane chain end symmetric
CH3 stretch
vibration/antisymmetric infraredactive CH2 stretch
Raman-active Femi resonance
CH2 stretch
Chain end CH3 symmetric stretch
CH2 symmetric stretch band
C-H stretch
C=O
C=C, Amide I
Coupled and conjugated C=C inplane stretch
CH2 bend
CH2 twist
=C-H in-plane deformation,
unconjugated
C-C stretch in conjugated C=C
molecules
Raman skeletal optical mode Ag
vibrational modes of all-trans
rotamers
Raman skeletal optical mode for
gauche rotamers
Raman skeletal optical mode B1g
vibrational modes of all-trans
rotamers
C-C twist

Table 5.2(3).332 Raman Band Assignment. Band assignment were made from this data. The band numbers
labeled in Figure 5.2(4) correspond with numbers in the first column (moving from the left). The data for
these bands are also similar to the data in this table
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Raman Analysis
Human TR showed significantly (P = 0.005) higher peak height intensity ratio,
I2886/I2850, and SLATERAL, compared with human meibum alone [Table 5.2(4)]. This
analysis favors the native tear lipids in TR as being much more ordered than human
meibum alone. Equivalently to TR (native tear lipids), hydrocarbon chain order of human
meibum placed on the surface of TR in vitro undoubtedly became significantly (P < 0.01)
more ordered as the ratio I2886/I2850 and SLATERAL were significantly (P < 0.01) higher
compared with human meibum alone [Table 5.2(4)]. The data also show no significant
difference (P > 0.05) between the ratios, I2886/I2850, or SLATERAL, of meibum placed on the
surface of human TR compared with TR (native tear lipids) or meibum placed on the
surface of the PBS.
As previously published, Figure 5.2(4) Ci shows the Raman skeletal optical mode
region for meibum lipids. The bands were seen at 1064 and 1133 cm−1 are assigned to the
B1g, and Ag vibrational modes of all-trans-, ordered- chain segments. The intensity in
the two bands is smaller in the spectrum of human meibum compared [Figure 5.2(4) Ci]
with the spectrum of meibum on TR [Figure 5.2(4) Cii] and TR (native tear lipids) alone
[Figure 5.2(4) Ciii].332 Contrary to the bands seen at 1064 and 1133 cm−1, the band near
1080 cm−1 is due to gauche rotations that lead to disordered hydrocarbon chains,40 and
the intensity of the band is much more prominent in the spectrum of human meibum
compared [Figure 5.2(4) Ci] with the spectrum of meibum on TR [Figure 5.2(4) Cii] and
TR (native tear lipids) alone [Figure 5.2(4) Ciii].
The CH2 stretching band intensity measurements infer that when meibum was placed
on the surface of TR in vitro, the hydrocarbon chains became more ordered and that TR
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(native lipids) ordered containing trans rotamers. These results were confirmed by
Raman skeletal optical mode.
Meibum placed on the surface of TR in vitro undoubtedly became significantly (P <
0.01) more ordered as the ratio I2886/I2850 and SLATERAL were significantly (P < 0.01)
higher compared with human meibum alone [Table 6.2(4)]. The data also show no
significant difference (P > 0.05) between the ratios, I2886/I2850, or SLATERAL, of meibum
placed on the surface of human TR compared with TR alone or meibum placed on the
surface of the PBS.
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Sample Number
1 sample on Tears
2 pooled on Tears
3 pooled on Tears
3 pooled on Buffer
Reflex Tears
Meibum

Demographics*‡†
C61M
C21F, C19F, B39F,
C61M
C4M, C4M, C6F
C4M, C4M, C6F
C61M (3 pools)
Samples 1, 2, and 3

Average H-1 I2886/I2850
1.67 ± 0.06 (n = 5)
1.7 ± 0.2 (n = 3)

Average Slateral
0.64 ± 0.04

1.52 ± 0.07 (n = 12)
1.5 ± 0.2 (n = 12)
1.7 ± 0.1 (n = 8)
1.14 ± 0.04 (n=3)†

0.55 ± 0.05 (n = 12)
0.54 ± 0.11 (n = 5)
0.66 ± 0.07 (n = 8)
0.30 ± 0.01 (n = 3)†

Table 5.2(4). Pooled Meibum and Reflex Tear Sample Demographics.243 The average H-1 and average
S

lateral for meibum layered on the surface of tears, meibum layered on physiologically buffered saline,

tears alone and meibum alone. The average H-1 and Slateral for meibum on tears, meibum on
physiologically buffered saline, and tears alone was significantly higher (P < 0.01) than meibum alone. The
numbers in parentheses represent the number of samples tested for each row. C= Caucasian; B= Black; F=
Female; M= Male
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5.3. DISCUSSION- SPECIFIC AIM 2A.
As stated previously, the notion that the meibum must be fluid enough to exit the
Meibomian gland and ridged enough to withstand shear forces to delay breakup time on
the TF surface was supported by our data. Spectroscopy and microscopy show that
meibum, when placed on the surface of tears or PBS, forms a continuous but irregular
layer of lipid. Hydrocarbon chain conformation changed from a disordered to ordered
conformation, moving from primarily gauche rotamers to mostly trans rotamers. There is
a strong correlation between lipid order and viscosity. The lipid hydrocarbon chains can
pack more closely together due to an increased number of trans rotamers. Van der Waal’s
interactions are maximized, so the lipids are less free to move and are more viscous.
Experiments were repeated over 60 times by several investigators during the current
study, and contrary to what the hypothesis speculated, investigators found that meibum
did not inhibit the Revap. These findings are concurrent with other studies.284, 291-292, 309,
314, 321, 329-330, 341

One explanation for why we do not see evaporation inhibition involves

water behavior on an irregular surface. At the lipid-aqueous interface, water travels
around the islands of lipids and evaporates through the thin monolayer between islands.
The ability of lipids to inhibit Revap is complicated and is supported by a bilayer study.
Investigators stated, “…even if 99.8% of the surface is occupied by bilayer, the presence
of only 0.2% of the surface as monolayer is sufficient to reduce the specific resistance of
a bilayer surface film…”350
Another possibility for why meibum did not inhibit Revap could be explained by the
material used as the aqueous subphase in experiments. In previous studies,284, 291, 314 PBS
instead of human tears were used. This observation is relevant because the rheology of
meibum on tears is different for meibum on the PBS.285 Water is excluded at the TFLL128

aqueous tear interface during interaction of meibum with tears, and as a result of this
interaction, it was speculated that Revap was inhibited.351 This current study tested the
idea that factors in TR (such as proteins in TR) interact with human meibum placed on
the surface of human TR, and together they inhibit Revap. In any case, where PBS or
tears were used as an aqueous sub-phase, Revap was not deterred by meibum.
To determine if differences between aqueous subphases played a role in why changes
in the Revap were not observed, PBS and TR alone were compared. The results showed
no difference between the Revap of TR and PBS. Additionally, where either subphase
was used in combination with meibum, no changes were observed. In conclusion, when
looking at the data it does not appear that the aqueous subphase used in experiments is a
factor in Revap.
Raman analysis show that meibum behaves different with TR compared with PBS.
This would suggest that we don’t see differences with Revap because of the differences
in rheology, still, no differences are seen. Perhaps the differences in Revap seen with
DED occurs because of factors involving the composition of meibum alone. It would be
informative to test meibum from different sources, as presented in the next section, to
determine if disease state has an effect on Revap. There may be factors involved with
disease meibum that cause it to behave differently in DED. The interaction between
diseases meibum and the aqueous subphase could accelerate the Revap, thus explaining
the increases seen with DED. In short, it could be the source or types of meibum rather
than meibum in a general sense that affects Revap. If changes in meibum composition
and structure occurring with the disease do not explain differences seen in Revap
between normal and disease meibum, it would be logical to consider the interphase as a
rationale for changes in Revap observed in vivo.
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6. SPECIFIC AIM 2/2B.

To investigate the role of disease meibum in altering the Revap.

6.1. RESEARCH DESIGN- SPECIFIC AIM 2B.
6.1.1. RATIONALE
The perception that TFLL functions to attenuate aqueous tear evaporation has been
widely accepted as a convention. In vitro studies involving human meibum, including
the study outlined in Section 5.1.2, do not corroborate these findings. One may surmise
that where meibum is deficient, the integrity of TFLL is compromised, and this breach
exposes the aqueous subphase to rapid evaporation. However, data from microscopic
studies outlined in the previous chapter refute this. Meibum has been shown to spread
across the whole surface of the aqueous subphase in vitro. According to the study's
observations, meibum spreads spontaneously to cover the surface, leaving irregular
dispersal of islands. Other studies support these observations and show this behavior to
be consistent with what is seen in vivo.

6.1.2. APPROACH
Our next objective was to determine the role of meibum from donor with DED (MDED)
and meibum from donors who have undergone HSCT (MHSCT) in altering Revap. We
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tested the hypothesis that changes could occur with diseased meibum to alter interactions
with aqueous subphases, thus altering the Revap. Perhaps the differences in Revap
observed between normal and disease states are only evident when disease is considered.
In other words, it is plausible that changes are only seen with disease states, and this
would explain why changes in Revap are not observed with healthy meibum. If there is
an association between meibum and tear evaporation, we should see changes. However,
if no changes are detected, we should consider that other ocular surface components have
an interrelationship with TF fluid retention.
Our samples from donor with DED were measured alongside normal meibum
(MNORMAL) and PBS alone. Recall that we are looking for 50% changes in evaporation if
evaporation is to play a role in decreased TF stability. As noted in sections 4.1.2 and
5.1.2, TBUT is 50% lower with DED, so one would expect a 50% decrease in Revap with
MDED on the surface compared with MNORMAL. We expect to see differences between the
Revap of aqueous subphase between disease and healthy state, as well as an aqueous
alone.

Preparation
Human meibum from donors diagnosed with DED [Table 3.1(1)] and donors who have
undergone HSCT [Table 3.1(1)] was collected as described in Section 3. For this study,
we decided to also control time and temperature to assess whether these factors
contribute significantly to Revap. Other factors such as wind and temperature may
contribute to Revap.
Revap were measured gravimetrically at physiological temperatures, Section 3.2.2.1.,
and at room temperature, Section 3.2.2.2. The samples were not sonicated in the eye
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model as reported before because sonication did contribute significantly to Revap.
Instead, the meibum installation to the aqueous surface was followed by a 10-minute
delay to allow for the natural dispersion of lipids.
The following combinations of models were studied in vitro. For experimental control
models, meibum from healthy donors with no sign or symptoms of DED (MNORMAL) was
layered on the surface of PBS. For disease models, meibum from donors diagnosed with
DED (MDED) or HSCT donors (MHSCT) were layered on the surface of PBS. Additionally,
models with PBS alone were consistently tested with experimental models in these
experiments.

3-Hour Dispersion
Phase one of the evaporation experiments was followed by an 80-minute delay, and the
end of the delay marked the 3-hour post meibum addition to the TF models. The aim was
to measure evaporation after a 3-hour equilibration of lipids. A temperature of 35°C was
maintained during the delay to mimic the physiological environment. The Revap of the
samples were then measured, as in Section 4.2.2. ’Measuring Revap’, for 100 minutes.

Evaluating Lipid Spreading
The spreading of meibum on the surface of the eye models was evaluated using
microscopy. The difference in the spreading of meibum on the aqueous surface was
assessed.243 The dispersion of islands, as observed in earlier experiments and
characteristic of the ocular surface in vivo, was quantified using Image J analyses
(Eliceiri/LOCI, University of Wisconsin-Madison; MPI-CBG, Dresden). This analysis is
described in Section 3.
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Statistics
Data are presented as the mean ± the standard deviation unless otherwise indicated." 243 A
P < 0.05 was considered statistically significant.

6.2. RESULTS- AIM 2B.
Revap
Our first objective here was to determine if MDED or MHSCT alters the Revap of the
aqueous component beneath. First, the Revap of evaporation was measured for PBS and
PBS with meibum. The meibum samples included MNORMAL, MDED, and MHSCT. Revap of
PBS with a film of human meibum 34.4 µm thick was measured at 35°C or 22°C for all
meibum types.

Physiological Temperatures- Rates of Evaporation After 10-Minute Equilibration Time
All Revap measured in this aim were linear with an average correlation coefficient r =
0.99 ± 0.01. The average Revap for PBS and PBS with MNORMAL or MHSCT was identical.
The Revap for PBS with MHSCT was not significantly different compared to PBS alone. In
comparing the PBS with MDED, the Revap was not significantly different compared with
unexposed PBS. In short, no statistically significant differences were observed with the
average Revap for PBS with any group of meibum compared with PBS alone [Figure
6.2(1)], P > 0.05. The Revap of MNORMAL and MDED, or MHSCT [Figure 6.2(1)] were not
different, P > 0.05. There was no significant difference between Revap of MDED and
MHSCT, P > 0.05.
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Physiological Temperatures- Rates of Evaporation After 3-Hour Equilibration Time
After measuring and recording the Revap, the samples were allowed to sit for an
additional 80 minutes. The measurements were then repeated. The average Revap was
not significantly higher for PBS exposed to any individual group of meibum compared
with PBS alone, P > 0.05, after 3 hours of equilibration. Similar to the first phase of the
experiments, no differences are seen in Revap of PBS alone compared to PBS exposed to
either MNORMAL, MDED, or MHSCT after 3 hours; P > 0.05 for all samples. Revap of
MNORMAL compared with either MDED or MHSCT was not significantly different, P > 0.05.
Significant changes were not observed, P > 0.05, between MDED and MHSCT [Figure
6.2(2)]. The Revap for all samples during this experiment were linear.
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Figure 6.2(1). Average Evaporation Rates of Physiologically Buffered Saline Exposed to Normal, Dry Eye
Disease, and Hematopoietic Stem Cell Transplant Human Meibum After a 10-Minute Equilibration. This
graph shows comparisons of the average rate of evaporation of physiologically buffered saline (PBS)
exposed to all meibum groups, with [MHSCT (hematopoietic stem cell transplant) and MDED (dry eye
disease)] and without disease (MNORMAL). After a 10-minute equilibration, the average rate of evaporation
was measured for PBS with 34.4 µm thick human meibum films at 35°C. Additionally, the average rate of
evaporation for PBS without meibum exposure was measured. The rate of evaporation for PBS with and
without meibum exposure were not significantly different (P > 0.05). The Bars represent the ± standard
error of the mean. The values in parentheses are the number of samples averaged for each group.
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Figure 6.2(2). Average Rate of Evaporation of Physiologically Buffered Saline Exposed to Normal, Dry
Eye Disease, and Hematopoietic Stem Cell Transplant Human Meibum After a 3-Hour Equilibration. The
average rate of evaporation was measured for physiologically buffered saline (PBS) exposed to 34.4 µm
thick human meibum films at 35°C, after the initial evaporation measurements. This graph shows
comparisons of the average rate of evaporation of the same samples of PBS exposed to meibum [MHSCT
(hematopoietic stem cell transplant) and MDED (dry eye disease)] and without disease (MNORMAL), see
Figure 6.2(1). Additionally, the average Rate of evaporation for the PBS without meibum exposure was
measured and compared to samples exposed to meibum. The average rate of evaporation for PBS with and
without meibum exposure was not significantly different (P > 0.05). Comparisons between each meibum
sample group were not significantly different, P > 0.05. The Bars represent the ± standard error of the
mean. The values in parentheses are indicative of the number of samples averaged. Sledge and the
Borchman lab provide the graph above.
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Rates of Evaporation Over Longer Equilibration Time
The next objective was to address the effects of a longer equilibration time on the
Revaps. To meet this objective, the next step involved measuring the Revap of PBS
exposed to meibum from MNORMAL and MHSCT donors at 35°C, after 10-minute and 24hour of equilibration time.
The average Revap were linear for all three samples at 10-minutes and 24-hour
equilibration times, average r = 0.99 ± 0.01. There was no difference in evaporation rates
of PBS exposed to either MNORMAL or MHSCT compared with PBS alone [Figure 6.2(3)], P
> 0.05. Similarly, the average Revaps did not differ between MNORMAL and MHSCT
compared with PBS alone after 24-hours, P > 0.05. There were insignificant differences
in the Revaps of PBS exposed to MNORMAL compared with MHSCT for both time intervals
[Figure 6.2(3) and Figure 6.2(4)]. The average Revaps did not differ within any group
over time [Figure 6.2(4)].

Rates of Evaporation with Temperature Variations
The final objective was to determine the effects of temperature on the Revap. To
address this question, Revap of PBS layered with meibum from MNORMAL and MHSCT
donors at 22°C and 35°C, after 10-minute and 24-Hour equilibration were compared.
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Figure 6.2(3). Average Evaporation Rates of Physiologically Buffered Saline Exposed to Normal and
Hematopoietic Stem Cell Transplant Human Meibum at 22°C and 35°C After a 10-Minute Equilibration.
The average evaporation rate was measured for physiologically buffered saline (PBS) exposed to 34.4 µm
thick human meibum films [MHSCT (hematopoietic stem cell transplant) and normal (MNORMAL)] at 22 and
35°C. At 22°C degrees, there was no difference in the rate of evaporation for PBS with meibum compared
with control. At 35°C degrees, there was no difference in rate of evaporation of PBS with meibum
compared with control. However, when temperature differences are compared, we see very significant
differences in the rate of evaporation, as one would expect, P < 0.01. Additionally, the average rate of
evaporation for PBS without meibum was measured and compared to samples with meibum. The rate of
evaporation for PBS with and without meibum was not significantly different (P > 0.05). The Bars
represent the ± standard error of the mean. The values in parentheses are the number of samples averaged.
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Figure 6.2(4). Average Evaporation Rates of Physiologically Buffered Saline Exposed to Normal and
Hematopoietic Stem Cell Transplant Human Meibum at 22°C and 35°C After a 24-Hour Equilibration. The
average rate of evaporation was measured for physiologically buffered saline (PBS) exposed to 34.4 µm
thick human meibum films at 22 and 35°C, after 24 hours. This graph shows comparisons of the average
rate of evaporation of PBS exposed to normal (MNORMAL) and HSCT (MHSCT) meibum. This graph shows
that the rate of evaporation for PBS exposed to MNORMAL and MHSCT is compared with temperature
differences and time. Time does not affect the rate of evaporation. Comparisons of the PBS after 24 hours,
at 22°C and 35°C do show minor differences in rates of evaporation (P < 0.01), but the rate of evaporation
does not differ compared to control within the same time interval. Additionally, the average rate of
evaporation for the PBS without meibum exposure was measured and compared to samples exposed to
meibum. The rate of evaporation was measured again for all groups at 35°C after a 24-hour equilibration
[see Figure 6.2(3)]. The rate of evaporation for PBS with and without meibum exposure were not
significantly different (P > 0.05). When temperature differences are compared, we see very significant
differences in the rate of evaporation, as one would expect when heat is applied, P < 0.01. The Bars
represent the ± standard error of the mean. The values in parentheses are indicative of the number of
samples averaged.
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At 10-minute equilibration, the average Revap differed significantly for PBS exposed
to either MNORMAL or MHSCT at 22°C compared with 35°C [Figure 6.2(3)], P < 0.05.
Likewise, comparing samples measured at 22°C and 35°C after 24-hours equilibration
yielded statistically significant differences for PBS with MNORMAL and MHSCT [Figure
6.2(4)], P < 0.05. Nevertheless, the average Revaps did not differ for either group when
comparing equilibration time.

Lipid spreading
MNORMAL on the surface of PBS appeared in vitro as 2-10 µm diameter 'islands' and as
no islands at all, similar to the analysis of meibum spreading by microscopy in Aim 1.
The islands were in motion and moved in and out of the field of view. Qualitative
analysis shows that the meibum's surface texture was rough, as described before. The
meibum from HSCT donors was contrasting [Figure 6.2(5)]. The meibum spread on the
surface had a web-like appearance, with 2-10 µm diameter pools of thinner meibum
within the webbing. As seen before in the analysis of MNORMAL donors, it was evident
that the lipid film covered the entire surface; however, the meibum's density varied
throughout the lipid film. DED meibum also appeared as rough patches of islands
floating atop the buffer [Figure 6.2(6)]. Images were taken from at least five regions on
each sample [Figure 6.2(5)] and [Figure 6.2(6)].
Meibum clustering was analyzed for each sample to determine whether the number of
clusters differed between donor and sample type. No significant differences between
MNORMAL, MDED and MHSCT types, (P > 0.05) was observed when clusters were quantified
using Fiji software (Eliceiri/LOCI, University of Wisconsin-Madison; MPI-CBG,
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Dresden). There were no differences seen between donors in each representative group (P
> 0.05).
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Figure 6.2(5). Hematopoietic Stem Cell Transplant Donor Meibum. The images above were captured using
the Raman microscope. These images were taken in 5 different locations on the surface of physiologically
buffered saline exposed to meibum from pooled hematopoietic stem cell transplant donors (MHSCT). MHSCT
meibum can be seen in all regions, but the spreading is not uniform. In contrast to images taken of normal
meibum, MHSCT has web-like appearance with pronounced thinner and thicker layering. However,
clustering can be seen at all points.
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Figure 6.2(6). Dry Eye Disease Donor Meibum. The images above were captured using the Raman
microscope. These images were taken in 5 different locations on the surface of physiologically buffered
saline exposed to meibum from a dry eye disease donor (MDED). MDED can be seen in all regions, but the
spreading is not uniform. The appearance of MDED is rough with pronounced thinner and thicker regions.
The thicker regions (lighter in color and sometimes white) are so concentrated and closely packed, the
MDED appears as floating islands on a sea of physiologically buffered saline. However, the area around the
islets represents a more dispersed lipid. These thinner regions appear as gaps or lakes in comparison to the
thicker, more condensed regions.
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6.3. DISCUSSION- AIM 2B.
It has been hypothesized that meibum alone serves as a barrier to evaporation. The
hypothesis was rejected as there was a negative correlation between meibum and Revap.
MNORMAL did not attenuate Revap. Additionally, the Revap was no different when the
subphase was either human TR or PBS. For this portion of the thesis, the idea that
changes occurring in meibum with EDED associated with MGD effect Revap was tested.
Investigators attempted to demonstrate that changes occurring with meibum, between
normal and disease states, disrupt the function of meibum as a barrier and essentially the
TF's integrity. Perhaps these alterations would cause the aqueous subphase to evaporate
at a higher rate. Affirmation would provide evidence that meibum is a vital component to
tear evaporation, and therefore, structural changes occurring with meibum and interaction
with other moieties, such as PLs, are essential to unmasking the true identity of meibum
function.
Comparisons of the average Revap of PBS exposed to all groups of meibum at 35°C,
after 10 minutes of equilibration time, did not exhibit statistically significant differences.
Afterward, the samples were allowed to sit for an additional 10 minutes marking a twohour time point since exposure to lipids, and the measurements were repeated. No
difference was seen in Revap after 3-hour equilibration time.
Next, the study aimed to address the effects of other factors on Revap. Factors
affecting TF stability were considered, such as the time it takes for lipids to migrate
within the TF, temperature, and which internal and external factors could potentially alter
Revap. Comparing the Revap of PBS and PBS exposed to meibum from donors (normal
and disease) at 22°C and 35°C, and before and after 24-hour equilibration were not
significantly different. The Revap with temperature differences were compared. At 22°C
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degrees, there was no difference in the Revap for PBS exposed to meibum compared with
control. At 35°C degrees, there was no difference in Revap of PBS with any type of
meibum compared. However, when temperature differences were compared, there was a
significant difference in Revap. These results were not exceptional, as one would expect
to see increases in Revap at higher temperatures.
Images were taken at different regions of our TFLL model for meibum from normal
and DED. The images show that the spreading of meibum was uniform. However, some
clustering could be seen in the healthy and disease models. Additional quantification of
clustering did not reveal any significant differences between healthy and disease models.
The data did not support the hypothesis that the meibum layer alone acts as a barrier to
evaporation.
Higher Revap has been explained by forming spontaneous holes in lipid monolayers,
which allow water to escape by movement around lipid islands.316 This explanation is
plausible, as disruption in the film's integrity does not allow complete coverage.
However, analysis of lipid spreading by Raman and microscopy in this and the previous
chapters show that meibum completely covers the surface, although coverage is nonuniform. One could argue that the thinner regions, where coverage is non-uniform, are
sufficient to account for increased Revap or do not support a structure that would impede
Revap.
It would be beneficial to turn the focus to the interface of the TF, as it is worth
exploring the spreadability at the aqueous-lipid interphase. An earlier statement by
investigators suggests that lipids and the superior subphase of the TF alone do not offer a
complete explanation for TF thinning,278, 292 and thus, decreased Revap. Perhaps other
lipids should be considered, such as the PLs found in aqueous tears. If the polar lipids
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facilitate the spreading of the bulk lipid by forming a monolayer at the TFLL-aqueous
interphase,298-299 one should see changes in the Revap.
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7. SPECIFIC AIM 3

Determine if a reduction of PLs in the TFLL is associated with an increase in Revap
associated with DED.

7.1. RESEARCH DESIGN- AIM 3.
7.1.1. RATIONALE
Lack of PLs in the TFLL has been proposed as the basis for evaporative DED and TF
instability.241, 303 241, 303 Lipid properties and structures related to a sound barrier to
evaporation were discussed in Section 2.1.2.

7.1.2. APPROACH
This investigation's final objective was to determine if reduced PL interaction with
meibum in the TFLL is associated with an increase in Revap. In the current study, to
assess PLs' contribution to the Revap, we measured the Revap using meibum that does
not contain PL from donors with and without DED, and synthetic PL purchased from
Sigma (Section 3). The idea that components in human tears, namely PLs, interact with
human meibum by creating a scaffold on the aqueous surface to facilitate the spreading of
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meibum, was tested. PLs were hypothesized as the missing component from previous
experiments, and together, meibum and PLs inhibit Revap. This study also considered the
influence of individual types of PLs on the surface of PBS alone.
Recall from section 4.1.2. that TBUT is decreased by 50% with DED; therefore, lipid
films, namely meibum, on the ocular surface are expected to increase tear breakup and
increase evaporation time by 50% compared with aqueous alone. If we were expecting
evaporation to contribute to DED, we would expect meibum to increase evaporation by
50% in donors with DED. So, if TBUT and Revap are related, one would expect to see a
significant 50% change in the Revap between control and aqueous subphases layered
MNormal, MDED, and MHSCT.
To determine PLs' influence on the Revap of TF aqueous, we tested the following
combinations: PBS with MNormal, MDED, and MHSCT layered on the surface of PBS with
synthetic PLs. We also assessed the influence of individual types of PLs layered on the
surface of PBS alone. Recall that the PLs we used are the major types of PLs found in
tears and these lipids represent the PLs described in Section 3. In all experiments, PBS
alone was used as the control.

Preparation
Revap were measured gravimetrically, as reported in previous experiments,243, 329-330
and specific aim 2, but with some exceptions. After placing PBS into its respective
container, the model was transferred to a heating apparatus, and PBS was heated to 35°C.
The PBS temperature was taken at random intervals to ensure the desired temperature
was reached and maintained.
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PLs Only
Vials of PLs in warm water were sonicated to disperse them into multilamellar
vesicles. PLs emulating the concentration and ratio of PLs from the literature review were
layered on the surface of PBS using a micropipette. A 10-minute delay followed PLs'
application to the models' aqueous surface of 750µl of PBS to allow them to spread. The
following combinations of models were studied. Control models contained PBS only.
Experimental models contained PBS layered with either synthetic phosphatidylserine
(PS), phosphatidylethanolamine (PE), phosphatidylcholine (PC), or sphingomyelin (SM).
PBS was also layered with a mixture (PLC) of all synthetic PLs types in the ratio
described in the literature.

Meibum Layered with PLs
Vials containing a mixture of PLs emulating TF PLs in warm water were sonicated for
five minutes. The PLs were then transferred from the vials and placed on the surface of
750 µl of PBS using a micropipette. Vials of meibum were also sonicated for 5 minutes
using warm water to ensure the lipids' mixing. Lipids were transferred from the storage
vial using a micropipette and placed on the PL-laced PBS surface. A 10-minute delay
followed the application to allow for the spreading and equilibration of the lipids. Models
included: PBS layered with a mixture of PLs in the concentration found in tears PLC
alone, PBS layered with PLC and MNORMAL, PBS layered with PLC and MDISEASE, and PBS
layered with PLC and MHSCT. PBS alone was used as a control in these experiments.
Revap was measured at 35°C for all models as described in Section 4.2.2.
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3-Hour dispersion
Phase one of the evaporation experiments was followed by an 80-minute delay, which
then marked the 3-hour post PL/meibum installation to the TF models. The aim was to
measure Revap after a 3-hour equilibration of lipids. Temperature was maintained during
the delay to mimic a physiological environment. Revap was measured as described in
Section 3 for 100 minutes.

Evaluating Lipid Spreading
The spreading of meibum on the surface of the TFLL models was evaluated using
microscopy. The difference in the spreading of meibum on the aqueous surface was
assessed." 243 Image J (also described in Section 3) was used to quantify the characteristic
clustering observed under microscopy on the models' surfaces.

7.2. RESULTS- AIM 3.
Revap- PLs
As reported and similar to previous studies, the Revap of PBS and all samples layered
with phospholipids and meibum was linear, with an average r = 0.99 ± 0.01. The
Revap of PBS and PBS layered with a film of synthetic PLs was measured at 35°C. The
average Revap of PBS and PBS layered with SM or PS did not differ significantly, P >
0.05, from Revap of PBS alone [Figure 7.2(1)]. However, when the average Revap of
PBS was compared to PBS with a film of PE [Figure 7.2(1)], a significant difference was
observed, P = 0.013. When the Revap of PBS layered with PC was compared with PBS
alone, a significant difference was seen, P = 0.02 [Figure 7.2(1)].
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The TFLL models were then allowed to sit undisturbed for an additional 80 minutes to
enable additional lipid dispersion [Figure 7.2(2)]. Physiological temperatures were
maintained during this time. The average Revap for PBS layered with PE or PC
decreased over time. The differences observed at the 10-minute equilibration time were
no longer observed after three hours of equilibration time, P > 0.05. The average Revap
was similar to PBS layered with SM and PS, which did not differ significantly from the
PBS alone, P > 0.05. The Revap decreased for all samples over time.
The average Revap of PBS alone and PBS exposed to PLC was measured and
compared [Figures 7.2(3) and 7.2(4). There was no significant difference between the
PBS and PBS layered with PLC after 10-minute or 3-hour equilibration time, P > 0.05.
The average Revap decreased for both models over time; nevertheless, the difference
between the average Revap for PBS and PBS layered with PLC remained unchanged, P >
0.05.
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Figure 7.2(1). The Average Rate of Evaporation of Physiologically Buffered Saline Layered with Different
Types of Phospholipids After a 10-Minute Equilibration, at 35°C. The phospholipids in the graphs above
were determined by literature; sphingomyelin (SM), phosphatidylethanolamine (PE), phosphatidylcholine
(PC) and phosphatidylserine (PS). Each group of phospholipids is layer on the surface of physiologically
buffered saline (PBS) and compared to PBS alone as a control. Each column is the average of four sample
runs. The Bars above the columns represent ± standard error of the mean. *Indicates a significant
difference, P > 0.05 compared with PBS. The graph does show small but significant changes between the
average rate of evaporation of PE, P = 0.0133, and PC, P = 0.0211, compared with PBS alone.
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Figure 7.2(2). The Average Rate of Evaporation of Physiologically Buffered Saline Layered with Different
Types of Phospholipids After a 3-Hour Equilibration, at 35°C. The phospholipids in the graphs above were
determined by literature; sphingomyelin (SM), phosphatidylethanolamine (PE), phosphatidylcholine (PC)
and phosphatidylserine (PS). Each group of phospholipids is layer on the surface of physiologically
buffered saline (PBS) and compared to PBS alone as a control. Analysis of PBS with phospholipids after 3
hours show no significant difference between the rate of evaporation of PBS and or PBS layered with any
of the phospholipids over time, P > 0.05 for all samples. This is a marked contrast from Figure 8.2(1),
which shows a difference in the rate of evaporation of PE and PC after only a 10-minute equilibration time.
Over time and with increased migration of lipids, the difference in average the rate of evaporation between
PBS and PBS layered with phospholipids is insignificant. Each column is the average of four sample runs.
The Bars represent ± standard error of the mean.
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Figure 7.2(3). Rate of Evaporation of Physiologically Buffered Saline Alone and Physiologically Buffered
Saline Layered with Combined Phospholipids After a 10-Minute Equilibration, at 35°C. Investigators
sought to answer whether combined phospholipids (PLC) on the surface of physiologically buffered saline
(PBS) attenuate evaporative water loss. There is no significant difference when PBS is compared to PBS
exposed to PLC after 10-minute equilibration time, P > 0.05. Each column represents the average of four
sample runs. The Bars represent ± standard error of the mean.
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Figure 7.2(4). Rate of Evaporation of Physiologically Buffered Saline Alone and Physiologically Buffered
Saline Layered with Combined Phospholipids After a 3-Hour Equilibration, at 35°C. Investigators sought
to answer whether combined phospholipids (PLC) on the surface of physiologically buffered saline (PBS)
attenuate evaporative water loss. There is no significant difference when PBS is compared to PBS exposed
to PLC after 3-hour equilibration time, P > 0.05. Paired comparisons of PBS exposed to PLC at 10-minute
(Figure 8.2(3) and 3-hour equilibration time show no significant changes, P > 0.05. Each column represents
the average of four sample runs. The Bars represent ± standard error of the mean.
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Revap- PLs with Meibum
The final phase of these evaporation studies involved MNormal and MDED layered on
PLC. The average Revap of PBS for all models was linear over a period of 100 minutes.
The average Revap of PBS and PBS exposed to a film of PLC layered with MNormal was
not significantly different, P > 0.05 [Figure 7.2(5)] as was the Revap of PBS alone
compared with PBS exposed to PLC and MHSCT, P > 0.05. [Figure 7.2(5)]. Comparison of
the Revap of all three models decreased over time; however, the average Revap between
models was not significantly different P > 0.05 [Figure 7.2(6)].
The average Revap of PBS alone compared with PBS layered with MDED and PLC
[Figure 7.2(7)] was not statistically different after the 10-minute equilibration time, P >
0.05. The same was true for comparing the average Revap of PBS with PBS layered with
MDED only, P > 0.05. A comparison of MDED with and without PLC was not significantly
different, P > 0.05. In contrast, when MDED samples were compared after the 3-hour
equilibration time [Figure 7.2(8)], a significant difference was observed. PBS with a
meibum film layered on the surface of PLC was significantly higher, P = 0.02, than PBS
exposed only to MDED only. PBS exposed to MDED alone and MDED layered with PLC
were not substantially different from PBS alone, P > 0.05. Similar to other experiments,
the Revap of PBS decreased for all samples over time.
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Figure 7.2(5). Rate of Evaporation of Combined Phospholipids Layered with Normal and Hematopoietic
Stem Cell Transplant Meibum, After a 10-Minute Equilibration, at 35°C. Each model contains either
physiologically buffered saline (PBS) layered with combined phospholipids (PLC) alone or PBS exposed to
a film of PLC and meibum after a 10-minute equilibration. Here, the effects of normal meibum (M NORMAL)
with PLC is compared to hematopoietic stem cell transplant meibum (MHSCT) with PLC. No significant
difference is observed between the two meibum cohorts, P > 0.05. No statistical significance is found when
PBS layered with PLC alone is compared with PBS layered with PLC and exposed to either MNormal or
MHSCT, P > 0.05. The MNORMAL cohort contains an n=2; The meibum cohort contains an n=4. The Bars
represent ± standard error of the mean.
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Figure 7.2(6). Rate of Evaporation of Combined Phospholipids Layered with Normal and Hematopoietic
Stem Cell Transplant Meibum, After a 3-Hour Equilibration, at 35°C. Each model contains either
physiologically buffered saline (PBS) layered with combined phospholipids (PLC) alone or PBS exposed to
a film of PLC and meibum after a 3-hour equilibration. Here, the effects of PBS layered with normal
meibum (MNORMAL) and PLC is compared to PBS layered with hematopoietic stem cell transplant meibum
(MHSCT) and PLC. No significant difference is observed between the two meibum cohorts after 3 hours of
equilibration, P > 0.05. No statistical significance is found when PBS layered with PLC alone is compared
with PBS layered with PLC and exposed to either MNormal or MHSCT, P > 0.05. The MNORMAL cohort contains
an n=2; The meibum cohort contains an n=4. The Bars represent ± standard error of the mean.

158

Figure 7.2(7). Rate of Evaporation of Physiologically Buffered Saline Layered with Dry Eye Disease
Meibum or Dry Eye Disease Meibum and Combined Phospholipids After a 10-Minute Equilibration, at
35°C. The Rate of evaporation of physiologically buffered saline (PBS) alone, PBS layered with combined
phospholipids (PLC), PBS layered with dry eye disease meibum (MDED), and PBS layered with PLC and
MDED are compared. There is no significant difference between PBS and PBS exposed PLC or MDED.
Additionally, there was no significant difference between PBS and M DED with or without PLC. Each
meibum cohort contains an n=4. The Bars represent ± standard error of the mean.
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Figure 7.2(8). Rate of Evaporation of Physiologically Buffered Saline Layered with Dry Eye Disease
Meibum or Dry Eye Disease Meibum and Combined Phospholipids After a 3-Hour Equilibration, at 35°C.
The rate of evaporation of physiologically buffered saline (PBS) alone, PBS layered with combined
phospholipids (PLC), PBS layered with dry eye disease meibum (MDED), and PBS layered with PLC and
MDED are compared. There is no significant difference between PBS and PBS exposed PLC or M DED. There
was no significant difference when PBS exposed to PLC alone was compared with PBS layered MDED alone
or with PLC and MDED. However, statistically significant changes were seen between MDED with and
without PLC after a 3-hour equilibration *(P = 0.02, Student’s paired t-test). The Bars represent ± standard
error of the mean from four trials.
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Lipid spreading and Hydrocarbon Chain Conformation
Microscopy
In the Raman spectrometer, the meibum layered on the surface of PBS appeared in
vitro as 1 µm diameter and larger 10-15 µm diameter mobile 'islands' and as no islands
similar to the other Raman cluster analysis conducted in this study. Human meibum
appeared as more densely packed islands on the PBS surface [Figure 8.2(9), A and B, top
row]. In contrast, when meibum from the same donor (MDED) was layered on PLC, the
islands appear to dissipate [Figure 8.2(9), A and B, bottom row]. Qualitative analysis also
shows that the MDED surface texture was rough when placed on the PBS; however,
meibum aggregation was not significantly greater than that of MNORMAL layered on the
PBS.

Cluster quantity and size
Fiji (GNU; LOCI, Madison, WI; and MPI-CBG, Dresden, Germany) software was
designed to determine the size and number of cells from micrographs. Our study used it
to determine the size and quantity of aggregated meibum lipid with and without PLC.

Cluster Size
Cluster size varied dramatically from region to region and from sample to sample. For
instance, the MDED cohort's cluster size averaged 10 ± 5 pixels/um and 20 ± 5 pixels/um
for two models and 3 ± 1 pixel/um in another sample. Figure 8.2(9), top row] depicts
variation between cluster sizes within the same sample. The clusters at the center of the
model were larger than clusters at the periphery. Due to the large variability, no
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statistically significant differences were detected, P > 0.05, between the meibum lipid
clusters' size with and without PLC or between cohorts, HSCT, normal,
DED.

Cluster Number
For the MDED sample [Figure 7.2(9)], the average number of clusters per µm
decreased significantly (P = 0.018, paired Student’s t-test) with the addition of PLC by 66
± 16 % [Figure 7.2(9), C and D] from an average of 267 ± 54 clusters per um2 to 88 ± 27
clusters per um2 [Figure 7.2(9), A and B]. For the other two cohorts, MHSCT and MNormal,
the average number of clusters per µm did not change significantly (P > 0.05, paired
Student’s t-test) with the addition of PLC. The standard error for individual samples was
two to five times lower for the PLC-containing samples than the samples without PLC
[Figure 7.2(9)].
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Figure 7.2(9). Micrographs of Human Meibum from Donors Clinically Diagnosed with Dry Eye Disease
Before and After Phospholipid Application. This figure illustrates marked difference between the
appearance of dry eye disease meibum (MDED) before and after combined phospholipids (PLC) application.
Images A and B (top row) are central and peripheral views of images taken of MDED layered on the surface
of physiologically buffered saline (PBS). The meibum on PBS's surface appeared as rough densely packed
islands throughout the space provided on the PBS surface. Also notice that clusters in the center of the
model were larger than the clusters at the periphery of the model. In images C and D (central and peripheral
views, bottom row) PL C was applied to the surface of PBS prior to layering of M DED. MDED appears to
dissipate in the presence of PLC. Although some clustering is seen, it appears to be very little or at least
much smaller in comparison to MDED layered directly on the PBS surface.
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7.3 DISCUSSION- AIM 3.
The role of lipid films in decreasing the Revap was evaluated and discussed in
previous sections. Investigations found that the lipid films, whether synthetic or meibum,
did not reduce the Revap. The focus then turned to the role of PL's role in the TFs, as PLs
not found in meibum could potentially come from tear lipids bound to lacrimal proteins
296-297

or free micelles that form a monolayer and interphase298-299 between the TFLL and

the aqueous layer. The study aimed to determine if a reduced presence of PLs in the
aqueous subphase is responsible for increased Revap seen with DED, hoping to use PLs
to attenuate EDED.
The idea that PLs are this missing moiety in evaporation studies is plausible for
several reasons. A “multilamellar sandwich model”303 composed of bulk nonpolar lipids
and polar lipids was proposed to provide the sound biological barrier to evaporation, with
spreadability being a significant and necessary characteristic for the barrier to be
effective. The polar lipids, forming the interphase, would encourage the spreading of the
bulk nonpolar lipid that would impede evaporation. PLs satisfied the idea, as PLs are
amphiphilic, and although they are not found in meibum, they are found in tears.
Additionally, PLs are the only shared component,303 between the most effective
biological barriers.
The idea of PLS in conjunction with meibum to produce a sound barrier to evaporation
was refuted in the current study. Our studies found that there was no correlation between
PLs and Revap. PLC applied to the aqueous subphase before lipid application was not
effective at reducing the Revap. The results were valid for MNORMAL and disease meibum,
MDED, and MHSCT.
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Our studies also included an investigation of the effects of PLc alone in reducing the
Revap. PLC, as found in the TF, did not reduce Revap. When considering each type of PL
alone, the results varied. SM and PS did not affect the Revap. PE and PC increased the
Revap; However, when considering each PL type over an extended period of time, no PL,
including PE and PC, had any effect on the Revap. Although differences with some PLs
were observed, the changes seen contributed to a small acceleration of evaporation rather
than attenuating it.
Moreover, although the changes in Revap for PE and PC are significant, it does not
come close to the differences we would expect with DED. Differences of 50% would
have to occur to contribute to TBUT. If anything, one could speculate that these PLs
increase the Revap on aqueous surfaces.
So having a high evaporation resistance, one of four necessary characteristics of a
sound biological barrier to evaporation,303 was not demonstrated with PLs and meibum.
Nevertheless, the characteristic of spreadability was proven. Microscopy was used to
evaluate spreading, as was done in all phases of the study. The spreading of normal and
disease meibum on the aqueous subphase was evaluated before and after exposure to PLs.
The results were then analyzed using Image J. The results were positive for the DED
cohort.
Frequently, although meibum was shown to cover the entire surface in the TFLL
models, micrographs showed non-uniform clustering of meibum about the entire surface
of the ocular surface models—meibum was visible in all zones, and the size of the
clusters varied by region. There were thinner regions of meibum with thicker clusters
resembling floating islands, which was the case for MNORMAL, MDED, and MHSCT samples
when applied to PBS. However, when MDED from the same patient was applied to a layer
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of mixed synthetic PL and PBS, the clustering diminished. A more uniform distribution
of meibum was observed. Quantitative analysis supported the observation, showing a
significant difference in clustering before and after PLC application. The characteristic of
good re-spreadability,303 is supported by the results of this study.
In conclusion, it was hypothesized that meibum alone or with PLs decrease Revap.
Our data do not support the hypothesis. Investigators found that meibum alone did not
influence Revap. Revap did not change with meibum from donors with EDED or any
other combination of meibum and PL. It appears that PLs inhibit the clustering of lipids
at the aqueous lipid interphase, and therefore facilitate the spreading of meibum.
Decreases with clustering were especially true for MDED. However, the results were
surprising, considering that PLs did not contribute to decreased Revap.
PLs have a role in TF function, however minimal, and there is some unknown
phenomenon occurring in DED. The role of meibum in TF function is possibly different
than what is conventionally accepted. Therefore, there is a possibility that a combination
of other factors, which could include WE or CE branched chain differences, protein
interactions, inflammation and environmental factors that lead to tear hyperosmolarity.
Whatever the case, it is evident that DED is a serious health concern and that more
research is needed in this area.
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8. DISCUSSION
8.1. GENERAL DISCUSSION
The notion that a lipid layer on an aqueous surface inhibits Revap of the underlying
aqueous subphase is intuitively logical and supported by many studies. Studies involving
lamellar lipids in the stratum corneum suggest that these lipids inhibit the Revap of
skin.352 In the belief that biological lipid layer are believed to inhibit Revap, studies
involving the TF that are not in the agreement are often overlooked. The idea that such
studies would contradict what is widely known and accepted is baffling. However, such
studies do exist that do not align with this widely accepted idea. Some of these studies are
presented in the discussion below and show that surface lipid layers are not responsible
for the inhibition of evaporation. They do not act as a barrier to evaporation, at least not
alone.

8.1.2. HYDROXYLCARBON CONFORMATION AND THE REVAP3
Intuitively, one would expect a hydrophobic uniform layer of lipid on an aqueous
surface would inhibit the Revap of water. As stated in the Introduction, studies done over
60 years ago suggest that lipids on the aqueous surface offer resistance to evaporation311312

and perhaps could be used to slow the evaporation of water in reservoirs.322 In the

This section of the chapter includes a slightly modified version of the discussion from “Evaporation and
hydrocarbon chain conformation of surface lipid films” published in The Ocular Surface 2016, 14 (4), 447459, the original source. © 2016 Elsevier Inc. All rights reserved
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current study, we repeated earlier studies involving the inhibition of evaporation by 1undecanol and other alcohols.309 Raman spectroscopy was used to measure human
meibum and synthetic lipids' conformation on the surface of TR and PBS in vitro. Raman
spectroscopy was also used to visualize the lipid film.
In our study, long-chain alcohols did not attenuate Revap of PBS, even when they were
an estimated 345 µm thick, more than ten times thicker than human TFLL. The results
are in agreement with four trials with control and experimental reservoirs (Capella study)
of equal size and one of three trials using the unequally sized reservoirs at Derenbandi
that showed that cetyl alcohol did not inhibit Revap,309 leading one to wonder if a thin
monolayer on the surface of a reservoir is sufficient to reduce Revap. If careful layering
of lipid on the surface of PBS in the laboratory did not inhibit evaporation, it is unlikely
that simply placing lipid on a pond with the wind, rain, lipid degradation, and impurities
will have much of an effect on the rate of evaporation.
Chain length had a significant but minimal effect on Revap, but the change was
opposite to a study that calculated the resistance to evaporation increased with
hydrocarbon chain length.312 The attenuation of Revap by lipids was minimal in our
study, and fluid long-chain alcohols such as 1-undecanol and very ordered long-chain
alcohols such as 1-tetradecane did not reduce Revap by more than a few percent. We
found that the amount of lipid on the surface (estimated to be 0.7 to over 7 µm thick) did
not affect Revap in agreement with in vivo studies.120, 257, 335-338 Our results indicate that
when a water molecule achieves sufficient energy to escape the surface, it escapes
whether the interface is a layer of lipid or air. The water molecules find their way into the
lipid layer and eventually make their way to escape as a gas into the air. So although the
lipid layer could slow water movement through the lipid,312 Revap is unaffected by lipid.
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Unexpectedly, the conformation of fluid 1-undecaol became more ordered when
layered on the surface of the PBS. We noticed a similar ordering when human meibum
was placed on the surface of human TR (discussed in the next section).

8.1.3. MEUIBUM SPREADING ON AQUEOUS SURFACE AND THE REVAP4
As stated previously, the notion that the meibum must be fluid enough to exit the
Meibomian gland and ridged enough to withstand shear forces to delay breakup time on
the TF surface was supported by our data. Spectroscopy and microscopy show that
meibum, when placed on the surface of TR or PBS, forms a continuous layer of lipid.
Hydrocarbon chain conformation changed from a disordered to ordered conformation,
moving from primarily gauche rotamers to mostly trans rotamers. There is a strong
correlation between lipid order and viscosity. The lipid hydrocarbon chains can pack
more closely together due to an increased number of trans rotamers. Van der Waal’s
interactions are maximized, so the lipids are less free to move and are more viscous.
From these studies, the changes in lipid order are confirmed. However, the causes of
the change are difficult to discern. When placed on the surface of an aqueous subphase,
the meibum on the TF surface rearranges to a less energetic, more ordered phase, and
aqueous is responsible for the phenomenon. Although proteins have been considered a
crucial component for these changes, proteins may or may not contribute to observed
changes, as the changes occur with a PBS subphase that does not contain protein. The
ordering cannot be explained by the presence of protein or a component in human tears.

This section of the chapter includes a slightly modified version of the discussion from “Evaporation and
hydrocarbon chain conformation of surface lipid films” published in The Ocular Surface 2016, 14 (4), 447459, the original source. © 2016 Elsevier Inc. All rights reserved
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Fluorescence shows that human tears increased the anisotropy of meibum at the waterlipid interface and confirms these results.351 Raman spectra were taken as snapshots
because mapping the Raman intensity of the entire film was technically impossible.
Raman spectra snapshots of a small area of the film were very similar, yet small regions
with imperfections or defects different from the bulk film may have been missed. It is
important to note that the magnitude of Raman bands depends on the optical quality and
structure of the film, making it difficult to accurately determine the thickness of the film
from Raman band intensities.
The visible appearance of the TFLL was smoother and more uniform when the subphase was human tears rather than the PBS. The recorded TFLL images looked very
similar to those measured in vivo using high-resolution microscopy.60 In vitro,
physiological saline evaporates at a rate of 8.0 ± 0.5 µm/min,55 which is similar to the
Revap for tears (9.3 ± 0.9 µm/min),55 and also similar to Revap measured in vivo for
contact lens wearers (6.97 µm/min).292 To an extent, the Revap of tears in vitro or in vivo
is not unusual. As stated previously, “…although evaporation seems to be an important
factor in TF breakup, it is too slow to offer a complete explanation of TF thinning.”292
Nearly all review articles suggest that one of the functions of the TFLL is to retard the
Revap of tears. Such a conclusion is strengthened when accepted views are considered,
and dissenting views are ignored. However, an idea is only as firm as the studies
supporting it. In vitro, it took upwards of 200 times more meibum lipid than is present in
the TFLL to show a significant decrease (9–20%) in Revap.329-330 Additionally, and
bearing in mind that wax esters account for the bulk lipids of the TFLL, experiments
done 60 years ago showed three wax esters (ethyl palmitate, ethyl linoleate, and ethyl
elaidate) do not attenuate Revap.321 Later, a pool of lipids resembling the TFLL did not
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inhibit Revap; a layer of olive oil decreased Revap, but only by 53% and requiring 2,000
times the thickness of the TFLL to show significance.290
There are several studies, in vitro and in vivo, that contradict the idea that the TFLL
inhibits the Revap. In vitro, when bovine285 or human meibum284, 291 was layered on top
of PBS, the Revap was not impeded, or inhibition was much less (6–8%)314 than the 50%
difference conventionally attributed to the TFLL, as stated previously. Theoretical
postulates that suggest exposed regions about the surface as the basis for evaporative loss
are logical. If lipids in these studies are not spread across the entire surface, gaps will
decrease evaporative resistance, but there is no experimental evidence to support this
idea. In the current study, Raman scattering intensity of the lipid films suggests that lipids
distributed similarly across the aqueous subphase surface. The amount of hydroxyl lipids
at a given spot on the surface deviated by only 7%, while the meibum films varied by
21% across the entire film, and is confirmed by microscopic observation. These studies
also showed that all of the lipids were structurally ordered indicating that lipids have to
pack linearly and tightly together, and therefore, lipid-lipid interactions were maximal.
When steps were taken to ensure complete and uniform coverage of meibum lipids
cover the aqueous phase, meibum film only inhibited the Revap by 7%.314 This was
evident from color interference patterns. Additionally, X-ray diffraction studies of
meibum films showed that above a surface pressure greater than 18 mNm−1, which is the
case for the Revap experiments, stacked monolayers 3–8 layers’ thick form with no
single monolayers present.353 Brewster angle microscopy,354 fluorescence spectroscopy,
and high-resolution color microscopy355 also showed that at physiological temperature
and higher surface pressures, meibum spontaneously spreads, covering the entire surface,
and revealing ‘islands’ of lipid similar to those observed in vivo.356 Thus, the meibum in
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the evaporation studies form multilamellar duplex film, as indicated by King-Smith et
al.,303 containing a 5 nm thick monolayer composed of surfactants, like biological barriers
in the lungs, and a superficial multilamellar collecting layer containing islands of
lipids.355 The multilamellar sheets are likely to be joined by interdigitated lipid
hydrocarbon chains. One would expect that large ‘islands’ of tightly packed lipids, 70
times thicker than the TFLL, might decrease the rate of evaporation as it has been
estimated that “…in some areas where the meibum is thickest, it acts as a better barrier to
evaporation,”39 although the total Revap was unchanged with normal and diseased
meibum.
Our earlier experiments were repeated over 60 times by several investigators and
meibum did not inhibit Revap. These findings are concurrent with other studies.284, 291-292,
309, 314, 321, 329-330, 341

One explanation for why we do not see Revap inhibition involves

water behavior on an irregular surface. At the lipid-aqueous interface, water travels
around the islands of lipids and evaporates through the thin monolayer between islands.
The ability of lipids to inhibit Revap is complicated and is supported by a bilayer study.
Investigators stated, “…even if 99.8% of the surface is occupied by bilayer, the presence
of only 0.2% of the surface as monolayer is sufficient to reduce the specific resistance of
a bilayer surface film…”350
Another possibility for why meibum did not inhibit Revap could be explained by the
material used as the aqueous subphase in experiments. In previous studies,284, 291, 314 PBS
instead of human tears were used. This observation is relevant because the rheology of
meibum on artificial tears is different for meibum on human tears.285 Water is excluded
at the TFLL-aqueous tear interface during interaction of meibum with tears, and as a
result of this interaction, Revap was inhibited.351 This study tested the idea that unknown
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factors in tears, such as proteins, interact with human meibum placed on the surface of
TR, and together they inhibit Revap. In any case, where PBS or tears were used as an
aqueous sub-phase, Revap was not inhibited by meibum.
The six most recent studies published in the last ten years related to TFLL
thickness in vivo show that TFLL thickness is not related to increased TBUT or a
decreased thinning rate attributed chiefly to evaporation.120, 257, 335-338 Patients with
seasonal allergic conjunctivitis had a TFLL that was thicker than controls, yet the
stability of their TF and TBUT decreased, opposite of what one would expect.335 For 29
young336 and 86 older338 normal subjects, and 110 patients with DED,337 there was no
correlation between TFLL thickness and non-invasive tear breakup time. Thinning rate
and Revap are related. The correlation between thinning rate and lipid thickness, although
significant, was nevertheless relatively low (r about 0.3).120 Most people have a TF
thickness between 30 to 150 nm, and it has been shown that in this range of TFLL
thickness, Revap does not change.120, 343 One needs the absence of a TFLL (which rarely
occurs) to observe an increase in Revap.343
Some studies suggest that local changes in evaporation could influence tear breakup,
and tear breakup occurred where the TFLL was either relatively thin or relatively thick,
suggesting that “the lipid was a poor barrier to evaporation, perhaps because of
deficiency in composition and structure.”356 Indeed, as pointed out in the Introduction,
thermographic images are remarkably similar to fluorescein breakup images, implying
that localized breakup is caused by localized high evaporation.344-349, 357 The most likely
cause of local high evaporation is that the lipid layer has a poor evaporation resistance in
that region compared to higher resistance in surrounding regions. However, as pointed
out, many subjects exhibited ocular surface cooling without fluorescein tear thinning, and
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breakup and some showed no evidence of ocular surface cooling or fluorescein tear
thinning and breakup.344 Some or all of the local cooling in the TFLL breakup areas
could result from the breaking of strong hydrophobic van der Waal’s lipid-lipid
interactions and not evaporation. Cooling increases van der Waal’s interactions between
lipids. Thermographic in vivo studies are associated with large standard deviations, 0.5–
0.8°C, relative to the difference in temperature 0.04 to 0.44°C, between subjects with and
without DED.357-358 Also, one should not overlook the studies that showed no correlation
between TBUT and ocular surface temperature in normal subjects336 and surface
temperature differences in subjects with DED.282 Furthermore, one should consider that
subjects with DED had the same33 surface temperatures compared with normal subjects.

8.1.4. PHOSPHOLIPIDS AND THE REVAP
It has been suggested that a sound biological barrier must have high evaporative
resistance (Section 2.1.2.), which is one of four characteristics necessary to produce an
effective lipid layer. The studies conducted thus far have failed to meet this criterion.
Meibum does not attenuate Revap.
After confirming MNORMAL did not attenuate Revap, to strengthen the current study's
observations, meibum from donors with DED was considered. The rationale for using
MDED was that if meibum from normal donors did not inhibit Revap, perhaps meibum
from donors with DED had some effect that would account for evaporative differences
between normal and disease states. Some unforeseen phenomenon occurring with a
condition may cause Revap to accelerate. Lack of interactions between meibum from
donors with DED and other TF moieties compromise the TFLL integrity, thus disrupting
the barrier. Meibum from donors who have undergone HSCT are less stable with reduced
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TBUT. However, in experiments involving both disease states, Revap was unchanged.
Meibum, regardless of type, still did not retard Revap of the aqueous subphase.
In this case, higher Revap, or the lack of evaporative resistance, can be explained by
spontaneous holes that form in lipid monolayers,316 which allow water to escape by
movement around lipid islands. This explanation is plausible, as disruption in the
integrity of the film does not allow complete coverage. However, analysis of lipid
spreading by Raman and microscopy in previous chapters show that meibum completely
covers the surface, although coverage is non-uniform.
One could then argue that the uneven distribution could account for the negative
results. Perhaps, thinner regions, where coverage is non-uniform, are sufficient to account
for why Revap did not decrease with meibum. One study supported inhibition of Revap
through lipid bilayers.309 A small monolayer formed350 within the bulk lipid was
sufficient to disrupt the barrier. Therefore it is possible that exposing only a tiny
amount350 of the aqueous subphase to a thin layer of meibum will sufficiently reduce
evaporation resistance in these studies, assuming a monolayer in those areas. However,
PLs can refute this argument.
PLs were applied to stabilize the TF and attenuate Revap. PLs were considered the
missing moiety to explain why the study did not corroborate what was conventionally
accepted as meibum’s role in TF stability. Perhaps PLs would function as a scaffold to
facilitate the spreading of meibum lipids and thus reduce evaporative loss of tears. Our
results did not fully support this theory. Meibum exposed to PL did not reduce the Revap.
However, some results were positive. MDED exposed to PL showed a significant reduction
in clustering. Analysis showed that meibum distribution was more uniform, assuming
complete coverage with bulk nonpolar lipid and eliminating the prospect of monolayers
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formed with uneven distribution. Although the Revap did not decrease, the experiments
showed that with complete coverage, non-uniform or uniform coverage, and no coverage
at all, Revap was unchanged.
There were no significant changes in Revap to support the hypothesis; nevertheless,
the characteristic of spreadability295 was observed. As shown in computer models,308 PL's
role as a scaffold to facilitate meibum spreading was supported by our study. The results
supported the idea of PLs' role in supporting the uniform distribution of meibum. For the
DED cohort, PLs significantly decreased the number of clusters per area. This change
suggests that PLs are surface-active, allowing the meibum to spread on the surface of
tears. The lower number of clusters for the DED cohort may be due to the hypothesis
that with DED meibum, there is a deficiency of surface-active surfactants such as PLs
compared with normal meibum. The addition of PLs ameliorates this deficiency allowing
the meibum to spread. The HSCT and normal meibum samples may not have a
deficiency of surface-active surfactants, so more surface-active PLs do not affect the
number of clusters.
When PLs were applied, some experiments had different outcomes. PLs were
considered the missing moiety to explain why the study did not corroborate what has
been conventionally accepted as meibum’s role in TF stability. Perhaps PLs would
function as a scaffold and interact with meibum lipids to reduce evaporative loss of tears.
Our results did not support this study. However, when meibum from donors confirmed
with DED was layered on PBS, the results were positive. The results supported the idea
of PLs' role in supporting the uniform distribution of meibum. For the DED samples, PLs
significantly decreased the number of clusters per area. This change suggests that PLs are
surface-active, allowing the meibum to spread on the surface of tears. The lower number
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of clusters for the DED samples may be due to the hypothesis that with DED meibum,
there is a deficiency of surface-active surfactants such as PLs compared with normal
meibum. The addition of PLs ameliorates this deficiency allowing the meibum to spread.
The hematopoietic stem cell transplant and normal meibum samples may not have a
deficiency of surface-active surfactants, so more surface-active PLs do not affect the
number of clusters.
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9. CONCLUSION

9.1. OVERALL SUMMARY
We found that long-chain alcohols, regardless of their fluidity, chain length, or
thickness, do not inhibit the Revap of the PBS. Additionally, meibum from normal and
disease donors do not inhibit Revap of PBS or TR in vitro. The experiments have
demonstrated that the TFFL covering the aqueous sub phases has no bearing on
evaporative resistance. Synthetic lipids and meibum form a relatively tightly packed layer
on the surface, although not consistently uniform. PLs, do not contribute to Revap
reduction. However, PLs may play on role in facilitating the uniform spreading of lipids
on the ocular surface. Therefore, our results provide a basis for investigating the
interaction of PLs with other ocular surface lipids.

9. 2. RECOMMENDATIONS FOR FUTURE STUDIES
Although meibum did not reduce the Revap in our TF studies, further work is required
to understand why meibum is widely accepted as a barrier to tear evaporation despite the
overwhelming amount of conflicting information. Clinicians see changes between normal
and disease states that warrant exploration of the role of meibum in the TF and disease.
Direct studies and the role of other TF components could strengthen our understanding of
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these changes. At the very least, it could help explain the conflicting findings of TF
studies.
Recent studies by others in our laboratory have explored the relationships between
meibum composition, conformation (structure) and tear film stability. It was exciting to
find a strong correlation between meibum stiffness and tear film stability as lipids that
pack tightly together do not spread well. The relationships between meibum
conformation and tear film stability were made indirectly, therefore, direct studies may
strengthen the findings. Direct comparisons of the major DED types, ADDE and MGD
and the relationships between meibum composition, conformation and tear film stability
have yet to be performed and would likely be fruitful.
Future studies could also be directed toward elucidating the potential role of proteins
found in tears and Revap. Recent studies have shown that hydroxyl fatty acids facilitate
the spreading of tears. It has yet to be shown whether the amount of these lipids change
with dry eye. They compose about 5% of meibum and could warrant further study.
Furthermore, it would be beneficial to develop an appropriate animal model to help
elucidate the etiology of DED as an animal model does not exist.
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LIST OF ABBREVIATIONS

Abbreviations

Definitions

ADDE

Aqueous Deficient Dry Eye

AT

Artificial Tears

BSCVA

Best Spectacle-Corrected Visual Acuity

CDCl3

Deuterated Chloroform

CE

Cholesterol Ester

DED

Dry Eye Disease

EDED

Evaporative Dry Eye Disease

GVHD

Graft-versus-Host Disease

HLA

Human Leukocyte Antigen

HSCT

Hematopoietic Stem Cell Transplantations

IVCM

in vivo Confocal Microscopy

LIPCOF

Lid-Parallel Conjunctiva Folds

MDED

Dry Eye Disease Meibum

MGD

Meibomian Gland Dysfunction

MHSCT

Hematopoietic Stem Cell Transplantations Meibum

MNORMAL

Normal Meibum

NMR

Nuclear Magnetic Resonance
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OAHFA

(O-acyl)-Omega-Hydroxyl Fatty Acid

OPI

Intraocular Pressure

OSDI

Ocular Surface Disease Index

PBS

Physiological/Phosphate Buffered Saline

PC

Phosphatidylcholine

PE

Phosphatidylethanolamine

PL

Phospholipids

PLC

Combined Phospholipids

PS

Phosphatidylserine

Revap

Rate of Evaporation

SM

Sphingomyelin

TBUT

Tear Break-Up Time

TF

Tear Film

TFL

Tear Film Layer

TFLL

Tear Film Lipid Layer

TLn

Normal Tears

TR

Reflexed Tears

WE

Wax Esters
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Meibum on the Rate of Evaporation in Adolescents and Adults with Graftversus-host Disease. Category: Ophthalmic Disorders and
Treatments. May. World Eye and Vision Congress. Dubai, UAE

2018

Presenter- Conformational and Thermodynamic Features of Meibum in
Adolescents and Adults with Graft-versus-host Disease. Category:
Cornea. Association for Research in Vision and Ophthalmology (ARVO).
April. Honolulu, HI., USA

2018

Presenter- Conformational and Thermodynamic Features of Meibum in
Adolescents and Adults with Graft-versus-host Disease.
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Category: Inflammation and immunopathology. Experimental Biology
(EB). April. San Diego, CA., USA
2017

Presenter- Research! Louisville. The University of Louisville. September.
Louisville, KY., USA

2015

Presenter- National Association for Minority Medical Educators
Conference. October. Louisville, KY., USA

Non-Conference Presentations
2014

Presenter- Summer Cardiovascular Physiology Research Forum,
University of Louisville School of Medicine. August. Louisville, KY.

Research Interests








Eye and Vision Disorders
Evolutionary Medicine
Chronic Diseases
Psychological effects of diseases
Natural Selection
Pathophysiology
Cancer, especially lung and breast cancer
Professional Organizations

2017-

Association for Research in Vision and Ophthalmology

2017-

American Physiological Society

Academic Organizations
2017-

Golden Key International Honor Society

2017-2019

Graduate Student Council (GSC) Proxy.

2016-2021

Science Policy and Outreach Group (SPOG), University of Louisville

Community Organizations
2019-

Alpha Kappa Alpha Sorority, Incorporated. Eta Omega Chapter,
Louisville, KY.
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2016-

My Secret Isn’t a Secret Anymore Abuse Ministry

2015-2020

Family Community Clinic, Inc.

2012-

Bates Memorial Baptist Church

Community Service
2020-

Gilda’s Club Kentuckiana

2020-

Change Today Change Tomorrow (CTCT)

2020

Judge (Best of Fair)- Kentucky Science and Engineering Fair

2019-2020

Judge (Best of Fair)- Louisville Regional Science and Engineering Fair

2015-2020

Clinic Volunteer, Family Community Clinic, Inc. Louisville, KY.

2006-2008

Crisis and Information Center Operator (Suicide Counseling, Information
and Referrals, Directory Assisting and Teen Talk and Help), Seven
Counties. Louisville, KY.
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i

Study conducted in Beaver Dam, Wisconsin containing 3722 participants.
Similar Men’s and Women’s Health Studies conducted with over 24,000 and 39,000 US participants
respectively.
ii
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